Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS
Document Type and Number:
WIPO Patent Application WO/2024/030633
Kind Code:
A1
Abstract:
Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulating (e g., inhibiting) KRAS (e.g., KRAS having a Q61H, G12D, G12V, G12C, G12S, G12A, G12R, or G13D mutation or wild-type KRAS) and treating diseases or disorders such as cancers in subjects in need thereof.

Inventors:
ZHANG ZUHUI (US)
WANG BIN (US)
WALLACE ELI (US)
XU RUI (US)
WEHN PAUL (US)
YANG YUE (US)
LIGHTSTONE FELICE (US)
PEI JUN (US)
MACIAG ANNA ELZBIETA (US)
TURNER DAVID MICHAEL (US)
SIMANSHU DHIRENDRA KUMAR (US)
CHAN ALBERT HAY WAH (US)
BRASSARD CHRISTOPHER JOHN (US)
LIAO TAO (US)
Application Number:
PCT/US2023/029520
Publication Date:
February 08, 2024
Filing Date:
August 04, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
THERAS INC (US)
LEIDOS BIOMEDICAL RES INC (US)
L LIVERMORE NAT SECURITY LLC (US)
International Classes:
C07D409/04; A61K31/519; A61P35/00; C07D409/14; C07D417/04; C07D417/14; C07D487/04; C07D487/10; C07D519/00
Domestic Patent References:
WO2022105855A12022-05-27
WO2016164675A12016-10-13
WO2022002102A12022-01-06
WO2017172979A12017-10-05
WO2023179703A12023-09-28
WO2023141300A12023-07-27
WO2023004102A22023-01-26
WO2022177917A22022-08-25
Other References:
LIEBERMAN, PHARMACEUTICAL DOSAGE FORMS, vol. 1-3, 1992
LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999
PICKAR, DOSAGE CALCULATIONS, 1999
"Remington: The Science and Practice of Pharmacy", 2003, WILLIAMS & WILKINS
Attorney, Agent or Firm:
D'AMATO, Erica M. et al. (US)
Download PDF:
Claims:
Claims 1. A compound represented by Formula II’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 is selected from H, C1-6alkyl, and a 3-6 membered carbocycle, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13; R3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R10; R4 is H; R5 is selected from H, halogen, -CN, -OR12, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R15; R7 is selected from halogen; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R10 is independently selected from deuterium, -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OH, -C(O)(C1-6alkyl), -C(O)O(C1-6alkyl), -C(O)N(R14)2, -C(O)OR14, -C(O)(3-6 membered carbocycle), -C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), - C(O)O(C1-6alkylene)(3-6 membered heterocycle), -S(O)2(C1-6alkyl), halogen, a 5-6 membered heteroaryl, a 3-6 membered carbocycle, a 3-6 membered heterocycle, and C1- 6alkyl, wherein any C1-6alkyl is optionally deuterated and is unsubstituted or substituted with one or more R20, wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R12 or R20, and wherein two R10s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6 alkyl is optionally deuterated; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, -OC1-6haloalkyl, =O, -CN, -NH2, - NHC1-6alkyl, -C(O)(C1-6alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, a 3-6 membered carbocycle, -OR12, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13. 2. A compound represented by Formula II: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 is selected from H, C1-6alkyl, and a 3-6 membered carbocycle, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13; R3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R10, provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R10, or (ii) the heterocycle does not comprise an –NH- moiety; R4 is H; R5 is selected from H, halogen, -CN, -OR12, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl lis substituted with one or more R15; R7 is selected from halogen; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R10 is independently selected from deuterium, -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OH, -C(O)(C1-6alkyl), -C(O)O(C1-6alkyl), -C(O)N(R14)2, -C(O)OR14, -C(O)(3-6 membered carbocycle), -C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), - C(O)O(C1-6alkylene)(3-6 membered heterocycle), -S(O)2(C1-6alkyl), halogen, a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C1-6alkyl, wherein any C1-6alkyl is optionally deuterated and is unsubstituted or substituted with one or more R20, wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R12 or R20, and wherein two R10s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6 alkyl is optionally deuterated; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, -OC1-6haloalkyl, =O, -CN, -NH2, - NHC1-6alkyl, -C(O)(C1-6alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, a 3-6 membered carbocycle, -OR12, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13. 3. The compound of claim 1 or 2, wherein the compound is of Formula II-a: salt (e.g., pharmaceutically acceptable salt) thereof. 4. The compound of any one of claims 1-3, wherein R3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N. 5. The compound of claim 4, wherein R3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R10, provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R10. 6. The compound of any one of claims 1-5, wherein R3 is a pyrrolidine that is substituted with 0-4 R10, provided that the nitrogen atom is substituted with R10. 7. The compound of any one of claims 1-5, wherein R3 is an oxetane or thietane that is substituted with 0-4 R10. 8. The compound of any one of claims 1-5, wherein R3 is a tetrahydrofuran or tetrahydrothiopene that is substituted with 0-4 R10. 9. The compound of any one of claims 1-5, wherein R3 is a 4-6 membered heterocycle that is substituted with one or more R10, provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R10, and each R10 is independently selected from -C(O)(C1- 6alkyl), -C(O)(3-6 membered carbocycle), -C(O)O(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, and any 3-6 membered carbocycle is unsubstituted or substituted with one or more R12 or R20. 10. The compound of any one of claims 1-5, wherein R3 is a 4-6 membered heterocycle that is substituted with one or more R10, wherein at least one R10 is selected from -OR12 and a C1-6alkyl substituted with -OH. 11. The compound of any one of claims 1-10, wherein R3 is a 4-6 membered heterocycle that is substituted with one or more R10, wherein at least one R10 is an unsubstituted C1-6alkyl. 1 , ,

, , any of which is optionally further substituted with one or more R10. 13. The compound of any one of claims 1-3, wherein R3 is a 7-9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R10. 14. The compound of claim 13, wherein R3 is a 7-9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R10, provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R10 or (ii) the heterocycle does not comprise an –NH- moiety. 15. The compound of claim 13 or 14, wherein R3 is a 7-9 membered bridged heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the bridged heterocycle is unsubstituted or is substituted with one or more R10. 16. The compound of claim 13 or 14, wherein R3 is a 7-9 membered heterocycle comprising a fused ring system that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R10. 17. The compound of any one of claims 1, 2, 3, or 13-16, wherein R3 is selected from:

1 The compound of any one of claims 1-17, wherein the compound is a compound according to Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, or IIZ:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Rd is independently selected from H, deuterium, -OR12, =O, -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OH, -C(O)(C1-6alkyl), -C(O)N(R14)2, -C(O)(3-6 membered carbocycle), -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R12 or R20; Re, if present, is selected from -C(O)(C1-6alkyl)CN, -C(O)(C1-6alkyl)OH, -C(O)(C1-6alkyl), - C(O)O(C1-6alkyl), -C(O)N(R14)2, -C(O)OR14, -C(O)(3-6 membered carbocycle), -C(O)(3- 8 membered heterocycle), -C(O)(5-6 membered heteraryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), -C(O)O(C1-6alkylene)(3-6 membered heterocycle), -S(O)2(C1-6alkyl), a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C1-6alkyl, wherein any C1-6alkyl is optionally deuterated and is unsubstituted or substituted with one or more R20, and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R12 or R20; and each Rf is optionally absent and, if present, is selected from =O, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2. 19. The compound of any one of claims 1-17, wherein the compound is a compound according to Formula IIAA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Rd is independently selected from deuterium, H, -OR12, =O, -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OH, -C(O)(C1-6alkyl), -C(O)(3-6 membered carbocycle), -S(O)2(C1- 6alkyl), halogen, a 3-6 membered carbocycle, a 3-6 membered heterocycle, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, wherein any 3-6 membered carbocycle or 3-6 membered heterocycle, is unsubstituted or substituted with one or more R12 or R20; and (i) Rq1, Rq2, and Rp2 are each independently selected from Rd, and Re and Rp1, together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more Rd; or (ii) Rp1, Rp2, and Rq2 are each independently selected from Rd, and Re and Rq1, together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more Rd. 20. The compound of any one of claims 1-19, wherein R6 is a monocyclic heteroaryl that is substituted with one or more R15. 21. The compound of claim 20, wherein R6 is a pyridine substituted with one or more R15. 22. The compound of claim 21, wherein R6 has the structure . 23. The compound of any one of claims 1-19, wherein R6 is a bicyclic heteroaryl that is substituted with one or more R15.

24. The compound of claim 23, wherein R6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 25. 26.

27. The compound of any one of claims 23-26, wherein R6 is selected from: , , 28. The compound of any one of claims 1-27, wherein the compound is a compound according to Formula IIA1, IIB1, IIC1, IID1, IIE1, IIF1, IIG1, IIH1, IIJ1, IIK1, IIL1, IIM1, IIN1, IIP1, IIQ1, IIR1, IIS1, IIT1, IIU1, IIV1, IIW1, IIX1, IIY1, or IIZ1:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Rd is independently selected from H, deuterium, -OR12, =O, -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OH, -C(O)(C1-6alkyl), -C(O)N(R14)2, -C(O)(3-6 membered carbocycle), -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R12 or R20; Re, if present, is selected from -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OH, -C(O)(C1-6alkyl), -C(O)O(C1-6alkyl), -C(O)N(R14)2, -C(O)OR14, -C(O)(3-6 membered carbocycle), - C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteraryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), -C(O)O(C1-6alkylene)(3-6 membered heterocycle), -S(O)2(C1-6alkyl), a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C1-6alkyl, wherein any C1-6alkyl is optionally deuterated and is unsubstituted or substituted with one or more R20, and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R12 or R20; each Rf is optionally absent and, if present, is selected from =O, -NH2, -NHC1-6alkyl, and -N(C1- 6alkyl)2; X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 29. The compound of any one of claims 1-27, wherein the compound is a compound according to Formula IIAA1: each Rd is independently selected from H, deuterium, -OR12, =O, -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OH, -C(O)(C1-6alkyl), -C(O)(3-6 membered carbocycle), - C(O)N(R14)2, -S(O)2(C1-6alkyl), a 3-6 membered carbocycle, a 3-6 membered heterocycle, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, and wherein any 3-6 membered carbocycle or 3-6 membered heterocycle is unsubstituted or substituted with one or more R12 or R20; X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and (i) Rq1, Rq2, and Rp2 are each independently selected from Rd, and Re and Rp1, together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more Rd; or (ii) Rp1, Rp2, and Rq2 are each independently selected from Rd, and Re and Rq1, together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more Rd. 30. The compound of claim 28 or 29, wherein X is C-CN, Y is S, and R23 is -N(R12)2. 31. The compound of any one of claims 28-30, wherein one or more of R24, R25, and R26 is a halogen (e.g., F). 32. The compound of claim 18 or 28, wherein each Rf is =O. 33. The compound of claim 18 or 28, wherein each Rf is absent. 34. The compound of claim 18 or 28, wherein Re is C1-6alkyl that is unsubstituted or substituted with one or more R20. 35. The compound of claim 18 or 28, wherein Re is -C(O)(3-6 membered carbocycle). 36. The compound of claim 18 or 28, wherein Re is selected from -C(O)(C1-6alkyl), -C(O)(3-6 membered carbocycle), and -C(O)O(C1-6alkyl), wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, and any 3-6 membered carbocycle is unsubstituted or substituted with one or more R12 or R20. 37. The compound of any one of claims 18-36, wherein each Rd is H. 38. The compound of any one of claims 18-36, wherein at least one Rd is selected from -OR12 and a C1-6alkyl substituted with -OH. 39. The compound of any one of claims 1-38, wherein R2 is H. 40. The compound of any one of claims 1-38, wherein R2 is selected from C1-6alkyl that is unsubstituted or is substituted with one or more R13. 41. The compound of claim 40, wherein R2 is selected from C1-2alkyl. 42. The compound of any one of claims 1-38, wherein R2 is selected from a 3-6 membered carbocycle. 43. The compound of any one of claims 1-42, wherein R1 is selected from -OR8. 44. The compound of claim 43, wherein R1 is selected from: , wherein Ra1, Ra2, Rb1, and Rb2 are each independently selected from deuterium, halogen, C1-6alkyl, -OR12, and H, wherein Ra2 and Rb2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R13. 45. The compound of claim 44, wherein R1 is selected from: 46. are each independently selected from halogen, C1-6alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13. 47. The compound of claim 46, wherein R1 is selected from: . 48. The compound of claim 43, wherein R1 is selected from: wherein each Ra and Rb is independently selected from halogen, C1-6 alkyl, -OR12, and H; and Rc is selected from C1-6 alkyl, wherein an Ra and Rb or Rc optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13.

49. The compound of claim 48, wherein R1 is selected from: , 50. The compound of any one of claims 1-42, wherein R1 is selected from . 51. The compound of any one of claims 1-50, wherein R5 is H. 52. The compound of any one of claims 1-50, wherein R5 is a halogen (e.g., F or Cl). 53. The compound of any one of claims 1-50, wherein R5 is selected from C1-6alkyl that is unsubstituted or substituted with one or more R13. 54. The compound of claim 53, wherein R5 is selected from C1-6alkyl that is substituted with one or more halogens or -CN. 55. The compound of claim 54, wherein R5 is selected from -CF2H, -CF3, -CH2CN, and -CH2CH3. 56. The compound of claim 55, wherein R5 is -CF3. 57. The compound of any one of claims 1-56, wherein the compound is a not a compound included in Table 1.  58. A compound represented by Formula III’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 and R3, together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R11; R4 is H; R5 is selected from halogen and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R15; R7 is selected from halogen; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R11 is independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)O(C1-6alkyl), -C(O)N(R14)2, -C(O)(3-6 membered carbocycle or heterocycle), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), - N(R14)C(O)(C1-6alkylene)OR14, halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R20; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, -CN, -NH2, -NHC1-6alkyl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, a 3-6 membered carbocycle, -OR12, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13. 59. A compound represented by Formula III: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 and R3, together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R11, provided that when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R11; R4 is H; R5 is selected from halogen and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R15; R7 is selected from halogen; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R11 is independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)O(C1-6alkyl), -C(O)N(R14)2, -C(O)(3-6 membered carbocycle or heterocycle), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), - N(R14)C(O)(C1-6alkylene)OR14, halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R20; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, -CN, -NH2, -NHC1-6alkyl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, a 3-6 membered carbocycle, -OR12, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13. 60. The compound of claim 58 or 59, wherein the compound is of Formula III-a: or a salt (e.g., a pharmaceutically acceptable salt) thereof. 61. The compound of any one of claims 58-60, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle. 62. The compound of claim 61, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. 63. The compound of claim 62, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R11. 64. The compound of any one of claims 58-63, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a pyrrolidine that is substituted with 0-4 R11. 65. The compound of any one of claims 58-63, wherein R2 and R3, together with the nitrogen atom to which they are attached, form an azetidine that is substituted with 0-4 R11.

66. The compound of any one of claims 58-63, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a piperidine that is substituted with 0-4 R11. 67. The compound of any one of claims 58-63, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a piperazine that is substituted with 0-4 R11. 68. The compound of any one of claims 58-63, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a morpholine or thiomorpholine that is substituted with 0-4 R11. 69. The compound of any one of claims 58-63, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N. 70. The compound of any one of claims 58-69, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle substituted with one or more R11, wherein at least one R11 is selected from -OR12 and a C1-6alkyl substituted with -OH. 71. The compound of any one of claims 58-70, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle substituted with one or more R11, wherein at least one R11 is an unsubstituted C1-6alkyl. 72. The compound of any one of claims 58-69, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that is unsubstituted. 73. The compound of any one of claims 58-60, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged heterocycle. 74. The compound of claim 73, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. 75. The compound of claim 74, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the bridged heterocycle is substituted with 1-4 R11. 76. The compound of any one of claims 73-75, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged piperidine that is substituted with 0-4 R11. 77. The compound of any one of claims 73-75, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged piperazine that is substituted with 0-4 R11. 78. The compound of any one of claims 73-75, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged morpholine or thiomorpholine that is substituted with 0-4 R11. 79. The compound of any one of claims 73-78, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R11, wherein at least one R11 is selected from -OR12 and a C1-6alkyl substituted with -OH.

80. The compound of any one of claims 73-79, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R11, wherein at least one R11 is an unsubstituted C1-6alkyl. 81. The compound of any one of claims 73-78, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a bridged heterocycle that is unsubstituted. 82. The compound of any one of claims 58-60, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a spirocycle. 83. The compound of any one of claims 58-60, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings. 84. The compound of any one of claims 58-71, 73-80, 82, and 83, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is substituted with one or more R11, wherein the one or more R11 are independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1- 6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl that is unsubstituted or substituted with one or more R20. 85. The compound of claim 84, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is substituted with one or more R11, wherein the one or more R11 are independently selected from -OR12, -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1- 6alkylene)OR14, halogen, and C1-6alkyl that is unsubstituted or substituted with one or more R20. 86. The compound of any one of claims 58-85, wherein R2 and R3, together with the nitrogen atom to which they are attached, form a structure selected from: , , , , ,

, , , , , , , , , , , , ,

87. The compound of any one of claims 58-86, wherein the compound is a compound according to Formula IIIA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Re is independently selected from deuterium, hydrogen, -OR12, =O, =N(R14), -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1- 6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; and Rf and Rg are each independently selected from hydrogen, deuterium, -OR12, =O, -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, or Rf and Rg join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 88. The compound of claim 87, wherein each Re, Rf, and Rg is independently selected from hydrogen, -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 89. The compound of claim 87, wherein each Re, Rf, and Rg is independently selected from hydrogen, -OR12, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), halogen, and C1-6alkyl that is unsubstituted or substituted with one or more R20. 90. The compound of any one of claims 87-89, wherein each Re is hydrogen. 91. The compound of any one of claims 87-90, wherein Rf and Rg join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, - C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 92. The compound of claim 91, wherein Rf and Rg join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted.

93. The compound of claim 91, wherein Rf and Rg join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 94. The compound of claim 91, wherein Rf and Rg join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 95. The compound of claim 94, wherein Rf and Rg join together to form a cyclopropane that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1- 6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 96. The compound of claim 91, wherein Rf and Rg join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 97. The compound of claim 96, wherein Rf and Rg join together to form an oxetane that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1- 6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 98. The compound of any one of claims 58-86, wherein the compound is a compound according to Formula IIIB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Re is independently selected from hydrogen, deuterium, -OR12, =O, =N(R14), -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1- 6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 99. The compound of claim 98, wherein each Re is hydrogen. 100. The compound of any one of claims 58-86, wherein the compound is a compound according to Formula IIIC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Re is independently selected from hydrogen, deuterium, -OR12, =O, =N(R14), -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1- 6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl or heteroaryl is unsubstituted or substituted with one or more R20. 101. The compound of claim 100, wherein each Re is hydrogen. 102. The compound of any one of claims 58-86, wherein the compound is a compound according to Formula IIIC1: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Re is independently selected from hydrogen, deuterium, -OR12, =O, =N(R14), -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1- 6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; and Rf , Rg, and Rh are each independently selected from hydrogen, deuterium, -OR12, =O, -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, optionally wherein (i) Rf and Rg join together to form a 3-6 membered carbocycle or heterocycle or a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1- 6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; or (ii) Rg and Rh join together to form a 3-6 membered carbocycle or heterocycle or a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1- 6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 103. The compound of claim 102, wherein each Re is hydrogen. 104. The compound of claim 102 or 103, wherein Rf and Rg join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), - S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 105. The compound of claim 104, wherein Rf and Rg join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 106. The compound of claim 104, wherein Rf and Rg join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 107. The compound of claim 102 or 103, wherein Rg and Rh join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), - S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 108. The compound of claim 107, wherein Rg and Rh join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 109. The compound of claim 107, wherein Rg and Rh join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 110. The compound of any one of claims 58-86, wherein the compound is a compound according to Formula IIID: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: Q is selected from CRhRj, NRg, O, S, and SO2; each Re and Rf is independently selected from R11 and hydrogen, wherein: (i) an Re and an Rf can optionally join together to form a 4-6 membered ring; (ii) a first Rf and a second Rf connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first Re and a second Re connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first Rf and a second Rf connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more Re and/or one or more Rf is unsubstituted or substituted with one or more R11; Rg, when present, is R11; and Rh and Rj, when present, are independently selected from R11 and hydrogen, or can optionally join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR12, =O, =N(R14), -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1- 6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, or a Rh and a Re or a Rh and a Rf optionally join together to form a 3-6 membered ring that is unsubstituted or substituted with one or more R11. 111. The compound of claim 110, wherein Q is NRg, and Rg is selected from -C(O)(C1-6alkylene)CN, - C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 112. The compound of claim 110, wherein Q is O. 113. The compound of claim 110, wherein the compound is a compound according to Formula IIIE: or a salt (e.g., pharmaceutically acceptable salt) thereof. 114. The compound of claim 113, wherein an Re and an Rf join together to form a 4-6 membered ring. 115. The compound of claim 113 or 114, wherein Rh and Rj are independently selected from R11 and hydrogen. 116. The compound of any one of claims 113-115, wherein Rh and/or Rj is selected from deuterium, - OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20. 117. The compound of any one of claims 113-115, wherein Rh and Rj are each hydrogen. 118. The compound of claim 113, wherein Rh and Rj join together to form a 3-4 membered carbocycle or heterocycle. 119. The compound of claim 118, wherein Rh and Rj join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted. 120. The compound of claim 118, wherein Rh and Rj join together to form a 3-4 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR12, =O, - C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl that is unsubstituted or substituted with one or more R20. 121. The compound of any one of claims 118-120, wherein no combination of one or more Res and/or one or more Rfs join together to form a ring. 122. The compound of any one of claims 118-121, wherein each Re and Rf is hydrogen. 123. The compound of claim 110, wherein the compound is a compound according to Formula IIIF, IIIG, or IIIH: or a salt (e.g., pharmaceutically acceptable salt) thereof. 124. The compound of claim 123, wherein each Re and Rf is independently selected from R11 and hydrogen. 125. The compound of claim 123, wherein an Re and an Rf join together to form a 4-6 membered ring. 126. The compound of claim 110, wherein the compound is a compound according to Formula IIIJ: or a salt (e.g., pharmaceutically acceptable salt) thereof. 127. The compound of claim 126, wherein each Re and Rf is independently selected from R11 and hydrogen. 128. The compound of claim 126, wherein an Re and an Rf join together to form a 4-6 membered ring. 129. The compound of any one of claims 110-128, wherein the compound is a compound according to Formula IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, or IIIR:

or a salt (e.g., pharmaceutically acceptable salt) wherein: each Re and Rf is independently selected from R11 and hydrogen; Rg, when present, is R11; and Rh and Rj, when present, are each independently selected from R11 and hydrogen. 130. The compound of claim 129, wherein Q is selected from CRhRj, NRg, and O. 131. The compound of claim 130, wherein Q is CRhRj. 132. The compound of claim 131, wherein Rh and Rj, when present, are each independently selected from R11 and hydrogen, wherein each R11 is independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, - C(O)(3-6 membered carbocycle or heterocycle), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), - N(R14)C(O)(C1-6alkylene)OR14, halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C1- 6alkyl, wherein any C1-6alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R20. 133. The compound of claim 132, wherein Rh and/or Rj, when present, is each independently selected from -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), - C(O)N(R14)2, -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 134. The compound of claim 131, wherein Rh and Rj are each hydrogen. 135. The compound of claim 130, wherein Q is NRg. 136. The compound of claim 135, wherein Rg is selected from -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 137. The compound of claim 130, wherein Q is O. 138. The compound of claim 129, wherein Q is S or SO2. 139. The compound of any one of claims 129-138, wherein each Re and Rf is independently selected from R11 and hydrogen, wherein each R11 is independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, - C(O)(3-6 membered carbocycle or heterocycle), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), - N(R14)C(O)(C1-6alkylene)OR14, halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C1- 6alkyl, wherein any C1-6alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R20. 140. The compound of claim 139, wherein each Re and/or Rf is independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1- 6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl that is unsubstituted or substituted with one or more R20. 141. The compound of claim 140, wherein each Re and Rf is hydrogen. 142. The compound of any one of claims 58-86, wherein the compound is a compound according to Formula IIIS: or a salt (e.g., pharmaceutically acceptable salt) wherein: Q1 is selected from NRg1, O, SRh 2, and CRiRj; Q2 is selected from NRg2, O, SRh 2, and CRiRj; Rg1 and Rg2, when present, are independently selected from hydrogen, -C(O)(C1-6alkyl), and C1- 6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; each Rh is absent or, when present, is independently selected from =O, =N(R14), and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; each Ri and Rj, when present, are independently selected from hydrogen, deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), - C(O)N(R14)2, -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; and each Re1, Re2, Re3, and Re4 are independently selected from hydrogen, deuterium, -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), - C(O)N(R14)2, -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, wherein (i) an Re2 and an Re3 optionally join together to form a 5-6 membered ring; or (ii) when Q2 is NRg2, Rg2 and an Re3, together with the atoms to which they are attached, optionally join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R11, wherein each R11 is independently selected from deuterium, -OR12, =O, =N(R14), -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, - S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 143. The compound of claim 142, wherein Q1 and Q2 are each CRiRj. 144. The compound of claim 143, wherein at least one Re1, Re2, Re3, or Re4 is selected from -OR12, =O, =N(R14), -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -C(O)N(R14)2, - S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 145. The compound of claim 144, wherein each Re1, Re2, Re3, and Re4 is hydrogen. 146. The compound of claim 143, wherein an Re2 and an Re3 join together to form a 5-6 membered ring. 147. The compound of claim 142, wherein Q1 is CRiRj and Q2 is NRg2. 148. The compound of claim 147, wherein Rg2 and an Re3, together with the atoms to which they are attached, join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R11.

149. The compound of claim 147, wherein Rg2 is selected from hydrogen, -C(O)(C1-6alkyl), and C1- 6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 150. The compound of claim 142, wherein Q2 is CRiRj and Q1 is NRg1. 151. The compound of claim 150, wherein Rg1 is selected from hydrogen, -C(O)(C1-6alkyl), and C1- 6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 152. The compound of claim 150 or 151, wherein each Re1, Re2, Re3, and Re4 is hydrogen. 153. The compound of claim 142, wherein (i) Q1 is CRiRj and Q2 is O or (ii) Q2 is CRiRj and Q1 is O. 154. The compound of claim 153, wherein each Re1, Re2, Re3, and Re4 is hydrogen. 155. The compound of claim 153, wherein an Re2 and an Re3 join together to form a 5-6 membered ring. 156. The compound of claim 142, wherein (i) Q1 is CRiRj and Q2 is SRh 2 or (ii) Q2 is CRiRj and Q1 is SRh 2. 157. The compound of claim 156, wherein each Re1, Re2, Re3, and Re4 is hydrogen. 158. The compound of claim 156, wherein an Re2 and an Re3 join together to form a 5-6 membered ring. 159. The compound of any one of claims 156-158, wherein each Rh is =O. 160. The compound of any one of claims 142-159, wherein each Ri and Rj are hydrogen. 161. The compound of claim 142, wherein (i) NRg1 and Q2 is SRh 2 or (ii) NRg2 and Q1 is SRh 2. 162. The compound of claim 161, wherein each Re1, Re2, Re3, and Re4 is hydrogen. 163. The compound of claim 161, wherein an Re2 and an Re3 join together to form a 5-6 membered ring. 164. The compound of any one of claims 161-163, wherein each Rh is =O. 165. The compound of any one of claims 59-86, wherein the compound is a compound according to Formula IIIT: or a salt (e.g., pharmaceutically acceptable salt) wherein: dashed lines represent single or double bonds, such that the ring containing Q1, Q2, Q3, and Q4 is aromatic; Q1, Q2, Q3, and Q4 are independently selected from C, N, O, and S wherein at least one of Q1, Q2, Q3, and Q4 is N; each Re and Rf is independently selected from R11 and hydrogen; and each Rg is absent or is independently selected from R11 and hydrogen. 166. The compound of claim 165, wherein Q1 is C. 167. The compound of claim 166, wherein Q2 is C, Q3 is N, and Q4 is N. 168. The compound of claim 165, wherein Q1 is N. 169. The compound of claim 168, wherein Q2 is N, and Q3 and Q4 are C. 170. The compound of claim 168, wherein Q2 and Q3 are N, and Q4 is C. 171. The compound of claim 168, wherein Q3 and Q4 are N, and Q2 is C. 172. The compound of claim 168, wherein Q2 and Q4 are N, and Q3 is C. 173. The compound of claim 165, wherein , has a structure selected from 174. The compound of any one of claims 165-173, wherein each Rg is hydrogen or is absent. 175. The compound of any one of claims 58-174, wherein R6 is a bicyclic heteroaryl that is substituted with one or more R15.

176. The compound of claim 175, wherein R6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 177. The compound of claim 175 or 176, wherein R6 is selected from: any of which is substituted with one or more R15. 178. The compound of any one of claims 175-177, wherein R6 is selected from: , , ,

179. The compound of any one of claims 175-178, wherein R6 is selected from: , , 180. The compound of any one of claims 58-174, wherein R6 is a monocyclic heteroaryl that is substituted with one or more R15. 181. The compound of claim 180, wherein R6 is a pyridine substituted with one or more R15. 182. The compound of claim 181, wherein R6 has the structure .  183. The compound of any one of claims 58-182, wherein R1 is selected from -OR8. 184. The compound of claim 183, wherein R1 is selected from: , wherein Ra1, Ra2, Rb1, and Rb2 are each independently selected from deuterium, halogen, C1-6alkyl, -OR12, and H, wherein Ra2 and Rb2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R13. 185. The compound of claim 184, wherein R1 is selected from: 186. Rb are each independently selected from halogen, C1-6alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13. 187. The compound of claim 186, wherein R1 is selected from: 188. The compound of claim 183, wherein R1 is selected from: wherein each Ra and Rb is independently selected from halogen, C1-6 alkyl, -OR12, and H; and Rc is selected from C1-6 alkyl, wherein an Ra and Rb or Rc optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13.

189. 190. The compound of any one of claims 58-182, wherein R1 is selected from 191. The compound of any one of claims 58-190, wherein each R11 is independently selected from - OR12, =O, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OR14, -C(O)(C1-6alkyl), -S(O)2(C1-6alkyl), -N(R14)C(O)(C1-6alkyl), -N(R14)C(O)(C1-6alkylene)OR14, halogen, and C1-6alkyl that is unsubstituted or substituted with one or more R20. 192. The compound of any one of claims 58-191, wherein R5 is a halogen (e.g., F or Cl). 193. The compound of any one of claims 58-191, wherein R5 is selected from C1-6alkyl that is unsubstituted or substituted with one or more R13. 194. The compound of claim 193, wherein R5 is selected from C1-6alkyl that is substituted with one or more halogens or -CN. 195. The compound of claim 194, wherein R5 is selected from -CF2H, -CF3, -CH2CN, and -CH2CH3. 196. The compound of claim 195, wherein R5 is –CF3. 197. The compound of any one of claims 58-196, wherein the compound is a not a compound included in Table 2. 

198. A compound represented by Formula I: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 is selected from H and C1-6alkyl, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13; R3 is selected from a 3-11 membered carbocycle that is unsubstituted or substituted with one or more R10; R4 is H; R5 is selected from H, halogen, -CN, -OR12, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a bicyclic heteroaryl substituted with one or more R15; R7 is selected from halogen, -CN, and H; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R10 is independently selected from -OR12, -C(O)(C1-6alkylene)CN, -C(O)(C1-6alkylene)OH, - C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1- 6alkyl is unsubstituted or substituted with one or more R20; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, -CN, -NH2, -NHC1-6alkyl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, a 3-6 membered carbocycle, -OR12, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13. 199. The compound of claim 198, wherein the compound is of Formula I-a: or a salt (e.g., a pharmaceutically acceptable salt) thereof. 200. The compound of claim 198 or 199, wherein R3 is a 3-6 membered carbocycle that is unsubstituted or is substituted with one or more R10. 201. The compound of claim 200, wherein R3 is a 3-6 membered carbocycle that is substituted with 1- 4 R10. 202. The compound of claim 200, wherein R3 is a cyclopropane that is substituted with 0-4 R10. 203. The compound of claim 200, wherein R3 is a cyclobutane that is substituted with 0-4 R10. 204. The compound of claim 200, wherein R3 is a cyclopentane that is substituted with 0-4 R10. 205. The compound of claim 200, wherein R3 is a cyclohexane that is substituted with 0-4 R10. 206. The compound of any one of claims 198-200, wherein R3 is a spirocycle that is unsubstituted or is substituted with one or more R10. 207. The compound of any one of claims 198-200, wherein R3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R10. 208. The compound of any one of claims 198-207, wherein R3 is substituted with one or more R10, wherein at least one R10 is selected from -OR12 and a C1-6alkyl substituted with -OH. 209. The compound of any one of claims 198-208, wherein R3 is substituted with one or more R10, wherein at least one R10 is an unsubstituted C1-6alkyl. 210. The compound of any one of claims 198-209, wherein the compound is a compound according to Formula IA, IB, IC, ID, IE, or IF:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Rd is independently selected from H, -OR12, -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OH, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 211. The compound of claim 210, wherein at least one Rd is selected from -OR12, -C(O)(C1- 6alkylene)CN, -C(O)(C1-6alkylene)OH, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 212. The compound of claim 211, wherein at least one Rd is selected from -OR12 and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 213. The compound of any one of claims 198-212, wherein R6 is selected from: , wherein: X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 214. The compound of any one of claims 198-213, wherein R6 is selected from:

216. 217. The compound of any one of claims 198-216, wherein the compound is a compound according to Formula IA1, IB1, IC1, ID1, IE1, or IF1:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Rd is independently selected from H, -OR12, -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OH, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 218. The compound of claim 217, wherein X is C-CN, Y is S, and R23 is -N(R12)2. 219. The compound of claim 217 or 218, wherein one or more of R24, R25, and R26 is a halogen (e.g., F). 220. The compound of any one of claims 198-219, wherein R1 is selected from -OR8. 221. The compound of claim 220, wherein R1 is selected from: , wherein Ra and Rb are each independently selected from halogen, C1-6alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13. 222. The compound of claim 221, wherein R1 is selected from: 223. The compound of claim 220, wherein R1 is selected from: wherein each Ra and Rb is independently selected from halogen, C1-6 alkyl, -OR12, and H; and Rc is selected from C1-6 alkyl, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13, and wherein an Ra and Rb or Rc optionally join together to form a 3-6 membered carbocycle or heterocycle. 224. , 225. The compound of any one of claims 198-219, wherein R1 is selected from 226. The compound of any one of claims 198-225, wherein the compound is a compound according to Formula IA2, IB2, IC2, ID2, IE2, or IF2:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: Ra and Rb are each independently selected from halogen, C1-6 alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13; each Rd is independently selected from H, -OR12, -C(O)(C1-6alkylene)CN, -C(O)(C1- 6alkylene)OH, -C(O)(C1-6alkyl), -C(O)N(R14)2, -S(O)2(C1-6alkyl), halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 227. The compound of claim 226, wherein Ra is a halogen (e.g., F). 228. The compound of claim 226 or 227, wherein Rb is H. 229. The compound of any one of claims 226-228, wherein X is C-CN, Y is S, and R23 is -N(R12)2. 230. The compound of any one of claims 226-229, wherein one or more of R24, R25, and R26 is a halogen (e.g., F). 231. The compound of any one of claims 198-230, wherein R2 is H. 232. The compound of any one of claims 198-230, wherein R2 is selected from C1-6alkyl that is unsubstituted or is substituted with one or more R13. 233. The compound of claim 232, wherein R2 is selected from C1-2alkyl. 234. The compound of any one of claims 198-223, wherein R5 is H. 235. The compound of any one of claims 198-223, wherein R5 is a halogen (e.g., F or Cl). 236. The compound of any one of claims 198-223, wherein R5 is selected from C1-6alkyl that is unsubstituted or substituted with one or more R13. 237. The compound of claim 236, wherein R5 is selected from C1-6alkyl that is substituted with one or more halogens or -CN. 238. The compound of claim 237, wherein R5 is selected from -CF2H, -CF3, -CH2CN, and -CH2CH3. 239. The compound of claim 238, wherein R5 is -CF3. 240. The compound of any one of claims 198-239, wherein R7 is H. 241. The compound of any one of claims 198-239, wherein R7 is a halogen (e.g., F or Cl). 242. The compound of any one of claims 198-239, wherein R7 is -CN. 243. A compound represented by Formula IV: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 is selected from H, C1-6alkyl, and a 3-6 membered carbocycle, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13; R3 is selected from C1-6alkyl that is unsubstituted or is substituted with one or more R10; R4 is H; R5 is selected from H, halogen, -CN, -OR12, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a bicyclic heteroaryl substituted with one or more R15; R7 is selected from halogen, -CN, and H; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R10 is independently selected from -OR14, =O, -CN, -N(R14)2, a 3-6 membered carbocycle, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, phenyl, -S(O)2(C1-6alkyl), - N(R14)C(O)(C1-6alkyl), C1-6alkyl, and halogen, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, any 3-6 membered carbocycle is unsubstituted or substituted with one or more R12, and any 3-6 membered heterocycle or 5-6 membered heteroaryl is unsubstituted or substituted with one or more =O, R12, or R13; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, -CN, -NH2, -NHC1-6alkyl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from halogen, C1-6 alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13, and wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle. 244. The compound of claim 243, wherein the compound is of Formula IV-a:

or a salt (e.g., pharmaceutically acceptable salt) thereof. 245. The compound of claim 243 or 244, wherein the compound is a compound according to Formula IVA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each Ri and Rh are independently selected from H and R10. 246. The compound of claim 245, wherein each Ri and Rh are independently selected from H and C1- 6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 247. The compound of claim 245 or 246, wherein R14 is H. 248. The compound of any one of claims 243-247, wherein R6 is selected from: , wherein: X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 249. The compound of any one of claims 243-248, wherein R6 is selected from:

any of which is substituted with one or more R15. 250. The compound of any one of claims 243-249, wherein R6 is selected from: , .

251. 252. The compound of claim 243, wherein the compound is a compound according to Formula IVB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, -OR12, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 253. The compound of any one of claims 243-252, wherein R1 is selected from -OR8. 254. The compound of claim 253, wherein R1 is selected from: , wherein Ra and Rb are each independently selected from halogen, C1-6alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13. 255. The compound of claim 254, wherein R1 is selected from:

256. wherein each Ra and Rb is independently selected from halogen, C1-6 alkyl, -OR12, and H; and Rc is selected from C1-6 alkyl, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13, and wherein an Ra and Rb or Rc optionally join together to form a 3-6 membered carbocycle or heterocycle. 257. , 258. The compound of any one of claims 243-252, wherein R1 is selected from

259. The compound of any one of claims 243-258, wherein the compound is a compound according to Formula IVC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: Ra and Rb are each independently selected from halogen, C1-6 alkyl, -OR12, and H, wherein any C1-6alkyl is unsubstituted or is substituted with one or more R13; X is selected from N and C-CN; Y is selected from O and S; R23 is selected from -N(R12)2, C1-6alkyl, and C1-6alkyl-N(R14)2, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; and R24, R25, and R26 are independently selected from H, deuterium, halogen, -OR12, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13. 260. The compound of claim 259, wherein Ra is a halogen (e.g., F). 261. The compound of claim 259 or 260, wherein Rb is H. 262. The compound of any one of claims 252-261, wherein X is C-CN, Y is S, and R23 is selected from -N(R12)2. 263. The compound of any one of claims 252-262, wherein at least one of R24, R25, and R26 is a halogen (e.g., F). 264. The compound of any one of claims 243, 244, and 252-263, wherein R3 is selected from C1-3alkyl that is unsubstituted or is substituted with one or more R10. 265. The compound of claim 264, wherein each R10 is independently selected from -OR14, =O, -CN, - NH(R16), -N(R16)2, a 3-6 membered carbocycle, C1-6alkyl, and halogen, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20, wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R12, and wherein each R16 is independently selected from C1-6alkyl and C2-6alkenyl. 266. The compound of claim 265, wherein each R10 is independently selected from -OR14, -CN, C1- 6alkyl, and halogen, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20. 267. The compound of claim 266, wherein each R10 is independently selected from halogen. 268. The compound of claim 264, wherein R3 is selected from C1-3alkyl that is unsubstituted.

269. The compound of any one of claims 243, 244, and 252-263, wherein the moiety is

more R10. 270. The compound of any one of claims 243-269, wherein R2 is H. 271. The compound of any one of claims 243-269, wherein R2 is selected from C1-6alkyl that is unsubstituted or is substituted with one or more R13. 272. The compound of claim 271, wherein R2 is selected from C1-2alkyl that is unsubstituted. 273. The compound of any one of claims 243-269, wherein R2 is a 3-6 membered carbocycle. 274. The compound of any one of claims 243-273, wherein R5 is H. 275. The compound of any one of claims 243-273, wherein R5 is a halogen (e.g., F or Cl). 276. The compound of any one of claims 243-273, wherein R5 is selected from C1-6alkyl that is unsubstituted or substituted with one or more R13. 277. The compound of claim 276, wherein R5 is selected from C1-6alkyl that is substituted with one or more halogens or -CN. 278. The compound of claim 277, wherein R5 is selected from -CF2H, -CF3, -CH2CN, and -CH2CH3. 279. The compound of claim 278, wherein R5 is –CF3. 280. The compound of any one of claims 243-279, wherein R7 is H. 281. The compound of any one of claims 243-279, wherein R7 is a halogen (e.g., F or Cl). 282. The compound of any one of claims 243-279, wherein R7 is -CN. 283. The compound of any one of claims 243-282, wherein the compound is a not a compound included in Table 3.  284. A compound represented by Formula V: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from Rm is selected from hydrogen and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R4 is H; R5 is selected from halogen and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R15; R7 is selected from halogen; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; and Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, a 3-6 membered carbocycle, -OR12, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13. 285. A compound represented by Formula VI: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R1 is selected from R2 is selected from H, C1-6 alkyl, and a 3-6 membered carbocycle, wherein any C1-6 alkyl is unsubstituted or is substituted with one or more R13; R4 is H; R5 is selected from H, halogen, -CN, -OR12, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; R6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R15; R7 is selected from H and halogen; R8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more Ra or Rb, and wherein an alkyl moiety of any alkylheterocycle is selected from C1-6alkyl; each R12 is independently selected from C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl or C2-6 alkenyl is unsubstituted or substituted with one or more R13; each R13 is independently selected from -OR14, -CN, -N(R14)2, and halogen; each R14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C1-6 alkyl, C2-6 alkenyl, and H, wherein any C1-6alkyl is optionally deuterated; each R15 is independently selected from deuterium, halogen, -N(R12)2, -CN, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R13; each R20 is independently selected from -OH, -OC1-6alkyl, =O, -CN, -NH2, -NHC1-6alkyl, - C(O)(C1-6alkyl), a 3-6 membered carbocycle, a 5-6 membered aryl, and halogen; R27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R28; each R28 is independently selected from C1-6alkyl and halogen; Ra and Rb are each independently selected from deuterium, halogen, C1-6 alkyl, -OR12, a 3-6 membered carbocycle, and H, wherein an Ra and Rb optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C1-6alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R13; each Rd is independently selected from H, halogen, and C1-6alkyl, wherein any C1-6alkyl is unsubstituted or substituted with one or more R20; Re is selected from Rf is selected from H, halogen, and C1-6alkyl; Rg and Rh are independently selected from H and C1-6alkyl; and Rj is selected from C1-6alkyl, provided that Re is not . 286. The compound of claim 285, wherein the compound is a not a compound included in Table 4. 287. A compound shown in Table 5, or a salt (e.g., pharmaceutically acceptable salt) thereof. 288. A compound shown in Table 6, or a salt (e.g., pharmaceutically acceptable salt) thereof. 289. A compound shown in Table 7, or a salt (e.g., pharmaceutically acceptable salt) thereof. 290. A compound shown in Table 8, or a salt (e.g., pharmaceutically acceptable salt) thereof. 291. A compound shown in Table 9, or a salt (e.g., pharmaceutically acceptable salt) thereof. 292. A compound shown in Table 10, or a salt (e.g., pharmaceutically acceptable salt) thereof. 293. A pharmaceutical composition comprising a compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof, and a pharmaceutically acceptable excipient. 294. A compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use as a medicament. 295. The compound of claim 294, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. 296. The compound of claim 295, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of wild-type KRAS. 297. The compound of claim 295, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. 298. The compound of any one of claims 294-296, wherein the medicament is useful in the prevention or treatment of a cancer. 299. The compound of claim 298, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 300. A compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use in the treatment of a disease, disorder, or condition.

301. The compound of claim 300, wherein the disease, disorder, or condition is a cancer. 302. The compound of claim 301, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 303. The compound of any one of claims 300-302, wherein the compound is used in the treatment of a disease, disorder, or condition in a subject in need thereof. 304. A compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use in the manufacture of a medicament. 305. The compound of claim 304, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. 306. The compound of claim 305, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of wild-type KRAS. 307. The compound of claim 305, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. 308. The compound of any one of claims 304-307, wherein the medicament is useful in the treatment of a cancer. 309. The compound of claim 308, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 310. A method, comprising administering a therapeutically effective amount of a compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof, to a subject in need thereof. 311. The method of claim 310, wherein the subject has a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. 312. The method of claim 311, wherein the disease, disorder, or condition is ameliorated by the inhibition of wild-type KRAS. 313. The method of claim 311, wherein the disease, disorder, or condition is ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. 314. The method of any one of claims 310-313, wherein the subject has a cancer. 315. The method of claim 314, wherein the subject was previously diagnosed with the cancer. 316. The method of claim 314, wherein the subject has previously undergone a treatment regimen for the cancer. 317. The method of claim 315 or 316, wherein the subject has previously entered remission from the cancer.

318. The method of any one of claims 314-317, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 319. The method of any one of claims 310-318, wherein the compound, or the salt thereof, is administered in combination with an additional therapeutic agent. 320. The use of a compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof, for the manufacture of a medicament for the treatment of a cancer. 321. The use of claim 320, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 322. A method, comprising contacting a KRAS protein with a compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof. 323. The method of claim 322, wherein contacting the KRAS protein with the compound modulates KRAS. 324. The method of claim 322 or 323, wherein the KRAS protein has a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation. 325. The method of claim 322 or 323, wherein the KRAS protein is a wild-type KRAS protein. 326. The method of any one of claims 322-325, wherein the KRAS protein is in an active (GTP- bound) state. 327. The method of any one of claims 322-325, wherein the KRAS protein is in an inactive (GDP- bound) state. 328. The method of any one of claims 322-327, wherein the KRAS protein is located within a cell. 329. The method of claim 328, wherein the cell is located within a subject. 330. The method of claim 329, wherein the subject is a human. 331. The method of claim 329 or 330, wherein the subject has a cancer. 332. The method of claim 331, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 333. A method of inhibiting the function of a wild-type KRAS protein or a KRAS protein having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, comprising contacting the KRAS protein with a compound of any one of claims 1-292, or a salt (e.g., pharmaceutically acceptable salt) thereof. 334. The method of claim 333, wherein the KRAS protein is a wild-type KRAS protein. 335. The method of claim 333, wherein the KRAS protein has a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation. 336. The method of claim 335, wherein the KRAS protein has a G12D, G12V, or G12R mutation. 337. The method of any one of claims 333-336, wherein the KRAS protein is in an active (GTP- bound) state.

338. The method of any one of claims 333-336, wherein the KRAS protein is in an inactive (GDP- bound) state. 339. The method of any one of claims 333-338, wherein the KRAS protein is located within a cell. 340. The method of claim 339, wherein the cell is located within a subject. 341. The method of claim 340, wherein the subject is a human. 342. The method of claim 340 or 341, wherein the subject has a cancer. 343. The method of claim 342, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. 344. A compound capable of inhibiting a wild-type KRAS protein or a KRAS protein having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation in both its active (GTP-bound) and inactive (GDP-bound) state. 345. The compound of claim 344, wherein the compound: (i) has IC50 ≤0.1 µM, 0.1 µM< IC50 ≤1 µM, 1 µM< IC50 ≤10 µM, or 10 µM< IC50 in the assay of Biological Example 1 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS G12R (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS G12V (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS WT (amino acids 1- 169) GppNHp/ RAF1 RBD-3xFLAG (52-151); and/or 75 nM Avi-RAF1 RBD- 3xFLAG); and/or (ii) has IC50 ≤0.1 µM, 0.1 µM< IC50 ≤1 µM, or IC50>1 µM in the assay of Biological Example 2 or 4 (e.g., cell-based pERK HTRF assay in GP2d (G12D) or SW620 (G12V) cell); and/or (iii) has IC50 ≤0.1 µM, 0.1 µM< IC50 ≤1 µM, 1 µM< IC50 ≤10 µM, or 10 µM< IC50 in the assay of Biological Example 3 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (2-169) GTP/ RAF1 RBD-3xFLAG (51-131); 50 nM Avi-KRAS G12C (2-169) GTP/ RAF1 RBD- 3xFLAG (51-131); 50 nM Avi-KRAS G12V (2-169) GTP/ RAF1 RBD-3xFLAG (51- 131); 50 nM Avi-KRAS WT (2-169) GTP/ RAF1 RBD-3xFLAG (51-131); and/or 75 nM 3xFLAG-RAF1 RBD (51-131)-Avi); and/or (iv) has IC50 ≤0.1 µM, 0.1 µM< IC50 ≤1 µM, or IC50>1 µM in the assay of Biological Example 5 (e.g., cell-based pERK HTRF assay in AsPC-1, SW1900, HPAC, Capan-2, RKN, H358, HCT116, KP-2, H1573, A549, MKN1, or HT1080 cells); and/or (v) has IC50 ≤0.1 µM, 0.1 µM< IC50 ≤1 µM, or IC50>1 µM in the assay of Biological Example 6 (e.g., 3D cell viability assay in AsPC-1, SW1900, HPAC, Capan-2, RKN, H358, HCT116, KP-2, H1573, A549, MKN1, or HT1080 cells). 346. The compound of claim 345, wherein the compound: (i) has IC50 ≤0.1 µM or 0.1 µM< IC50 ≤1 µM in the assay of Biological Example 1 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS G12R (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS G12V (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS WT (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); and/or 75 nM Avi-RAF1 RBD-3xFLAG; and/or (ii) has IC50 ≤0.1 µM or 0.1 µM< IC50 ≤1 µM in the assay of Biological Example 2 or 4(e.g., cell-based pERK HTRF assay in GP2d (G12D) and SW620 (G12V) cell); and/or (iii) has IC50 ≤0.1 µM or 0.1 µM< IC50 ≤1 µM in the assay of Biological Example 3 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (2-169) GTP/ RAF1 RBD-3xFLAG (51-131); 50 nM Avi-KRAS G12C (2-169) GTP/ RAF1 RBD-3xFLAG (51-131); 50 nM Avi-KRAS G12V (2-169) GTP/ RAF1 RBD-3xFLAG (51-131); 50 nM Avi-KRAS WT (2-169) GTP/ RAF1 RBD-3xFLAG (51-131); and/or 75 nM 3xFLAG-RAF1 RBD (51-131)-Avi); and/or (iv) has IC50 ≤0.1 µM or 0.1 µM< IC50 ≤1 µM in the assay of Biological Example 5 (e.g., cell-based pERK HTRF assay in AsPC-1, SW1900, HPAC, Capan-2, RKN, H358, HCT116, KP-2, H1573, A549, MKN1, or HT1080 cells); and/or (v) has IC50 ≤0.1 µM or 0.1 µM< IC50 ≤1 µM in the assay of Biological Example 6 (e.g., 3D cell viability assay in AsPC-1, SW1900, HPAC, Capan-2, RKN, H358, HCT116, KP-2, H1573, A549, MKN1, or HT1080 cells). 347. The compound of any one of claims 344-346, wherein the compound is capable of irreversibly binding the KRAS protein. 348. The compound of any one of claims 344-346, wherein the compound is capable of reversibly binding the KRAS protein. 349. The compound of any one of claims 344-348, wherein the compound is a compound according to any one of claims 1-292.

Description:
COMPOSITIONS AND METHODS FOR INHIBITION OF RAS STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT [0001] This invention was made with government support under (1) Contract No.: 75N91019D00024 awarded by the National Institutes of Health and (2) Contract No. DE-AC52-07NA27344 awarded by the United States Department of Energy. The government has certain rights in the invention. RELATED APPLICATIONS [0002] This application claims priority to and benefit of U.S. Application No.63/395,699, filed August 5, 2022, U.S. Application No. 63/386,285, filed December 6, 2022, and U.S. Application No. 63/496,873, filed April 18, 2023, the entire contents of each of which are hereby incorporated by reference. BACKGROUND [0003] RAS protein functions as a molecular switch, cycling between inactive (“GDP-bound”) and active (“GTP-bound”) states. RAS signaling occurs through engagement with effector proteins that adapt the signaling cascades regulating tumor cell survival and proliferation. Aberrant activation of RAS by oncogenic mutations results in increased GTP-bound KRAS and constitutive downstream signaling. [0004] RAS is the most frequently mutated oncogene. Activating mutations in KRAS occur in over 90% of pancreatic tumors. Mutated KRAS is also observed at high frequency in other common tumors, including colorectal cancer (∼44%) and non–small cell lung cancer (NSCLC; ∼20-30%). Cancer-associated mutations in KRAS cluster in three hotspots (G12, G13, and Q61), with a majority (77%) of mutations causing single amino acid substitutions at G12. The KRAS missense mutation G12D is the most predominant variant in human malignancies (35%), followed by G12V (29%). Besides G12, the hotspots G13 and Q61 show mutation rates of 10% and 6% respectively. [0005] The development of small molecule KRAS inhibitors has proven to be a challenge. Recent clinical development of covalent KRAS G12C inhibitors indicates potential of targeting the KRAS oncogenic protein directly. Results from clinical trials with the two covalent inhibitors, AMG510 (sotorasib) and MRTX849 (adagrasib), have been promising. These inhibitors demonstrated clinical activity primarily in NSCLC, where the KRAS G12C mutation frequency is highest. Unfortunately, they appeared less effective in KRAS G12C colorectal cancers. Both compounds only target the inactive (GDP-bound) form of KRAS G12C, and a lack of activity against active (GTP-bound) KRAS G12C may contribute to development of drug resistance. Moreover, these covalent inhibitors are limited to the specific G12C mutant that accounts for approximately 13% of all KRAS-driven cancers, leaving a large population of non-G12C KRAS cancers still undruggable. Therefore, KRAS therapeutics that target additional KRAS alterations or combinations thereof are an unmet clinical need. Pan-KRAS inhibitors hold promise for impact across the majority of KRAS mutant alleles, including the most prevalent G12D and G12V, or KRAS wildtype-amplified cancers. [0006] KRAS is essential for mouse development, whereas NRAS and HRAS are dispensable. This requirement for KRAS creates toxicity concerns when targeting the wild-type KRAS protein. However, when KRAS is replaced with HRAS, mice are viable, which reduces toxicity concerns and suggests that in contrast to the pan-RAS inhibitors that could pose toxicity issues, KRAS isoform-specific inhibitors should be tolerated. If so, additional advantages of pan-KRAS inhibitors could come from targeting cancers with acquired resistance to KRAS G12C inhibitors. Recent reports provide insights into mechanisms of resistance to the KRAS G12C inhibitors in the clinic, suggesting restoration of RAS/MAPK as a driver of the resistance. Acquisition of a diverse set of mutations in response to KRAS G12C inhibitors in addition to activation of the KRAS wildtype allele through upstream RTK signaling has been shown. It is possible that direct pan-KRAS agents may suppress these events. Accordingly, there remains a need for allele- specific and pan-KRAS inhibitors that could be used to treat KRAS-driven cancers regardless of mutation status. SUMMARY [0007] The present disclosure provides compounds, as well as compositions and kits comprising the same, and methods of using the same in the treatment of diseases and disorders such as cancers. The present disclosure provides compounds that may be capable of inhibiting one or more mutant forms of KRAS, such as KRAS having a G12D, G12V, G12C, G12S, G12A, G12R, Q61H, or G13D mutation, or wild-type KRAS. Such compounds may be considered pan-KRAS inhibitors. In some embodiments, the compounds provided herein may be capable of targeting both active GTP-bound protein and inactive GDP-bound protein, which inhibitors may provide therapeutic advantages over compounds capable of targeting only the inactive GDP-bound protein. In some embodiments, compounds provided herein have inhibitory activity against a KRAS protein comprising a glycine to aspartic acid, valine, cysteine, serine, alanine, or arginine mutation at codon 12 (i.e., a G12D, G12V, G12C, G12S, G12A, or G12R mutation); or a glycine to aspartic acid mutation at codon 13 (e.g., a G13D mutation); or a glutamine to histidine mutation at codon 61 (e.g., a Q61H mutation) in both its active and inactive conformations. In some embodiments, compounds provided herein have inhibitory activity against wild-type KRAS. In some embodiments, compounds provided herein are useful in the treatment of cancers, such as cancers characterized by KRAS proteins having a mutation at codon 12, such as a G12D, G12V, G12C, G12S, G12A, or G12R mutation; or a mutation at codon 13, such as a G13D mutation; or a mutation at codon 61, such as a Q61H mutation, or cancers that may benefit from inhibiton of wild-type KRAS. [0008] In an aspect, the present disclosure provides compositions comprising compounds represented by Formula X: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as provided herein. In some embodiments, the compound is a compound according to any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a provided herein, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, can modulate (e.g., inhibit) the activity of a KRAS protein, such as a KRAS protein having a mutation at codon 12, such as a G12D, G12V, G12C, G12S, G12A, or G12R mutation; a KRAS protein having a mutation at codon 13, such as G13D; a KRAS protein having a mutation at codon 61, such as Q61H; or a wild-type KRAS. In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of interacting with a KRAS protein comprising a glycine to aspartic acid, valine, cysteine, serine, alanine, or arginine mutation at codon 12 (i.e., a G12D, G12V, G12C, G12S, G12A, or G12R mutation) or a glycine to aspartic acid mutation at codon 13 (e.g., a G13D mutation) or a glutamine to histidine mutation at codon 61 (e.g., a Q61H mutation) in both its active and inactive conformations. In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, has inhibitory activity against wild-type KRAS. In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding a KRAS protein in an active (“GTP- bound”) conformation. In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding a KRAS protein in an inactive (“GDP- bound”) conformation. In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding a KRAS protein in both its active (“GTP- bound”) and inactive (“GDP-bound”) conformations. [0009] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound provided herein (e.g., a compound represented by one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a, or any other formula set forth herein), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, together with a pharmaceutically acceptable carrier. [0010] In a further aspect, the present disclosure provides a method of inhibition of KRAS activity in a human or animal subject for the treatment of a disease such as cancer, including pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), colorectal cancer, endometrial endometrioid adenocarcinoma, rectal adenocarcinoma, gastric cancer, and lung cancer, using, e.g., a compound provided herein (e.g., a compound represented by one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III- a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a, or any other formula set forth herein), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising the same. [0011] In another aspect, the present disclosure provides a use of a compound provided herein (e.g., a compound represented by one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III- a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a, or any other formula set forth herein), or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, in the manufacture of a medicament for the treatment of a disease, disorder, or condition (e.g., a cancer) ameliorated, treated, inhibited, or reduced by inhibition of KRAS, including KRAS having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), KRAS having a mutation at codon 13 (e.g., a G13D mutation), KRAS having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS. In some embodiments, the disease, disorder, or condition is pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), colorectal cancer, or lung cancer. [0012] In a further aspect, the present disclosure provides a compound as provided herein (e.g., a compound represented by one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III- a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a, or any other formula set forth herein), or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, for use as a medicament. In some embodiments, the medicament is used in the treatment of a disease, disorder, or condition (e.g., a cancer). In some embodiments, the disease, disorder, or condition is pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), colorectal cancer, or lung cancer. DETAILED DESCRIPTION [0013] The present disclosure provides compounds (e.g., compounds of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), which compounds may possess useful KRAS inhibitory activity, and may be used in the treatment or prophylaxis of a disease, disorder, or condition in which KRAS plays an active role. In particular, certain compounds provided herein may possess useful inhibitory activity of a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein, which KRAS protein is in an active (GTP-bound) or inactive (GDP-bound) conformation. Certain compounds provided herein may be capable of inhibiting both active and inactive forms of KRAS. The present disclosure also provides pharmaceutical compositions comprising one or more compounds provided herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions. The present disclosure also provides methods for inhibiting KRAS, including a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein, which KRAS is in an active or inactive conformation. In an aspect, the present disclosure provides a method for treating a disorder mediated by KRAS including a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild- type KRAS protein in a subject in need of such treatment, which method comprises administering to the subject a therapeutically effective amount of a compound or composition provided herein. Also provided herein is the use of certain compounds provided herein in the manufacture of a medicament for the treatment of a disease, disorder, or condition ameliorated, treated, inhibited, or reduced by inhibition of KRAS, including a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein. In some embodiments, the disease, disorder, or condition is a cancer (e.g., as described herein). [0014] When ranges of values are disclosed, and the notation “from n 1 … to n 2 ” or “between n 1 … and n 2 ” is used, where n 1 and n 2 are the numbers, then unless otherwise specified, this notation is intended to include the numbers themselves and the range between them. This range may be integral or continuous between and including the end values. By way of example, the range “from 2 to 6 carbons” is intended to include two, three, four, five, and six carbons, since carbons come in integer units. Compare, by way of example, the range “from 1 to 3 µM (micromolar),” which is intended to include 1 µM, 3 µM, and everything in between to any number of significant figures (e.g., 1.255 µM, 2.1 µM, 2.9999 µM, etc.). [0015] “About,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass the recited value and the range which would be included by rounding up or down to that figure as well, taking into account significant figures. [0016] “Acyl,” as used herein, alone or in combination, refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety where the atom attached to the carbonyl is carbon. An “acetyl” group refers to a –C(O)CH 3 group. An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl. [0017] “Alkenyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms. The term “alkenylene” refers to a carbon-carbon double bond system attached at two or more positions such as ethenylene [(-CH=CH-), (- C::C-)]. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl and the like. Unless otherwise specified, the term “alkenyl” may include “alkenylene” groups. [0018] “Alkynyl” refers to either a straight chain or branched-chain hydrocarbon having at least 2 carbon atoms and at least one triple bond and having the number of carbon atoms indicated (i.e., C 2-6 means to two to six carbons). Alkynyl can include any number of carbons, such as C 2 , C 2-3 , C 2-4 , C 2-5 , C 2-6 , C 2-7 , C 2-8 , C 2-9 , C 2-10 , C 3 , C 3-4 , C 3-5 , C 3-6 , C 4 , C 4-5 , C 4-6 , C 5 , C 5-6 , and C 6 . Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, and 1,3,5-hexatriynyl. [0019] “Alkoxy,” as used herein, alone or in combination, refers to an alkyl ether radical, wherein the term alkyl is as described herein. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like. [0020] “Alkyl,” as used herein, alone or in combination, refers to a straight-chain or branched-chain alkyl radical containing from 1 to 20 carbon atoms (e.g., C 1-20 alkyl). In certain embodiments, said alkyl will comprise from 1 to 10 carbon atoms (e.g., C 1-10 alkyl). In further embodiments, said alkyl will comprise from 1 to 8 carbon atoms (e.g., C 1-8 alkyl). In further embodiments, said alkyl will comprise from 1 to 6 carbon atoms (e.g., C 1-6 alkyl). In further embodiments, said alkyl will comprise from 1 to 3 carbon atoms (e.g., C 1-3 alkyl). Alkyl groups are unsubstituted or substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl, and the like. The term “alkylene,” as used herein, alone or in combination, refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (-CH 2 -). Unless otherwise specified, the term “alkyl” may include “alkylene” groups. [0021] “Alkylamino,” as used herein, alone or in combination, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N- ethylmethylamino, and the like. [0022] “Alkylthio,” as used herein, alone or in combination, refers to an alkyl thioether (R–S–) radical wherein the term alkyl is as described herein and wherein the sulfur may be singly or doubly oxidized. Examples of suitable alkyl thioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n- butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like. [0023] “Amido” and “carbamoyl,” as used herein, alone or in combination, refer to an amino group as described herein attached to the parent molecular moiety through a carbonyl group, or vice versa. The “amido” group as used herein incudes “C-amido” and “N-amido” groups. The term “C-amido” as used herein, alone or in combination, refers to a -C(O)N(RR’) group with R and R’ as defined herein or as defined by the specifically enumerated “R” groups designated. In some embodiments, the “amido” group includes -C(O)NH 2 , C 1-4 alkylamido, and di(C 1-4 alkyl)amido. The term “C 1-4 alkylamido”, as used herein, refers to -C(O)NH(C 1-4 alkyl), wherein C 1-4 alkyl is as defined herein. The term “N-amido” as used herein, alone or in combination, refers to a RC(O)N(R’)- group, with R and R’ as defined herein or as defined by the specifically enumerated “R” groups designated. The term “acylamino” as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group. An example of an “acylamino” group is acetylamino (CH 3 C(O)NH-). [0024] “Amino,” as used herein, alone or in combination, refers to -NRR’, wherein R and R’ are independently selected from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be unsubstituted or substituted. Additionally, R and R’ may combine to form a heterocycloalkyl, which is unsubstituted or substituted. An “amino” group may be a primary amine (e.g., -NH 2 ), secondary or di-substituted amine (e.g., -NHR where R is not hydrogen), or tertiary or tri-substituted amine (e.g., -NRR’ where neither R nor R’ is hydrogen). [0025] “Aryl,” as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two, or three rings wherein such polycyclic ring systems are fused together. The term “aryl” embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl. An aryl moiety may include, for example, between 5 to 20 carbon atoms, such as between 5 to 12 carbon atoms, such as 5 or 6 carbon atoms. [0026] “Arylalkenyl” or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group. [0027] “Arylalkoxy” or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group. [0028] “Arylalkyl” or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group. [0029] “Aryloxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an oxy. [0030] “Carbamate,” as used herein, alone or in combination, refers to an ester of carbamic acid (- NHCOO-) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which is unsubstituted or substituted as defined herein. [0031] “O-carbamyl” as used herein, alone or in combination, refers to a -OC(O)NRR’ group, with R and R’ as defined herein. [0032] “N-carbamyl” as used herein, alone or in combination, refers to a ROC(O)NR’- group, with R and R’ as defined herein. [0033] “Carbonyl,” as used herein, when alone includes formyl [-C(O)H] and in combination is a -C(O)- group. [0034] “Carboxyl” or “carboxy,” as used herein, refers to -C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt. An “O-carboxy” group refers to a RC(O)O- group, where R is as defined herein. A “C-carboxy” group refers to a -C(O)OR groups where R is as defined herein. [0035] “Cyano,” as used herein, alone or in combination, refers to -CN. [0036] “Cycloalkyl,” or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic, or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is unsubstituted or substituted as defined herein. A carbocycle may comprise a bridged ring system and/or a spiro ring system (e.g., a system including two rings sharing a single carbon atom). The term “cycloalkenyl” refers to a cycloalkyl group having one or two double bonds. In certain embodiments, said cycloalkyl (or cycloalkenyl) will comprise from 5 to 7 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, tetrahydronapthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl, and the like. “Bicyclic” and “tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene and octahydronaphthalene, as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane. [0037] “Ester,” as used herein, alone or in combination, refers to a carboxy group bridging two moieties linked at carbon atoms. [0038] “Ether,” as used herein, alone or in combination, refers to an oxy group bridging two moieties linked at carbon atoms. [0039] “Halo,” or “halogen,” as used herein, alone or in combination, refers to fluorine, chlorine, bromine, or iodine. [0040] “Haloalkoxy,” as used herein, alone or in combination, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom. [0041] “Haloalkyl,” as used herein, alone or in combination, refers to an alkyl radical having the meaning as described herein wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have an iodo, bromo, chloro, or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. “Haloalkylene” refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (-CFH-), difluoromethylene (-CF 2 - ), chloromethylene (-CHCl-) and the like. [0042] “Heteroalkyl,” as used herein, alone or in combination, refers to a stable straight or branched hydrocarbon chain, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from N, O, and S, and wherein the N and S atoms may optionally be oxidized and the N heteroatom may optionally be quaternized. The heteroatom(s) may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, -CH 2 -NH-OCH 3 . [0043] “Heteroaryl,” as used herein, alone or in combination, refers to a 3- to 15-membered aromatic monocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which ring or ring system contains at least one atom selected from N, O, and S. In certain embodiments, said heteroaryl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said heteroaryl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said heteroaryl will comprise from 5 to 7 atoms. The term also embraces fused polycyclic groups wherein heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings. Examples of heteroaryl groups include pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like. [0044] “Heterocycloalkyl” and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently selected from nitrogen, oxygen, and sulfur. In some embodiments, a heterocycle comprises a heteroaryl ring fused to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) ring that optionally contains a heteroatom. In some embodiments, a heterocycle comprises an aryl ring fused to a saturated, partially unsaturated, or fully unsaturated (but nonaromatic) ring that contains a heteroatom. In some embodiments, a heterocycle comprises a carbocycle ring fused to a saturated, partially unsaturated, or fully unsaturated ring that contains a heteroatom. In some embodiments, a heterocycle comprises a first ring that is saturated, partially unsaturated, or fully unsaturated ring that contains a heteroatom and a second ring that is saturated, partially unsaturated, or fully unsaturated ring that optionally contains a heteroatom. In some embodiments, the first ring and the second ring share a single heteroatom. In certain embodiments, said heterocycloalkyl will comprise from 1 to 4 heteroatoms as ring members. In further embodiments, said heterocycloalkyl will comprise from 1 to 2 heteroatoms as ring members. In certain embodiments, said heterocycloalkyl will comprise from 3 to 8 ring members in each ring. In further embodiments, said heterocycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said heterocycloalkyl will comprise from 5 to 6 ring members in each ring. A heterocycle may comprise a bridged ring system and/or a spiro ring system (e.g., a system including two rings sharing a single atom, such as a single carbon atom). “Heterocycloalkyl” and “heterocycle” are intended to include sulfones, sulfoxides, N-oxides of tertiary nitrogen ring members, and carbocyclic fused and benzo fused ring systems; additionally, both terms also include systems where a heterocycle ring is fused to an aryl group, as defined herein, or an additional heterocycle group. Examples of heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine, 4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyrazine, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine, 1- methyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine, 3- oxa-9-azabicyclo[3.3.1]nonane, hexahydro-3,6-epiminofuro[3,2-b]furan, and the like. The heterocycle groups are unsubstituted or substituted unless specifically prohibited. [0045] “Hydrazinyl” as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., -N-N-. [0046] “Hydroxy,” as used herein, alone or in combination, refers to -OH. [0047] “Hydroxyalkyl,” as used herein, alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group. [0048] “Iminohydroxy,” as used herein, alone or in combination, refers to =N(OH) and =N-O-. [0049] “Lower amino,” as used herein, alone or in combination, refers to -NRR’, wherein R and R’ are independently selected from hydrogen and lower alkyl (e.g., C 1-4 alkyl), either of which is unsubstituted or substituted. [0050] “Mercaptyl” as used herein, alone or in combination, refers to an RS- group, where R is as defined herein. [0051] “Nitro,” as used herein, alone or in combination, refers to –NO 2 . [0052] “Oxy” or “oxa,” as used herein, alone or in combination, refer to –O–. [0053] “Oxo,” as used herein, alone or in combination, refers to =O. [0054] “Perhaloalkoxy” refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms. [0055] “Perhaloalkyl” as used herein, alone or in combination, refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms. [0056] “Ring,” or equivalently, “cycle,” as used herein, in reference to a chemical structure or portion thereof, means a group in which every atom is a member of a common cyclic structure. A ring can be saturated or unsaturated, including aromatic, unless otherwise provided, and may have between 3 and 9 members. If the ring is a heterocycle, it may contain between 1 and 4 heteroatoms or heteroatom- comprising groups selected from B, N, O, S, C(O), and S(O) m , wherein m is 0, 1, or 2. Unless specifically prohibited, a ring is unsubstituted or substituted. Two or more rings may be fused together (e.g., they may share a bond and two common atoms). Two or more rings may be linked together in a spiro arrangement such that only a single atom is shared between two rings. Two or more rings may also or alternatively be configured in a bridged arrangement such that three or more atoms are shared between two or more rings. [0057] “Sulfonate,” “sulfonic acid,” and “sulfonic,” as used herein, alone or in combination, refer to the – SO 3 H group and its anion as the sulfonic acid is used in salt formation. [0058] “Sulfanyl,” as used herein, alone or in combination, refers to –S–. [0059] “Sulfinyl,” as used herein, alone or in combination, refers to –S(O)–. [0060] “Sulfonyl,” as used herein, alone or in combination, refers to –S(O) 2 –. [0061] “N-sulfonamido” refers to a RS(=O) 2 NR’- group with R and R’ as defined herein. [0062] “S-sulfonamido” refers to a -S(=O) 2 NRR’, group, with R and R’ as defined herein. [0063] “Tautomer”, as use herein, alone or in combination, refers to one of two or more isomers that rapidly interconvert. Generally, this interconversion is sufficiently fast so that an individual tautomer is not isolated in the absence of another tautomer. The ratio of the amount of tautomers can be dependent on solvent composition, ionic strength, and pH, as well as other solution parameters. The ratio of the amount of tautomers can be different in a particular solution and in the microenvironment of a biomolecular binding site in said solution. Examples of tautomers that are well known in the art include keto / enol, enamine / imine, and lactam / lactim tautomers. Examples of tautomers that are well known in the art also include 2- hydroxypyridine / 2(1H)-pyridone and 2-aminopyridine / 2(1H)-iminopyridone tautomers. [0064] “Thia” and “thio,” as used herein, alone or in combination, refer to a –S– group or an ether wherein the oxygen is replaced with sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included in the definition of thia and thio. [0065] “Thiol,” as used herein, alone or in combination, refers to an –SH group. [0066] “Thiocarbonyl,” as used herein, when alone includes thioformyl –C(S)H and in combination is a – C(S)– group. [0067] “N-thiocarbamyl” refers to an ROC(S)NR’– group, with R and R’ as defined herein. [0068] “O-thiocarbamyl” refers to a –OC(S)NRR’ group, with R and R’ as defined herein. [0069] “Thiocyanato” refers to a –CNS group. [0070] Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule through an alkyl group. [0071] As described herein, groups may be substituted or unsubstituted (e.g., “optionally substituted”). Unless otherwise specified, any group may be substituted with one or more substituents, such as one or more substituents provided herein. Examples of substituents that may substitute a group include, but are not limited to, one or more substituents independently selected from the following groups or a particular designated set of groups, alone or in combination: alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), alkanoyl (e.g., C 1-20 alkanoyl, such as C 1- 10 alkanoyl, such as C 1-6 alkanoyl), heteroalkyl (e.g., a heteroalkyl moiety including 1-20 carbon atoms and 1-6 heteroatoms, such as a heteroalkyl moiety including 1-6 carbon atoms and 1-3 heteroatoms), haloalkyl (e.g., a halo-substituted C 1-20 alkyl, such as a halo-substituted C 1-10 alkyl, a halo-substituted C 1-6 alkyl), haloalkenyl (e.g., a halo-substituted C 2-20 alkenyl, such as a halo-substituted C 2-6 alkenyl), haloalkynyl (e.g., a halo-substituted C 2-20 alkynyl, such as a halo-substituted C 2-6 alkynyl), perhaloalkyl (e.g., C 1-20 perhaloalkyl, such as C 1-6 perhaloalkyl, such as C 1-3 perhaloalkyl), perhaloalkoxy (e.g., C 1-20 perhaloalkoxy, such as C 1-6 perhaloalkoxy), phenyl, aryl (e.g., C 5-20 aryl, such as C 5-10 aryl, such as C 5-6 aryl), aryloxy (e.g., C 5-20 aryloxy, such as C 5-10 aryloxy, such as C 5-6 aryloxy), alkoxy (e.g., C 1-20 alkoxy, such as C 1-10 alkoxy, such as C 1-6 alkoxy), haloalkoxy (e.g., C 1-20 haloalkoxy, such as C 1-10 haloalkoxy, such as C 1-6 haloalkoxy), oxo, acyloxy (e.g., an acyloxy group including 1-20 carbon atoms, such as 1-10 carbon atoms, such as 1-6 carbon atoms), carbonyl (e.g., C(O) or C=O), carboxyl (e.g., C(O)O), alkylcarbonyl (e.g., C 1-20 alkylcarbonyl, such as C 1-10 alkylcarbonyl, such as C 1-6 alkylcarbonyl, such as C 1-3 alkylcarbonyl), carboxyester (e.g., C(O)OR where R is, e.g., alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), any of which may be substituted by any group provided herein), carboxamido, cyano (e.g., CN), hydrogen, halogen (e.g., iodine, bromine, chlorine, or fluorine), hydroxy, amino (e.g., NR’R” where R’ and R” are independently, e.g., hydrogen, alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2- 6 alkynyl), any of which may be substituted by any group provided herein), alkylamino (e.g., NR’R” where R’ is alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl) and R” is, e.g., hydrogen, alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2- 20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), any of which may be substituted by any group provided herein), arylamino (e.g., NR’R” where R’ is aryl (e.g., C 5-20 aryl, such as C 5-10 aryl, such as C 5-6 aryl) and R” is, e.g., hydrogen, alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), any of which may be substituted by any group provided herein), amido (e.g., C(O)NR’R” where R’ and R” are independently, e.g., hydrogen, alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), any of which may be substituted by any group provided herein), nitro (e.g., NO 2 ), thiol (e.g., SH), alkylthio (e.g., C 1-20 alkyl substituted with a thiol group, such as C 1-10 alkyl substituted with a thiol group, such as C 1-6 alkyl substituted with a thiol group, such as C 1-3 alkyl substituted with a thiol group), haloalkylthio (e.g., C 1-20 haloalkylthio, such as C 1-10 haloalkylthio, such as C 1-6 haloalkylthio, such as C 1-3 haloalkylthio), perhaloalkylthio (e.g., C 1-20 perhaloalkylthio, such as C 1-10 perhaloalkylthio, such as C 1-6 perhaloalkylthio, such as C 1-3 perhaloalkylthio), arylthiol (e.g., C 5-20 arylthiol, such as C 5-10 arylthiol, such as C 5-6 arylthiol), sulfonate (e.g., S(O) 2 OR where R is, e.g., alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2- 10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), any of which may be substituted by any group provided herein), sulfonic acid (e.g., S(O) 2 OH), trisubstituted silyl (e.g., SiR’R”R* where R’, R”, and R* are independently selected from, e.g., alkyl (e.g., C 1-20 alkyl, such as C 1-10 alkyl, such as C 1-6 alkyl, such as C 1-3 alkyl), alkenyl (e.g., C 2-20 alkenyl, such as C 2-10 alkenyl, such as C 2-6 alkenyl), or alkynyl (e.g., C 2-20 alkynyl, such as C 2-10 alkynyl, such as C 2-6 alkynyl), any of which may be substituted by any group provided herein; in some cases, a trisubstituted silyl can be trimethylsilyl), N 3 , SCH 3 , C(O)CH 3 , CO 2 CH 3 , CO 2 H, pyridinyl, thiophene, furanyl, carbamate, and urea. Additional groups may also be contemplated. Where structurally feasible, two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms (e.g., N, O, S, etc.), for example forming methylenedioxy or ethylenedioxy. An unsubstituted or substituted group may be unsubstituted (e.g., -CH 2 CH 3 ), fully substituted (e.g., -CF 2 CF 3 ), monosubstituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and monosubstituted (e.g., -CH 2 CF 3 ). Where substituents are recited without qualification as to substitution, both substituted and unsubstituted forms are encompassed. Where a substituent is qualified as “substituted,” the substituted form is specifically intended. Additionally, different sets of optional substituents to a particular moiety may be defined as needed; in these cases, the optional substitution will be as defined, often immediately following the phrase, “unsubstituted or substituted with.” [0072] The terms R, R’, R”, R*, etc., appearing by themselves and without a number designation, unless otherwise defined, refer to a moiety selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which is unsubstituted or substituted (e.g., as described herein). Such R and R’ groups should be understood to be unsubstituted or substituted as defined herein. Whether an R group has a number designation or not, every R group, including R, R’ and R n where n=(1, 2, 3, …n), every substituent, and every term should be understood to be independent of every other in terms of selection from a group. Should any variable, substituent, or term (e.g., aryl, heterocycle, R, etc.) occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence. Those of skill in the art will further recognize that certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written. For example, an unsymmetrical group such as -C(O)N(R)- may be attached to the parent moiety at either the carbon or the nitrogen. [0073] “Bond” refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position. [0074] Asymmetric centers may exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the disclosure encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, atropisomeric, and epimeric forms, as well as d-isomers and 1-isomers, and mixtures thereof. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art. Additionally, the compounds disclosed herein may exist as geometric isomers. The present disclosure includes all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. Additionally, compounds may exist as tautomers; all tautomeric isomers are provided by this disclosure. Additionally, the compounds provided herein may comprise conformational isomers, which compounds comprise groups that can orient in different conformations in relation to another moiety. Additionally, the compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms. [0075] “Combination therapy” means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co- administration of these therapeutic agents in a substantially simultaneous manner, such as in a single dose unit (e.g., capsule) having a fixed ratio of active ingredients or in multiple, separate dose units (e.g., capsules) for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein. [0076] “KRAS inhibitor” is used herein to refer to a compound that exhibits an IC 50 with respect to KRAS activity of no more than about 100 μM and more typically not more than about 50 μM, as measured in the assays described generally herein, such as a surface plasmon resonance KRAS-G12D, G12V, G12C, G12S, G12A, G12R, G13D, or Q61H mutation or wild-type KRAS protein binding assay; and/or a KRAS G12D, G12V, G12C, G12S, G12A, G12R, G13D, or Q61H mutation or wild-type KRAS protein-effector protein interaction disruption assay. “IC 50 ” is that concentration of inhibitor which reduces the activity of an enzyme (e.g., KRAS) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit inhibition against KRAS. In certain embodiments, compounds exhibit an IC 50 with respect to KRAS (e.g., a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein) of no more than about 50 μM; in further embodiments, compounds exhibit an IC 50 with respect to KRAS (e.g., a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein) of no more than about 10 μM; in yet further embodiments, compounds exhibit an IC 50 with respect to KRAS (e.g., a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein) of not more than about 1 μM; in yet further embodiments, compounds exhibit an IC 50 with respect to KRAS (e.g., a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein) of not more than about 200 nanomolar (nM), as measured in the KRAS assay described herein. In some embodiments, compounds exhibit an IC 50 with respect to KRAS (e.g., a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein) of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In certain embodiments, compounds exhibit an IC 50 with respect to KRAS (e.g., a KRAS protein having a mutation at codon 12 (e.g., a G12D, G12V, G12C, G12S, G12A, or G12R mutation), a KRAS protein having a mutation at codon 13 (e.g., a G13D mutation), a KRAS protein having a mutation at codon 61 (e.g., a Q61H mutation), or a wild-type KRAS protein) of less than about 1 μM, such as less than about 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G12D mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G12V mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G12R mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G12A mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G12S mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G12C mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a G13D mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to KRAS having a Q61H mutation of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. In some embodiments, compounds exhibit an IC 50 with respect to wild-type KRAS of less than about 50 μM, such as less than about 40 μM, 30 μM, 20 μM, 10 μM, 9 μM, 8 μM, 7 μM, 6 μM, 5 μM, 4 μM, 3 μM, 2 μM, 1 μM, 900 nM, 800 nM, 700 nM, 600 nM, 500 nM, 400 nM, 300 nM, 200 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, or less. [0077] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G12D mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12C, G12R, G12S, G12A, G12V, or G13D mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G12D mutation relative to KRAS having another mutation such as a Q61H, G12C, G12R, G12S, G12A, G12V, or G13D mutation. [0078] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G12V mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12C, G12R, G12S, G12A, G12D, or G13D mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G12V mutation relative to KRAS having another mutation such as a Q61H, G12C, G12R, G12S, G12A, G12D, or G13D mutation. [0079] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G12R mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12C, G12D, G12S, G12A, G12V, or G13D mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G12R mutation relative to KRAS having another mutation such as a Q61H, G12C, G12D, G12S, G12A, G12V, or G13D mutation. [0080] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G12C mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12R, G12D, G12S, G12A, G12V, or G13D mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G12C mutation relative to KRAS having another mutation such as a Q61H, G12R, G12D, G12S, G12A, G12V, or G13D mutation. [0081] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G12S mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12C, G12D, G12R, G12A, G12V, or G13D mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G12S mutation relative to KRAS having another mutation such as a Q61H, G12C, G12D, G12R, G12A, G12V, or G13D mutation. [0082] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G12A mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12C, G12D, G12S, G12R, G12V, or G13D mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G12A mutation relative to KRAS having another mutation such as a Q61H, G12C, G12D, G12S, G12R, G12V, or G13D mutation. [0083] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a G13D mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a Q61H, G12C, G12D, G12S, G12R, G12V, or G12A mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a G13D mutation relative to KRAS having another mutation such as a Q61H, G12C, G12D, G12S, G12R, G12V, or G12A mutation. [0084] In some embodiments, a KRAS inhibitor has inhibitory activity against KRAS having a Q61H mutation that exceeds its inhibitory activity against KRAS having another mutation, such as a G13D, G12C, G12D, G12S, G12R, G12V, or G12A mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two-fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against KRAS having a Q61H mutation relative to KRAS having another mutation such as a G13D, G12C, G12D, G12S, G12R, G12V, or G12A mutation. [0085] In some embodiments, a KRAS inhibitor has inhibitory activity against a wild-type KRAS that exceeds its inhibitory activity against KRAS having a Q61H, G13D, G12C, G12D, G12S, G12R, G12V, or G12A mutation. For example, in some embodiments, a KRAS inhibitor provided herein has at least two- fold, five-fold, ten-fold, twenty-fold, thirty-fold, forty-fold, fifty-fold, one hundred-fold, or higher inhibitory activity against a wild-type KRAS relative to KRAS having a Q61H, G13D, G12C, G12D, G12S, G12R, G12V, or G12A mutation. [0086] In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a Q61H, G13D, G12D, G12S, G12R, G12V, or G12A mutation or a wild-type KRAS than against KRAS having a G12C mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D, G12V, or G12R mutation than against KRAS having a G12C mutation. [0087] In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against KRAS having a G12C mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against KRAS having a G12R mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against a KRAS having a G12S mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against KRAS having a G12A mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against KRAS having a G12V mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against KRAS having a G13D mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12D mutation than against KRAS having a Q61H mutation. [0088] In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against KRAS having a G12C mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against KRAS having a G12R mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against a KRAS having a G12S mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against KRAS having a G12A mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against KRAS having a G12D mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against KRAS having a G13D mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12V mutation than against KRAS having a Q61H mutation. [0089] In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against KRAS having a G12C mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against KRAS having a G12D mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against a KRAS having a G12S mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against KRAS having a G12A mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against KRAS having a G12V mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against KRAS having a G13D mutation. In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against KRAS having a G12R mutation than against KRAS having a Q61H mutation. [0090] In some embodiments, a KRAS inhibitor provided herein has greater inhibitory activity against active (“GTP-bound”) KRAS having a Q61H, G12D, G12V, G12R, G12A, G12S, G12C, or G13D mutation, or wild-type KRAS, than against an inactive (“GDP-bound”) KRAS having a Q61H, G12D, G12V, G12R, G12A, G12S, G12C, or G13D mutation or wild-type KRAS. In some embodiments, a KRAS inhibitor provided herein has lower inhibitory activity against active (“GTP-bound”) KRAS having a Q61H, G12D, G12V, G12R, G12A, G12S, G12C, or G13D mutation, or wild-type KRAS, than against an inactive (“GDP-bound”) KRAS having a Q61H, G12D, G12V, G12R, G12A, G12S, G12C, or G13D mutation or wild-type KRAS. In some embodiments, a KRAS inhibitor provided herein has inhibitory activity against both active (“GTP-bound”) and inactive (“GDP-bound”) KRAS having a Q61H, G12D, G12V, G12R, G12A, G12S, G12C, or G13D mutation or wild-type KRAS. In some embodiments, a KRAS inhibitor provided herein has similar inhibitory activity against active (“GTP-bound”) and inactive (“GDP-bound”) KRAS having a Q61H, G12D, G12V, G12R, G12A, G12S, G12C, or G13D mutation or wild-type KRAS. In some embodiments, a KRAS inhibitor provided herein has inhibitory activity against a K-RAS4a splice variant. In some embodiments, a KRAS inhibitor provided herein has inhibitory activity against a K- RAS4b splice variant. In some embodiments, a KRAS inhibitor provided herein has inhibitory activity against both K-RAS4a and K-RAS4b splice variants. [0091] “Therapeutically effective amount” refers to an amount of a compound or of a pharmaceutical composition useful for treating or ameliorating an identified disease, disorder, or condition, or for exhibiting a detectable therapeutic or inhibitory effect. The exact amounts will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). [0092] The term “therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. [0093] “Treat,” “treating,” and “treatment” refer to any indicia of success in the treatment or amelioration of an injury, pathology, disease, disorder, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology, disease, disorder, or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; and/or improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. Treatment may also be preemptive in nature; i.e., it may include prevention of a disease, disorder, or condition, prevention of onset of one or more symptoms of a disease, disorder, or condition, and/or prevention of escalation of a disease, disorder, or condition. Prevention of a disease, disorder, or condition may involve complete protection from disease, and/or prevention of disease progression (e.g., to a later stage of the disease, disorder, or condition). For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease, disorder, or condition to a clinically significant or detectable level. [0094] “Patient” or “subject” refers to a living organism suffering from or prone to a disease, disorder, or condition that can be treated by administration of a compound or pharmaceutical composition as provided herein. Non-limiting examples include humans, rats, mice, rabbits, hamsters, guinea pigs, cats, dogs, non- human primates (e.g., monkeys), goats, pigs, sheep, cows, deer, horses, and other non-mammalian animals. Examples of mammals that can be treated by administration of a compound or pharmaceutical composition provided herein include, for example, rodents (e.g., rats, mice, squirrels, guinea pigs, hamsters, etc.), lagomorphs (e.g., rabbits, hares, etc.), primates (e.g., monkeys, apes, etc.), bovines (e.g., cattle), odd-toed ungulates (e.g., horses), even-toed ungulates (e.g., bovines such as cattle, ovine such as sheep, caprine such as goats, porcine such as pigs, etc.), and marsupials (e.g., kangaroo, wallaby, wallaroo, sugar glider, etc.). In some embodiments, the patient or subject is human. In some embodiments, the patient or subject is a companion animal such as a cat or dog. In some embodiments, the patient or subject is a farm animal such as a goat, sheep, cow, pig, or horse. In some embodiments, the patient or subject is an exotic animal such as a primate (e.g., monkey), marsupial (e.g., kangaroo, wallaby, wallaroo, sugar glider, etc.), or a non- domesticated or hybrid cat or dog. [0095] “Composition,” as used herein, is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent, or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. [0096] “Pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject. Pharmaceutical excipients useful in the present disclosure include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure. [0097] The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs. Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. [0098] The compounds disclosed herein can exist as therapeutically acceptable salts (also referred to herein as “pharmaceutically acceptable salts”). The present disclosure includes compounds provided herein in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, non- pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable. [0099] The terms “therapeutically acceptable salt” and “pharmaceutically acceptable salt” as used herein, represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L- ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, para- toluenesulfonate (p-tosylate), and undecanoate. Also, basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion. Hence, the present disclosure contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like. [0100] Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N’-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine. [0101] A salt of a compound can be made by reacting the appropriate compound in the form of the free base with the appropriate acid. [0102] “KRAS positive cancer” refers to a cancer characterized by a KRAS mutation, such as a KRAS Q61H, G12C, G12D, G12R, G12A, G12S, G12V, or G13D mutation, and/or by amplified wild-type KRAS activity. In some embodiments, “KRAS positive cancer” refers to a cancer that may benefit from inhibition of KRAS, such as wild-type KRAS or KRAS having a Q61H, G12C, G12D, G12R, G12A, G12S, G12V, or G13D mutation. [0103] “KRAS G12C-positive cancer” refers to a cancer characterized by a KRAS G12C mutation. [0104] “KRAS G12D-positive cancer” refers to a cancer characterized by a KRAS G12D mutation. [0105] “KRAS G12R-positive cancer” refers to a cancer characterized by a KRAS G12R mutation. [0106] “KRAS G12V-positive cancer” refers to a cancer characterized by a KRAS G12V mutation. [0107] “KRAS G12A-positive cancer” refers to a cancer characterized by a KRAS G12A mutation. [0108] “KRAS G12S-positive cancer” refers to a cancer characterized by a KRAS G12S mutation. [0109] “KRAS G13D-positive cancer” refers to a cancer characterized by a KRAS G13D mutation. [0110] “KRAS Q61H-positive cancer” refers to a cancer characterized by a KRAS Q61H mutation. [0111] “Jointly therapeutically effective amount” as used herein means the amount at which the therapeutic agents, when given separately (in a chronologically staggered manner, especially a sequence-specific manner) to a warm-blooded animal, especially to a human to be treated, show an (additive, but preferably synergistic) interaction (joint therapeutic effect). Whether this is the case can be determined inter alia by following the blood levels, showing that both compounds are present in the blood of the human to be treated at least during certain time intervals. [0112] “Synergistic effect” as used herein refers to an effect of at least two therapeutic agents: a KRAS inhibitor, as defined herein, and an additional agent, which additional agent may be an agent configured to treat a disease, disorder, or condition or a symptom thereof. The effect can be, for example, slowing the symptomatic progression of a proliferative disease, such as cancer, particularly lung cancer, or symptoms thereof. Analogously, a “synergistically effective amount” refers to the amount needed to obtain a synergistic effect. [0113] “A,” “an,” or “a(n)”, when used in reference to a group of substituents or “substituent group” herein, mean at least one. For example, where a compound is substituted with “an” alkyl or aryl, the compound is unsubstituted or substituted with at least one alkyl and/or at least one aryl, wherein each alkyl and/or aryl is optionally different. In another example, where a compound is substituted with “a” substituent group, the compound is substituted with at least one substituent group, wherein each substituent group is optionally different. Compounds [0114] In an aspect, the present disclosure provides a compound represented by Formula I: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 3-11 membered carbocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, - C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0115] In some embodiments, the present disclosure provides a compound of Formula I, or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0116] In some embodiments, the present disclosure provides a compound of Formula I, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl; R 3 is selected from a 3-11 membered carbocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , -C(O)N(R 14 ) 2 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl and H, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from halogen; each R 14 is independently selected from C 1-6 alkyl; each R 15 is independently selected from halogen, -N(R 12 ) 2 , and -CN; each R 20 is independently selected from -OH, -OC 1-6 alkyl, and -CN; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted. [0117] In some embodiments, the present disclosure provides a compound of Formula I, wherein the compound is of Formula I-a: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R 2 and R 3 are as defined for Formula I above and described in classes and subclasses herein, both singly and in combination. In some embodiments, the present disclosure provides a compound of Formula I-a, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0118] In some embodiments for a compound according to Formula I or I-a, R 3 is selected from a 3-11 membered carbocycle that is unsubstituted. In some embodiments, R 3 is selected from a 3-11 membered carbocycle that is substituted with one or more R 10 . In some embodiments, R 3 is selected from a 3-8 membered carbocycle that is unsubstituted. In some embodiments, R 3 is selected from a 3-8 membered carbocycle that is substituted with one or more R 10 . In some embodiments, R 3 is a 3-6 membered carbocycle that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 3-6 membered carbocycle that is unsubstituted. In some embodiments, R 3 is a 3-6 membered carbocycle that is substituted with one or more R 10 . In some embodiments, R 3 is a 3-6 membered carbocycle that is substituted with 1-4 R 10 . In some embodiments, R 3 is a cyclopropane that is substituted with 0-4 R 10 . In some embodiments, R 3 is a cyclopropane that is substituted with 1-4 R 10 . In some embodiments, R 3 is a cyclopropyl that is substituted with one or more R 10 , wherein at least one of the one or more R 10 is a C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R 3 is a cyclobutane that is substituted with 0-4 R 10 . In some embodiments, R 3 is a cyclobutane that is substituted with 1-4 R 10 . In some embodiments, R 3 is a cyclopentane that is substituted with 0-4 R 10 . In some embodiments, R 3 is a cyclopentane that is substituted with 1-4 R 10 . In some embodiments, R 3 is a cyclohexane that is substituted with 0-4 R 10 . In some embodiments, R 3 is a cyclohexane that is substituted with 1-4 R 10 . In some embodiments, R 3 is a 3-6 membered carbocycle (e.g., a cyclopropane, cyclobutane, cyclopentane, or cyclohexane) that is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. In some embodiments, R 3 is a 3-6 membered carbocycle (e.g., a cyclopropane, cyclobutane, cyclopentane, or cyclohexane) that is substituted with one or more R 10 , wherein at least one R 10 is -OR 12 . In some embodiments, R 3 is a 3-6 membered carbocycle (e.g., a cyclopropane, cyclobutane, cyclopentane, or cyclohexane) that is substituted with one or more R 10 , wherein at least one R 10 is a C 1-6 alkyl substituted with -OH. In some embodiments, R 3 is a 3-6 membered carbocycle (e.g., a cyclopropane, cyclobutane, cyclopentane, or cyclohexane) that is substituted with one or more R 10 , wherein at least one R 10 is -C(O)N(R 14 ) 2 . In some embodiments, R 3 is a cyclopentane that is substituted with one or more R 10 , wherein at least one R 10 is -C(O)N(R 14 ) 2 . In some embodiments, R 3 is a 3-6 membered carbocycle (e.g., a cyclopropane, cyclobutane, cyclopentane, or cyclohexane) that is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl. [0119] In some embodiments for a compound according to Formula I or I-a, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 4-membered ring (e.g., a cyclobutane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 5-membered ring (e.g., a cyclopentane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 6-membered ring (e.g., a cyclohexane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 4-membered ring (e.g., a cyclobutane) and a 5-membered ring (e.g., a cyclopentane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 5-membered ring (e.g., a cyclopentane) and a 5-membered ring (e.g., a cyclopentane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 6-membered ring (e.g., a cyclohexane) and a 5-membered ring (e.g., a cyclopentane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 6-membered ring (e.g., a cyclohexane) and a 6-membered ring (e.g., a cyclohexane). In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein at least one of the one or more R 10 is -OR 12 . In some embodiments, R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 , wherein the spirocycle comprises a 4-membered ring (e.g., a cyclobutane) and a 5-membered ring (e.g., a cyclopentane), and at least one of the one or more R 10 is -OR 12 . [0120] In some embodiments for a compound according to Formula I or I-a, R 3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R 10 , wherein the bridged carbocycle comprises a 4-membered ring (e.g., a cyclobutane). In some embodiments, R 3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R 10 , wherein the bridged carbocycle comprises a 5- membered ring (e.g., a cyclopentane). In some embodiments, R 3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R 10 , wherein the bridged carbocycle comprises a 6- membered ring (e.g., a cyclohexane). In some embodiments, R 3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R 10 , wherein the one or more R 10 is C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . [0121] In some embodiments for a compound according to Formula I or I-a, when R 10 is -C(O)N(R 14 ) 2 , then at least one R 14 is not H. In some embodiments, when R 10 is -C(O)N(R 14 ) 2 , then each R 14 is C 1-6 alkyl (e.g., methyl or ethyl). [0122] In some embodiments for a compound according to Formula I or I-a, R 3 is selected from: , , , any of which is optionally further substituted with one or more R 10 .  [0123] In some embodiments, the compound is a compound according to Formula IA, IB, IC, ID, IE, or IF: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 , when present, is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; and each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0124] In some embodiments, the compound is a compound according to Formula IA, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IB, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IC, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula ID, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IE, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IF, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0125] In some embodiments, the compound is a compound according to Formula IA, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IB, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IC, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula ID, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IE, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IF, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0126] In some embodiments, for a compound according to any one of Formulas I, IA, IB, IC, ID, IE, and IF, R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1- 6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, R 24 is halogen (e.g., fluoro). In some embodiments, R 26 is deuterium. [0127] In some embodiments, for a compound according to any one of Formulas I, IA, IB, IC, ID, IE, and IF, R 6 is selected from: , any of which is substituted with one or more R 15 . [0128] In some embodiments, for a compound according to any one of Formulas I, IA, IB, IC, ID, IE, and IF, R 6 is selected from: [0130] In some embodiments, for a compound according to any one of Formulas I, IA, IB, IC, ID, IE, and [0131] In some embodiments, the compound is a compound according to Formula IA1, IB1, IC1, ID1, IE1, and IF1: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 , when present, is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . [0132] In some embodiments, the compound is a compound according to Formula IA1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IB1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IC1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula ID1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IE1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IF1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0133] In some embodiments, the compound is a compound according to Formula IA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula ID1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IE1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IF1, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0134] In some embodiments, for a compound according to any one of Formulas IA1, IB1, IC1, ID1, IE1, and IF1, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, X is C- CN, Y is S, R 23 is -N(R 12 ) 2 , and R 24 is a halogen (e.g., F). In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). In some embodiments, R 26 is deuterium. [0135] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from -OR 8 , wherein R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl. In some embodiments, R 8 is a heterocycle or an alkylheterocycle, wherein any heterocycle contains 4-8 members and is substituted with one or more R a or R b . In some embodiments, R 8 is a heterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is an alkylheterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is – CH 2 (heterocycle), where the heterocycle is unsubstituted or substituted with one or more R a or R b . In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is a 4-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is an 8-membered bicyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a halogen (e.g., F). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a C 1-6 alkyl (e.g., methyl). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a -OR 12 (e.g., -OCH 3 ). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a 3-6 membered carbocycle (e.g., a cyclopropane). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is deuterium. [0136] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. In some embodiments, R 1 is selected from: . [0137] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from: . [0138] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from: . In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R 1 is selected from: [0139] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, one R a or R b is selected from halogen, C 1-6 alkyl, and -OR 12 , and the other R a and R b groups are H. In some embodiments, one R a or R b is halogen (e.g., F). In some embodiments, two R a groups, two R b groups, or an R a and an R b are halogen (e.g., F). In some embodiments, one R a or R b is -OR 12 (e.g., -OCH 3 or -CHF 2 ). In some embodiments, one R a or R b is C 1-6 alkyl (e.g., methyl). In some embodiments, two R a groups, two R b groups, or an R a and an R b are C 1-6 alkyl (e.g., methyl). In some embodiments, R c is selected from -CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , and -CH 2 CH 2 CN. In some embodiments, an R a and R b join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, R 1 is selected from: , [0140] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from: . [0141] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IB, IB1, IC, IC1, ID, ID1, IE, IE1, IF, and IF1, R 1 is selected from:   [0142] In some embodiments, the compound is a compound according to Formula IA2, IB2, IC2, ID2, IE2, or IF2:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 , when present, is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen, -CN, and H; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . [0143] In some embodiments, the compound is a compound according to Formula IA2, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IB2, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IC2, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula ID2, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IE2, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IF2, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0144] In some embodiments, the compound is a compound according to Formula IA2, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IB2, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IC2, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula ID2, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IE2, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IF2, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0145] In some embodiments, for a compound according to any one of Formulas IA2, IB2, IC2, ID2, IE2, and IF2, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, X is C- CN, Y is S, R 23 is -N(R 12 ) 2 , and R 24 is a halogen (e.g., F). In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). In some embodiments, R 26 is deuterium. [0146] In some embodiments, for a compound according to any one of Formulas IA2, IB2, IC2, ID2, IE2, and IF2, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. [0147] In some embodiments, for a compound according to any one of Formulas IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, and IF2, at least one R d is selected from -OR 12 , - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R d is selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, - C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R d is selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R d is selected from -OR 12 and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R d is -OH. In some embodiments, at least one R d is a halogen (e.g., F). In some embodiments, at least one R d is -C(O)N(R 14 ) 2 . In some embodiments, at least one R d is -C(O)N(R 14 ) 2 , wherein each R 14 is independently selected from C 1-6 alkyl. In some embodiments, at least one R d is -C(O)N(CH 3 ) 2 . In some embodiments, when R d is -C(O)N(R 14 ) 2 , then at least one R 14 is not H. In some embodiments, when R d is -C(O)N(R 14 ) 2 , then each R 14 is C 1-6 alkyl (e.g., methyl or ethyl). In some embodiments, each R d is H. [0148] In some embodiments, for a compound according to any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, and IF2, R 2 is H. In some embodiments, R 2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is C 1-6 alkyl that is unsubstituted. In some embodiments, R 2 is C 1-6 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is C 1-2 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is C 1-2 alkyl that is unsubstituted. In some embodiments, R 2 is C 1-2 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl. [0149] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, and IF2, R 5 is H. In some embodiments, R 5 is a halogen (e.g., F or Cl). In some embodiments, R 5 is Cl. In some embodiments, R 5 is F. In some embodiments, R 5 is -CN. In some embodiments, R 5 is -OR 12 , wherein R 12 is selected from C 1-6 alkyl and H. In some embodiments, R 5 is -OCH 3 . In some embodiments, R 5 is -OCF 3 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-2 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted, such as methyl or ethyl. In some embodiments, R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more halogens, such as one or more fluorines. In some embodiments, R 5 is -CF 3 . In some embodiments, R 5 is -CHF 2 . In some embodiments, R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and -CH 2 CH 3 . In some embodiments, R 5 is selected from –CH 3 , -CH 2 CH 3 , -CF 2 H, -CF 3 , -CF 2 CH 3 , and -CH 2 CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more R 13 , wherein each R 13 is independently selected from -OR 14 , -CN, and -N(R 14 ) 2 . In some embodiments, R 5 is -CH 2 CN. In some embodiments, R 5 is a 3-6 membered heterocycle. In some embodiments, R 5 is a 5-6 membered heteroaryl, such as a furan. [0150] In some embodiments, for a compound according to any one of Formulas I, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, and IF2, R 7 is H. In some embodiments, R 7 is a halogen (e.g., F or Cl). In some embodiments, R 7 is Cl. In some embodiments, R 7 is F. In some embodiments, R 7 is -CN. [0151] In another aspect, the present disclosure provides a compound represented by Formula II’: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), - C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -S(O) 2 (C 1-6 alkyl), halogen, a 5-6 membered heteroaryl, a 3-6 membered carbocycle, a 3-6 membered heterocycle, and C 1- 6 alkyl, wherein any C 1-6 alkyl is optionally deuterated and is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 , and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, =O, -CN, -NH 2 , - NHC 1-6 alkyl, -C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0152] In some embodiments, the present disclosure provides a compound of Formula II’, or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0153] In another aspect, the present disclosure provides a compound represented by Formula II: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , or (ii) the heterocycle does not comprise an –NH- moiety; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), - C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -S(O) 2 (C 1-6 alkyl), halogen, a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is optionally deuterated and is unsubstituted or substituted with one or more R 20 ; wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, =O, -CN, -NH 2 , - NHC 1-6 alkyl, -C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , a 3-6 membered carbocycle, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0154] In some embodiments, the present disclosure provides a compound of Formula II, or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0155] In some embodiments, the present disclosure provides a compound of Formula II, wherein: R 1 is -OR 8 ; R 2 is selected from C 1-6 alkyl and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , or (ii) the heterocycle does not comprise an –NH- moiety; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is halogen; R 8 is an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), - C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is optionally deuterated and is unsubstituted or substituted with one or more R 20 ; wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; each R 12 is independently selected from C 1-6 alkyl and H, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , and -CN; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, -CN, -C(O)(C 1- 6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle. [0156] In some embodiments, the present disclosure provides a compound of Formula II’ or II, wherein the compound is of Formula II-a: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R 2 and R 3 are as defined for Formula II above and described in classes and subclasses herein, both singly and in combination. In some embodiments, R 2 and R 3 are as defined for Formula II’ above and described in classes and subclasses herein, both singly and in combination. In some embodiments, the present disclosure provides a compound of Formula II-a, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0157] In some embodiments, for a compound according to any one of Formulas II, II’, and II-a, R 3 is a 4- 6 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes one heteroatom selected from O and S, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes one heteroatom selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes a nitrogen atom, wherein the heterocycle is substituted with 1-4 R 10 , provided that the nitrogen atom is substituted with R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes a sulfur atom, wherein the heterocycle is substituted with 1-4 R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that includes an oxygen atom, wherein the heterocycle is substituted with 1-4 R 10 . In some embodiments, R 3 is a pyrrolidine that is substituted with 0-4 R 10 , provided that the nitrogen atom of the heterocycle is substituted with R 10 . In some embodiments, R 3 is a pyrrolidine that is substituted with 1-4 R 10 , provided that the nitrogen atom of the heterocycle is substituted with R 10 . In some embodiments, R 3 is an oxetane or thietane that is substituted with 0-4 R 10 . In some embodiments, R 3 is an oxetane or thietane that is substituted with 1-4 R 10 . In some embodiments, R 3 is a tetrahydrofuran or tetrahydrothiophene that is substituted with 0-4 R 10 . In some embodiments, R 3 is a tetrahydrofuran or tetrahydrothiophene that is substituted with 1-4 R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH, provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . In some embodiments, R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl, provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . In some embodiments, R 3 is selected from a 4-6 membered heterocycle that is substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , wherein each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R 3 is selected from a 4-6 membered heterocycle that is substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , wherein each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)(3-7 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -C(O)OR 14 , -S(O) 2 (C 1-6 alkyl), halogen, a 3-6 membered carbocycle, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R 3 is selected from a 4-6 membered heterocycle that is substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , and each R 10 is independently selected from -C(O)(C 1- 6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)O(C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R 3 is selected from a 4-6 membered heterocycle that is substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , wherein at least one R 10 is selected from -C(O)(C 1-6 alkyl) and -C(O)O(C 1-6 alkyl). In some embodiments, two R 10 s join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle. In some embodiments, two R 10 s connected to adjacent atoms join together to form, together with the atoms to which they are attached, a 3- 6 membered carbocycle or heterocycle. In some embodiments, two R 10 s connected to adjacent atoms join together to form, together with the atoms to which they are attached, a 5-6 membered heterocycle, such as a pyrrolidine or oxazolidine. In some embodiments, the 3-6 membered carbocycle or heterocycle formed by the joining of two R 10 s is substituted with one or more R 10 . In some embodiments, the 5-6 membered heterocycle formed by the joining of two R 10 s is substituted with one or more R 10 . In some embodiments, the 5-6 membered heterocycle (e.g., pyrrolidine or oxazolidine) formed by the joining of two R 10 s is substituted with =O. In some embodiments, each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle. In some embodiments, each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 10 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 10 is independently selected from -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)O(C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . [0158] In some embodiments, for a compound according to any one of Formulas II, II’, and II-a, R 3 is a 7- 9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 7-9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 or (ii) the heterocycle does not comprise an –NH- moiety. In some embodiments, R 3 is a 7-9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 or (ii) when the heterocycle contains a single ring, the heterocycle does not comprise an –NH- moiety. In some embodiments, R 3 is a 7-9 membered bridged heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the bridged heterocycle is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 7-9 membered bridged heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the bridged heterocycle is unsubstituted or is substituted with one or more R 10 , provided that (i) when the bridged heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 or (ii) the bridged heterocycle does not comprise an –NH- moiety. In some embodiments, R 3 is a bridged pyrrolidine that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a bridged pyrrolidine that is unsubstituted or is substituted with one or more R 10 , provided that the bridged pyrrolidine does not comprise an NH moiety. In some embodiments, R 3 is a bridged pyrrolidine that is substituted with one or more R 10 , provided that the bridged pyrrolidine does not comprise an NH moiety. In some embodiments, R 3 is a 7-9 membered heterocycle comprising a fused ring system that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 7-9 membered heterocycle comprising a fused ring system that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 or (ii) the heterocycle does not comprise an –NH- moiety. In some embodiments, R 3 is a 7-9 membered heterocycle comprising a fused ring system comprising two rings, wherein the heterocycle includes one or more heteroatoms selected from O, S, and N, and the heterocycle is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is a 7-9 membered heterocycle comprising a fused ring system comprising two rings, wherein the heterocycle includes one or more heteroatoms selected from O, S, and N, and the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 or (ii) the heterocycle does not comprise an –NH- moiety. In some embodiments, R 3 comprises a fused ring system comprising two rings, wherein at least one ring is a 5-membered heterocycle that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 comprises a fused ring system comprising two rings, wherein at least one ring is a pyrrolidine that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 comprises a fused ring system comprising two rings, wherein each ring is a 5-membered heterocycle that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 comprises a fused ring system comprising two rings, wherein one ring is a 5-membered heterocycle that is unsubstituted or is substituted with one or more R 10 and the second ring is a 6-membered heterocycle that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 comprises a fused ring system comprising two rings, wherein one ring is a pyrrolidine that is unsubstituted or is substituted with one or more R 10 and the second ring is a piperidine, oxazinane, oxazolidine, imidazolidine, or pyrrolidine that is unsubstituted or is substituted with one or more R 10 . In some embodiments, the fused ring system is substituted with at least one R 10 , wherein the at least one R 10 is selected from =O and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0159] In some embodiments, when R 10 is -C(O)N(R 14 ) 2 , then at least one R 14 is not H. In some embodiments, when R 10 is -C(O)N(R 14 ) 2 , then each R 14 is C 1-6 alkyl (e.g., methyl or ethyl). [0160] In some embodiments, for a compound according to Formula II’ or II-a, R 3 is selected from: any of which is optionally further substituted with one or more R 10 . [0161] In some embodiments, for a compound according to any one of Formulas II’, II, and II-a, R 3 is selected from: , ,

,

any of which is optionally further substituted with one or more R 10 .   [0162] In some embodiments, for a compound according to Formula II’ or II, R 3 is selected from:

any of which is optionally further substituted with one or more R 10 .   [0163] In some embodiments, the compound is a compound according to Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, or IIZ:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 , when present, is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, =O, -CN, -NH 2 , - NHC 1-6 alkyl, -C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , a 3-6 membered carbocycle, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1- 6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteraryl), -C(O)O(3-6 membered carbocycle), - C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is optionally deuterated and is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; and each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 . [0164] In some embodiments, the compound is a compound according to Formula IIA, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIB, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIC, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IID, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIE, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIF, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIG, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIH, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIJ, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIK, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIL, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIM, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIN, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIP, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIQ, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIR, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIS, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIT, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIU, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIV, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIW, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIX, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIY, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIZ, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0165] In some embodiments, the compound is a compound according to Formula IIA, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIB, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIC, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IID, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIE, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIF, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIG, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIH, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIJ, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIK, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIL, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIM, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIN, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIP, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIQ, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIR, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIS, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIT, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIU, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIV, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIW, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIX, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIY, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIZ, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0166] In some embodiments, the compound is a compound according to Formula IIAA: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, =O, -CN, -NH 2 , - NHC 1-6 alkyl, -C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , a 3-6 membered carbocycle, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1- 6 alkyl), halogen, a 3-6 membered carbocycle, a 3-6 membered heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle or 3-6 membered heterocycle, is unsubstituted or substituted with one or more R 12 or R 20 ; and (i) R q1 , R q2 , and R p2 are each independently selected from R d , and R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d ; or (ii) R p1 , R p2 , and R q2 are each independently selected from R d , and R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d . [0167] In some embodiments, the compound is a compound according to Formula IIAA, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0168] In some embodiments, for a compound according to any one of Formulas II, II’, II-a, IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, IIZ, and IIAA, R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is a pyridine substituted with one or more R 15 . In some embodiments, at least one R 15 is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, at least any of which is optionally substituted with one or more R 15 . In some embodiments, . [0169] In some embodiments, for a compound according to any one of Formulas II, II’, II-a, IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, IIZ, and IIAA, R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1- 6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, R 24 is a halogen (e.g., fluoro). In some embodiments, R 26 is deuterium. [0170] In some embodiments, for a compound according to any one of Formulas II, II’, II-a, IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, IIZ, and IIAA, R 6 is selected from: any of which is substituted with one or more R 15 . [0171] In some embodiments, for a compound according to any one of Formulas II, II’, II-a, IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, IIZ, and IIAA, R 6 is selected from: [0172] In some embodiments, for a compound according to any one of Formulas II, II’, II-a, IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, IIZ, and IIAA, R 6 is selected from:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 , when present, is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, =O, -CN, -NH 2 , - NHC 1-6 alkyl, -C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , a 3-6 membered carbocycle, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -C(O)N(R 14 ) 2 , - C(O)(3-8 membered heterocycle), -C(O)(5-6 membered heteraryl), -C(O)O(3-6 membered carbocycle), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -S(O) 2 (C 1-6 alkyl), a 5-6 membered heteroaryl, a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is optionally deuterated and is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 or 3-8 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . [0175] In some embodiments, the compound is a compound according to Formula IIA1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIB1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIC1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IID1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIE1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIF1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIG1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIH1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIJ1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIK1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIL1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIM1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIN1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIP1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIQ1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIR1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIS1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIT1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIU1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIV1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIW1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIX1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIY1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIZ1, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0176] In some embodiments, the compound is a compound according to Formula IIA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IID1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIE1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIF1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIG1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIH1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIJ1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIK1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIL1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIM1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIN1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIP1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIQ1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIR1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIS1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIT1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIU1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIV1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIW1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIX1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIY1, or a salt (e.g., pharmaceutically acceptable salt) thereof. In some embodiments, the compound is a compound according to Formula IIZ1, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0177] In some embodiments, the compound is a compound according to Formula IIAA1: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -OC 1-6 haloalkyl, =O, -CN, -NH 2 , - NHC 1-6 alkyl, -C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , a 3-6 membered carbocycle, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), a 3-6 membered carbocycle, a 3-6 membered heterocycle, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and (i) R q1 , R q2 , and R p2 are each independently selected from R d , and R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d ; or (ii) R p1 , R p2 , and R q2 are each independently selected from R d , and R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d . [0178] In some embodiments, the compound is a compound according to Formula IIAA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0179] In some embodiments, for a compound according to Formula IIAA or IIAA1, R q1 , R q2 , and R p2 are each independently selected from R d , and R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a 5-membered heterocycle that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a 6-membered heterocycle that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted. In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is substituted with one or more R d , provided that at least one R d is not H. In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a piperidine, oxazinane, oxazolidine, imidazolidine, or pyrrolidine that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a morpholine, piperidine, oxazinane, oxazolidine, imidazolidine, or pyrrolidine that is unsubstituted or is substituted with one or more R d . In some embodiments, R p2 is H. [0180] In some embodiments, for a compound according to Formula IIAA or IIAA1, R p1 , R p2 , and R q2 are each independently selected from R d , and R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R q1 , together with the atoms to which they are attached, form a 5-membered heterocycle that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R q1 , together with the atoms to which they are attached, form a 6-membered heterocycle that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted. In some embodiments, R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is substituted with one or more R d , provided that at least one R d is not H. In some embodiments, R e and R q1 , together with the atoms to which they are attached, form a piperidine, oxazinane, oxazolidine, imidazolidine, or pyrrolidine that is unsubstituted or is substituted with one or more R d . In some embodiments, R e and R p1 , together with the atoms to which they are attached, form a morpholine, piperidine, oxazinane, oxazolidine, imidazolidine, or pyrrolidine that is unsubstituted or is substituted with one or more R d . In some embodiments, R q2 is H. [0181] In some embodiments, for a compound according to any one of Formulas IIA1, IIB1, IIC1, IID1, IIE1, IIF1, IIG1, IIH1, IIJ1, IIK1, IIL1, IIM1, IIN1, IIP1, IIQ1, IIR1, IIS1, IIT1, IIU1, IIV1, IIW1, IIX1, IIY1, IIZ1, and IIAA1, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and R 24 is a halogen (e.g., F). In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). In some embodiments, R 26 is deuterium. [0182] In some embodiments, for a compound according to any one of Formulas IIC, IIC1, IIE, IIE1, IIL, IIL1, IIM, IIM1, IIQ, IIQ1, IIS, IIS1, IIY, IIY1, IIZ, and IIZ1, each R f is =O. In some embodiments, each R f is optionally absent and, if present, is =O. In some embodiments, each R f is absent. [0183] In some embodiments, for a compound of any one of Formulas IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, each R d is H. In some embodiments, at least one R d is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. In some embodiments, each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1- 6 alkyl that is unsubstituted or substituted with one or more R 20 . It will be appreciated that when R d is =O, the other R d on the same carbon atom is absent, such that the carbon has proper valency. [0184] In some embodiments, for a compound according to any one of Formulas IIA, IIA1, IID, IID1, IIG, IIG1, IIH, IIH1, IIN, IIN1, IIR, IIR1, IIU, IIU1, IIV, and IIV1, R e is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)N(R 14 ) 2 , -C(O)OR 14 , - S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -C(O)(3-7 membered heterocycle), - C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered heterocycle), and -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from - C(O)(3-6 membered carbocycle), -C(O)(3-7 membered heterocycle), -C(O)(5-6 membered heteroaryl), - C(O)O(3-6 membered heterocycle), and -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, - C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R e is selected from -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), and -C(O)O(C 1-6 alkyl), wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R e is C 1-6 alkyl that is substituted with one or more R 20 . In some embodiments, R e is C 1-6 alkyl that is substituted with one or more R 20 , wherein each R 20 is independently selected from -OH, - OC 1-6 alkyl, =O, and -CN. In some embodiments, R e is selected from -C(O)(C 1-6 alkyl), wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R e is selected from - C(O)(C 1-6 alkyl), wherein any C 1-6 alkyl is unsubstituted. In some embodiments, R e is selected from - C(O)(C 1-6 alkyl), wherein any C 1-6 alkyl is substituted with one or more R 20 , wherein the one or more R 20 are independently selected from -OC 1-6 alkyl, halogen, -OH, and -CN. In some embodiments, R e is selected from -C(O)(C 1-6 alkylene)CN, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R e is selected from -C(O)(C 1-6 alkylene)OH, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R e is selected from -C(O)N(R 14 ) 2 . In some embodiments, R e is selected from -C(O)N(R 14 ) 2 , wherein each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, and H. In some embodiments, R e is selected from -C(O)N(R 14 ) 2 , wherein each R 14 is independently selected from C 1-6 alkyl and H. In some embodiments, when R e is -C(O)N(R 14 ) 2 , then at least one R 14 is not H. In some embodiments, when R e is - C(O)N(R 14 ) 2 , then each R 14 is C 1-6 alkyl (e.g., methyl or ethyl). In some embodiments, R e is selected from -C(O)OR 14 . In some embodiments, R e is selected from -C(O)OR 14 , wherein R 14 is selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, and C 2-6 alkenyl, wherein any C 1-6 alkyl is optionally deuterated. In some embodiments, R e is selected from -C(O)OR 14 , wherein R 14 is selected from a 3-6 membered carbocycle and a 3-6 membered heterocycle. In some embodiments, R e is -S(O) 2 (C 1- 6 alkyl), wherein the C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R e is selected from -C(O)(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is -C(O)(3-6 membered carbocycle) that is unsubstituted. In some embodiments, R e is selected from -C(O)(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is cyclopropane or cyclobutane, and wherein the 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is -C(O)(cyclopropane). In some embodiments, R e is selected from -C(O)(cyclopropane), wherein the cyclopropane is substituted with one or more R 12 or R 20 (e.g., one or more fluoro). In some embodiments, R e is selected from -C(O)(3-8 membered heterocycle), wherein the 3-8 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3-8 membered heterocycle), wherein the 3-8 membered heterocycle is unsubstituted. In some embodiments, R e is selected from -C(O)(3-8 membered heterocycle), wherein the 3-8 membered heterocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from - C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is unsubstituted. In some embodiments, R e is selected from -C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3- 7 membered heterocycle), wherein the 3-7 membered heterocycle is oxetane, azetidine, pyrrolidine, azabicyclo[3.1.0]hexane, morpholine, a bridged morpholine, tetrahydropyran, piperidine, piperazine, or 2- oxa-6-azaspiro[3.3]heptane, and wherein the 3-7 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is oxetane, azetidine, pyrrolidine, morpholine, tetrahydropyran, piperidine, or piperazine, and wherein the 3-7 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is a morpholine or bridged morpholine, and wherein the morpholine or bridged morpholine is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is a bridged morpholine selected from , and wherein the bridged morpholine is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from - C(O)(3-7 membered heterocycle), wherein the 3-7 membered heterocycle is substituted with one or more R 12 or R 20 , wherein each R 12 is independently selected from C 1-6 alkyl and each R 20 is independently selected from -OC 1-6 alkyl, -C(O)(C 1-6 alkyl), and halogen. In some embodiments, R e is selected from -C(O)(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is unsubstituted. In some embodiments, R e is selected from -C(O)(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is thiophene, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, or pyrimidine, any of which is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is oxazole or isoxazole, and wherein the oxazole or isoxazole is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is unsubstituted. In some embodiments, R e is selected from -C(O)O(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(3-6 membered carbocycle), wherein the 3-6 membered carbocycle is cyclopropane or cyclobutane, and wherein the 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is unsubstituted. In some embodiments, R e is selected from -C(O)O(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is oxetane, tetrahydrofuran, tetrahydropyran, or pyrrolidine, and wherein the 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is selected from - C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is unsubstituted. In some embodiments, R e is selected from -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), wherein the 3-6 membered heterocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is a 3-6 membered carbocycle, wherein the 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is a 3-6 membered carbocycle, wherein the 3-6 membered carbocycle is unsubstituted. In some embodiments, R e is a 3-6 membered carbocycle, wherein the 3-6 membered carbocycle is substituted with one or more R 12 or R 20 . In some embodiments, R e is a 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is unsubstituted or substituted with one or more R 12 or R 20 . In some embodiments, R e is a 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is unsubstituted. In some embodiments, R e is a 5-6 membered heteroaryl, wherein the 3-6 membered carbocycle is substituted with one or more R 12 or R 20 . [0185] In some embodiments, for a compound of any one of Formulas IID, IID1, IIR, and IIR1, structure selected from:

,

, [0186] In some embodiments, for a compound of any one of Formulas II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 2 is H. In some embodiments, R 2 is a C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is a C 1-6 alkyl that is unsubstituted. In some embodiments, R 2 is a C 1-6 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is a C 1- 2 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is a C 1-2 alkyl that is unsubstituted. In some embodiments, R 2 is a C 1-2 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl. [0187] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from -OR 8 , wherein R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl. In some embodiments, R 8 is a heterocycle or an alkylheterocycle, wherein any heterocycle contains 4-8 members and is substituted with one or more R a or R b . In some embodiments, R 8 is a heterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is an alkylheterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is – CH 2 (heterocycle), where the heterocycle is unsubstituted or substituted with one or more R a or R b . In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is a 4-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is an 8-membered bicyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a halogen (e.g., F). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a C 1-6 alkyl (e.g., methyl). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a -OR 12 (e.g., -OCH 3 ). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a 3-6 membered carbocycle (e.g., a cyclopropane). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is deuterium. [0188] In some embodiments, for a compound according to any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b2 are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a1 and R b1 and/or R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is a halogen. In some embodiments, R a1 and/or R a2 is F. In some embodiments, R a1 and/or R a2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is methyl. In some embodiments, R a1 and/or R a2 is -OC 1- 6 alkyl. In some embodiments, R a1 and/or R a2 is H. In some embodiments, R b1 and/or R b2 is H. In some embodiments, R b1 and/or R b2 is a halogen. In some embodiments, R b1 and/or R b2 is F. In some embodiments, R b1 and/or R b2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b1 and/or R b2 is methyl. In some embodiments, each of R a1 and R b1 is F. In some embodiments, R a2 and/or R b2 is D. In some embodiments, R a2 and R b2 join together to form a 3-6 membered carbocycle (e.g., cyclopropane), which carbocycle is optionally substituted with one or more R 13 . In some embodiments, R a1 and R b1 join together to form a 3-6 membered carbocycle (e.g., cyclopropane). In some embodiments, R 1 is selected from: , [0189] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. In some embodiments, R 1 is selected from: . [0190] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from: . [0191] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from: . In some embodiments, R a is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R 1 is selected from: [0192] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and wherein an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1- 6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, one R a or R b is selected from halogen, C 1-6 alkyl, and -OR 12 , and the other R a and R b groups are H. In some embodiments, one R a or R b is halogen (e.g., F). In some embodiments, two R a groups, two R b groups, or an R a and an R b are halogen (e.g., F). In some embodiments, one R a or R b is -OR 12 (e.g., -OCH 3 or –CHF 2 ). In some embodiments, one R a or R b is C 1- 6 alkyl (e.g., methyl). In some embodiments, two R a groups, two R b groups, or an R a and an R b are C 1-6 alkyl (e.g., methyl). In some embodiments, R c is selected from –CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , and –CH 2 CH 2 CN. In some embodiments, an R a and R b join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, R 1 is selected from:

[0193] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from: . [0194] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 1 is selected from:   [0195] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 5 is H. In some embodiments, R 5 is a halogen (e.g., F or Cl). In some embodiments, R 5 is Cl. In some embodiments, R 5 is F. In some embodiments, R 5 is -CN. In some embodiments, R 5 is -OR 12 , wherein R 12 is selected from C 1-6 alkyl and H. In some embodiments, R 5 is - OCH 3 . In some embodiments, R 5 is -OCF 3 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-2 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted, such as methyl or ethyl. In some embodiments, R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more halogens, such as one or more fluorines. In some embodiments, R 5 is -CF 3 . In some embodiments, R 5 is -CHF 2 . In some embodiments, R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . In some embodiments, R 5 is selected from –CH 3 , -CH 2 CH 3 , -CF 2 H, -CF 3 , -CF 2 CH 3 , and -CH 2 CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more R 13 , wherein each R 13 is independently selected from -OR 14 , -CN, and -N(R 14 ) 2 . In some embodiments, R 5 is -CH 2 CN. In some embodiments, R 5 is a 3-6 membered heterocycle. In some embodiments, R 5 is a 5-6 membered heteroaryl, such as a furan. [0196] In some embodiments, for a compound of any one of Formulas II, II’, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, R 7 is Cl. In some embodiments, R 7 is F. [0197] In some embodiments, for a compound of any one of Formulas II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, and IIAA1, the compound is a not a compound included in Table 1, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. Table 1.

[0198] In another aspect, the present disclosure provides a compound represented by Formula III’: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0199] In some embodiments, the present disclosure provides a compound of Formula III’ or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0200] In another aspect, the present disclosure provides a compound represented by Formula III: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0201] In some embodiments, the present disclosure provides a compound of Formula III or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0202] In some embodiments, the present disclosure provides a compound of Formula III, wherein: R 1 is selected from -OR 8 ; R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety; R 4 is H; R 5 is C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl and H, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from halogen; each R 14 is independently selected from C 1-6 alkyl and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . [0203] In some embodiments, the present disclosure provides a compound of Formula III’ or III, wherein the compound is of Formula III-a: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R 2 and R 3 are as defined for Formula III above and described in classes and subclasses herein, both singly and in combination. In some embodiments, R 2 and R 3 are as defined for Formula III’ above and described in classes and subclasses herein, both singly and in combination. In some embodiments, the present disclosure provides a compound of Formula III-a, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0204] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that is unsubstituted or is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) when the heterocycle comprises a single ring, the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle comprising a single ring, wherein the heterocycle is unsubstituted or is substituted with one or more R 11 , provided that the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that is unsubstituted or is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) when the heterocycle comprises a single ring, the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that is unsubstituted, provided that the 4-6 membered heterocycle does not contain an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that is unsubstituted, provided that the 7-membered heterocycle does not contain an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a pyrrolidine that is substituted with 0-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form an azetidine that is substituted with 0-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperidine that is substituted with 0-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperazine that is substituted with 0-4 R 11 , provided that the additional nitrogen atom of the piperazine is substituted with R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a morpholine or thiomorpholine that is substituted with 0-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety, wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety, wherein at least one R 11 is an unsubstituted C 1-6 alkyl. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7- membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7- membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7- membered heterocycle that includes a nitrogen atom. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes a nitrogen atom and an oxygen atom. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes a nitrogen atom and a sulfur atom, which sulfur atom is optionally substituted with two oxo moieties. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes two nitrogen atoms. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7- membered heterocycle that includes one additional nitrogen atom, provided that the additional nitrogen atom is substituted with R 11 . [0205] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle that is unsubstituted or is substituted with one or more R 11 . In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the bridged heterocycle is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the bridged heterocycle is substituted with 1-4 R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperidine that is substituted with 0-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperazine that is substituted with 0-4 R 11 , provided that (i) the additional nitrogen atom of the piperazine is substituted with R 11 or (ii) the bridged piperazine does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged morpholine or thiomorpholine that is substituted with 0-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety, wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety, wherein at least one R 11 is an unsubstituted C 1-6 alkyl. [0206] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle that is unsubstituted or is substituted with one or more R 11 . In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the spirocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the spirocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle that is unsubstituted, provided that the spirocycle does not include an -NH- moiety. In some embodiments, R 2 and R 3 , together with the atom to which they are attached, form a spirocycle that is substituted with one or more R 11 , provided that (i) when the spirocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the spirocycle does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle comprising a 4-membered ring and a 3-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle comprising two 4-membered rings. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle comprising a 4-membered ring and a 5-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle comprising a 4-membered ring and a 6-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle comprising a 6-membered ring and a 5-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle comprising two 5-membered rings. [0207] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is unsubstituted or is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is unsubstituted or is substituted with one or more R 11 , and provided that the fused ring system does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein at least one of the rings is selected from azetidine, pyrrolidine, piperidine, piperazine, triazole (e.g., 1,2,3-triazole or 1,2,4-triazole), pyrazole, pyrrole, imidazole, isoxazole, thiazole, oxazolidine, morpholine, tetrahydrofuran, azepane, and diazepane, and wherein the fused ring system is unsubstituted or is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein at least one of the rings is selected from azetidine, pyrrolidine, piperidine, piperazine, triazole (e.g., 1,2,3-triazole or 1,2,4- triazole), pyrazole, pyrrole, imidazole, isoxazole, thiazole, oxazolidine, morpholine, pyridine, tetrahydrofuran, azepane, and diazepane, and wherein the fused ring system is unsubstituted or is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system comprising two 5-membered rings. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system comprising a 5- membered ring and a 6-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system comprising a 5-membered ring and a 4-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system comprising a 6-membered ring and a 3-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system comprising a 7- membered ring and a 5-membered ring. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is unsubstituted. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is unsubstituted, provided that the fused ring system does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is substituted with one or more R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is substituted with one or more R 11 , provided that (i) when the fused ring system contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the fused ring system does not comprise an -NH- moiety. In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is substituted with 1-4 R 11 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings, wherein the fused ring system is substituted with 1-4 R 11 , provided that (i) when the fused ring system contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the fused ring system does not comprise an -NH- moiety. [0208] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , wherein each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3- 6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 11 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R 11 is -C(O)(3-6 membered carbocycle or heterocycle), wherein any carbocycle or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R 11 is -C(O)(3-6 membered carbocycle), wherein the carbocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R 11 is -C(O)(3-6 membered heterocycle), wherein the heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one R 11 is -C(O)N(R 14 ) 2 . In some embodiments, at least one R 11 is =O. In some embodiments, when R 11 is -C(O)N(R 14 ) 2 , then at least one R 14 is not H. In some embodiments, when R 11 is -C(O)N(R 14 ) 2 , then each R 14 is C 1-6 alkyl (e.g., methyl or ethyl). [0209] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 , wherein the one or more R 11 are independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety, wherein the one or more R 11 are independently selected from deuterium, -OR 12 , =O, =N(R 14 ), - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that (i) when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 or (ii) the heterocycle does not comprise an -NH- moiety, wherein the one or more R 11 are independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . [0210] In some embodiments, for a compound according to Formula III, III’, or III-a, R 2 and R 3 , together with the nitrogen atom to which they are attached, form a structure selected from:

,

,

, any of which is optionally further substituted with one or more R 11 .   [0211] In some embodiments, the compound is a compound according to Formula IIIA: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f and R g are each independently selected from hydrogen, deuterium, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , or R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0212] In some embodiments, the present disclosure provides a compound of Formula IIIA or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0213] In some embodiments, for a compound according to Formula IIIA, each R e , R f , and R g is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R e , R f , and R g is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . It will be appreciated that when R e , R f , or R g is =O, the other R e , R f , or R g on the same carbon atom is absent, such that the carbon has proper valency. In some embodiments, each R e is independently hydrogen. In some embodiments, each R e , R f , and R g is independently hydrogen. [0214] In some embodiments, for a compound according to Formula IIIA, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a cyclopropane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a cyclobutane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form an oxetane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0215] In some embodiments, for a compound according to Formula I structure selected from: [0216] In some embodiments, the compound is a compound according to Formula IIIA1: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 . [0217] In some embodiments, the present disclosure provides a compound of Formula IIIA1 or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0218] In some embodiments, for a compound according to Formula IIIA1, each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, for a compound according to Formula IIIA1, each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . It will be appreciated that when R e is attached to a carbon that is also attached to R f or R g , R e is not =O or =N(R 14 ), and when R e is =O or =N(R 14 ), the other R e on the same carbon atom is absent, such that the carbon has proper valency. In some embodiments, each R e is independently hydrogen. [0219] In some embodiments, for a compound according to Formula IIIA1, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl that is unsubstituted or substituted with one or more R 20 , wherein any carbocycle or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form pyrrolidine that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form pyrrolidine that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, when the ring formed by joining R f and R g together is substituted with -C(O)N(R 14 ) 2 , at least one R 14 is C 1-6 alkyl. [0220] In some embodiments, for a compound according to Formula structure selected from: [0221] In some embodiments, the compound is a compound according to Formula IIIB:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; and each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0222] In some embodiments, the present disclosure provides a compound of Formula IIIB or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0223] In some embodiments, for a compound according to Formula IIIB, each R e is hydrogen. In some embodiments, at least one R e is -OR 12 . In some embodiments, each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . It will be appreciated that when R e is =O, the other R e on the same carbon atom is absent, such that the carbon has proper valency. [0224] In some embodiments, the compound is a compound according to Formula IIIC: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; and each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl or heteroaryl is unsubstituted or substituted with one or more R 20 . [0225] In some embodiments, the present disclosure provides a compound of Formula IIIC or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0226] In some embodiments, for a compound according to Formula structure selected from: . [0227] In some embodiments, the compound is a compound according to Formula IIIC1:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f , R g , and R h are each independently selected from hydrogen, deuterium, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , optionally wherein (i) R f and R g join together to form a 3-6 membered carbocycle or heterocycle or a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; or (ii) R g and R h join together to form a 3-6 membered carbocycle or heterocycle or a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0228] In some embodiments, the present disclosure provides a compound of Formula IIIC1 or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0229] In some embodiments, for a compound according to Formula IIIC or IIIC1, each R e is hydrogen. In some embodiments, at least one R e is selected from -OR 12 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl substituted with –OH). In some embodiments, each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . It will be appreciated that when R e is =O, the other R e , R f , R g , or R h on the same carbon atom is absent, such that the carbon has proper valency. [0230] In some embodiments, for a compound according to Formula IIIC1, (i) R f and R g or (ii) R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, (i) R f and R g or (ii) R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, (i) R f and R g or (ii) R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, (i) R f and R g or (ii) R g and R h join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, (i) R f and R g or (ii) R g and R h join together to form an tetrahydrofuran that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, (i) R f and R g or (ii) R g and R h join together to form a pyrrolidine that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, for a compound according to Formula IIIC1, (i) R f and R g or (ii) R g and R h join together to form a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R f and R g join together to form a 5-6 membered heteoraryl that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R g and R h join together to form a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, (i) R f and R g or (ii) R g and R h join together to form a 5-6 membered heteroaryl that is unsubstituted (e.g., a pyridine). In some embodiments, (i) R f and R g or (ii) R g and R h join together to form a 5-6 membered heteroaryl that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, the ring formed when (i) R f and R g or (ii) R g and R h join together does not comprise an -NH- moiety. It will be appreciated that when an R e , R f , R g , or R h is =O, another optional substitutent that would otherwise be on the same carbon atom is absent, such that the carbon has proper valency. [0231] In some embodiments, for a compound according to Formula structure selected from: [0232] In some embodiments, the compound is a compound according to Formula IIID: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; Q is selected from CR h R j , NR g , O, S, and SO 2 ; each R e and R f is independently selected from R 11 and hydrogen, wherein: (i) an R e and an R f can optionally join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 ; R g , when present, is R 11 ; and R h and R j , when present, are each independently selected from R 11 and hydrogen, or can optionally join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , or a R h and a R e or a R h and a R f optionally join together to form a 3-6 membered ring that is unsubstituted or substituted with one or more R 11 . [0233] In some embodiments, the present disclosure provides a compound of Formula IIID or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0234] In some embodiments, for a compound according to Formula IIID, Q is NR g . In some embodiments, R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . [0235] In some embodiments, for a compound according to Formula IIID, Q is O, S, or SO 2 . In some embodiments, Q is O. In some embodiments, Q is S. In some embodiments, Q is SO 2 . [0236] In some embodiments, for a compound according to Formula IIID, Q is CR h R j . In some embodiments, Q is CR h R j and an R e and an R f join together to form a 4-6 membered ring. In some embodiments, when Q is CR h R j and an R e and an R f join together to form a 4-6 membered ring, R h and R j do not join together to form a 3-4 membered carbocycle or heterocycle. In some embodiments, Q is CR h R j and R h and R j join together to form a 3-4 membered carbocycle or heterocycle. In some embodiments, when Q is CR h R j and R h and R j join together to form a 3-4 membered carbocycle or heterocycle, no combination of an R e and an R f join together to form a 4-6 membered ring. In some embodiments, when Q is CR h R j and R h and R j join together to form a 3-4 membered carbocycle or heterocycle, no combination of one or more R e s and/or one or more R f s join together to form a ring. In some embodiments, Q is CR h R j and R h and R j are each hydrogen. In some embodiments, Q is CR h R j , R h is hydrogen, and R j is selected from deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is CR h R j , R h is hydrogen, and R j is selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is CR h R j , R h is hydrogen, and R j is selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is CR h R j , R j is hydrogen, and a R h and a R e or a R h and a R f optionally join together to form a 3-6 membered ring (e.g., a pyridine) that is unsubstituted or substituted with one or more R 11 . [0237] In some embodiments, for a compound according to Formula IIID, R h and R j are independently selected from R 11 and hydrogen. In some embodiments, each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R h and R j is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, R h and R j are hydrogen. It will be appreciated that when R h or R j is =O, the R h or R j on the same carbon atom is absent, such that the carbon has proper valency. [0238] In some embodiments, for a compound according to Formula IIID, R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R h and R j is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, both R h and R j are hydrogen. It will be appreciated that when R h or R j is =O, the other R h or R j on the same carbon atom is absent, such that the carbon has proper valency. [0239] In some embodiments, for a compound according to Formula IIID, each R e and R f is independently selected from R 11 and hydrogen. In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R e and R f is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, each R e and R f is independently selected from hydrogen and R 11 , wherein each R 11 is independently selected from -OR 12 , halogen, a 5-6 membered heteroaryl, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, each R e is hydrogen. In some embodiments, each R f is hydrogen. In some embodiments, each R e and R f is hydrogen. It will be appreciated that when R e or R f is =O, the other R e or R f on the same carbon atom is absent, such that the carbon has proper valency. [0240] In some embodiments, the compound is a compound according to Formula IIIE: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R e and R f is independently selected from R 11 and hydrogen, wherein: (i) an R e and an R f can optionally join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 ; and R h and R j are each independently selected from R 11 and hydrogen, or can optionally join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , or a R h and a R e or a R h and a R f optionally join together to form a 3-6 membered ring that is unsubstituted or substituted with one or more R 11 . [0241] In some embodiments, the present disclosure provides a compound of Formula IIIE or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0242] In some embodiments, for a compound according to Formula IIIE, R h and R j are independently selected from R 11 and hydrogen. In some embodiments, each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R h and R j is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, R h is hydrogen and R j is R 11 . In some embodiments, R h and R j are hydrogen. It will be appreciated that when R h or R j is =O, the R h or R j on the same carbon atom is absent, such that the carbon has proper valency. In some embodiments, R h and R j are independently selected from R 11 and hydrogen, and (i) an R e and an R f join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 . [0243] In some embodiments, for a compound according to Formula IIIE, R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, for a compound according to Formula IIIE, R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, when R h and R j join together to form a 3-4 membered carbocycle or heterocycle, no combination of an R e and an R f join together to form a 4-6 membered ring. In some embodiments, when R h and R j join together to form a 3-4 membered carbocycle or heterocycle, no combination of one or more R e s and/or one or more R f s join together to form a ring. In some embodiments, R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R h and R j join together to form a 3-4 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R h and R j join together to form a cyclopropane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R h and R j join together to form a cyclobutane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R h and R j join together to form a 3-4 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R j is hydrogen, and a R h and a R e or a R h and a R f optionally join together to form a 3-6 membered ring (e.g., a pyridine) that is unsubstituted or substituted with one or more R 11 . [0244] In some embodiments for a compound according to Formula IIIE, each R e and R f is independently selected from R 11 and hydrogen. In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R e and R f is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, each R e and R f is independently selected from hydrogen and R 11 , wherein each R 11 is independently selected from -OR 12 , halogen, a 5-6 membered heteroaryl, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, each R e and R f is hydrogen. It will be appreciated that when R e or R f is =O, the other R e or R f on the same carbon atom is absent, such that the carbon has proper valency. [0245] In some embodiments, for a compound according to Formula selected from: [0246] In some embodiments, the compound is a compound according to Formula IIIF, IIIG, or IIIH: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; and each R e and R f is independently selected from R 11 and hydrogen, wherein: (i) an R e and an R f can optionally join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 . [0247] In some embodiments, the compound is a compound according to Formula IIIF, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIG, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIH, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0248] In some embodiments, the present disclosure provides a compound of Formula IIIF or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIG or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIH or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0249] In some embodiments, for a compound according to Formula IIIF, IIIG, or IIIH, each R e and R f is independently selected from R 11 and hydrogen. In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R e and R f is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, each R e is hydrogen. In some embodiments, each R f is hydrogen. In some embodiments, each R e and R f is hydrogen. It will be appreciated that when R e or R f is =O, the other R e or R f on the same carbon atom is absent, such that the carbon has proper valency. [0250] In some embodiments, for a compound according to Formula [0251] In some embodiments, the compound is a compound according to Formula IIIJ: (IIIJ), or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R e and R f is independently selected from R 11 and hydrogen, wherein: (i) an R e and an R f can optionally join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 ; and R g is R 11 , or a R g and a R e or a R g and a R f optionally join together to form a 3-6 membered ring that is unsubstituted or substituted with one or more R 11 . [0252] In some embodiments, the present disclosure provides a compound of Formula IIIJ or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0253] In some embodiments, for a compound according to Formula IIIJ, each R e and R f is independently selected from R 11 and hydrogen. In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R e and R f is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, each R e is hydrogen. In some embodiments, each R f is hydrogen. In some embodiments, each R e and R f is hydrogen. It will be appreciated that when R e or R f is =O, the other R e or R f on the same carbon atom is absent, such that the carbon has proper valency. In some embodiments, an R e and an R f join together to form a 4-6 membered ring. [0254] In some embodiments, for a compound according to Formula structure selected from: , [0255] In some embodiments, for a compound according to any one of Formulas IIID, IIIE, IIIF, IIIG, IIIH, and IIIJ, an R e and an R f join together to form a 4-6 membered ring. In some embodiments, the 4-6 membered ring is a 4-6 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, the 4-6 membered ring is a 4-6 membered carbocycle that is unsubstituted. In some embodiments, the 4-6 membered ring is a 4-6 membered heterocycle that is unsubstituted. In some embodiments, the 4-6 membered ring is a 4-6 membered carbocycle or heterocycle that is substituted with one or more R 11 . In some embodiments, when an R e and an R f join together to form a 4-6 membered ring, then no additional rings are formed by any combination of R e s and R f s. [0256] In some embodiments, for a compound according to any one of Formulas IIID, IIIE, IIIF, IIIG, IIIH, and IIIJ, a first R f and a second R f connected to adjacent atoms join together to form a 3-5 membered ring. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered heterocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle or heterocycle that is substituted with one or more R 11 . In some embodiments, when a first R f and a second R f connected to adjacent atoms join together to form a 3-5 membered ring, then no additional rings are formed by any combination of R e s and R f s. [0257] In some embodiments, for a compound according to any one of Formulas IIID, IIIE, IIIF, IIIG, IIIH, and IIIJ, a first R e and a second R e connected to adjacent atoms join together to form a 3-5 membered ring. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered heterocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle or heterocycle that is substituted with one or more R 11 . In some embodiments, when a first R e and a second R e connected to adjacent atoms join together to form a 3-5 membered ring, then no additional rings are formed by any combination of R e s and R f s. [0258] In some embodiments, for a compound according to any one of Formulas IIID, IIIE, IIIF, IIIG, IIIH, and IIIJ, a first R f and a second R f connected to the same atom join together to form a 3-5 membered ring. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle or heterocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered heterocycle that is unsubstituted. In some embodiments, the 3-5 membered ring is a 3-5 membered carbocycle or heterocycle that is substituted with one or more R 11 . In some embodiments, when a first R f and a second R f connected to the same atom join together to form a 3-5 membered ring, then no additional rings are formed by any combination of R e s and R f s. [0259] In some embodiments, for a compound according to Formula IIIJ, R g is selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R g is selected from -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R g is selected from -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, a R g and a R e or a R g and a R f optionally join together to form a 3-6 membered ring that is unsubstituted or substituted with one or more R 11 . [0260] In some embodiments, the compound is a compound according to Formula IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, or IIIR:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; Q is selected from CR h R j , NR g , O, S, and SO 2 ; each R e and R f is independently selected from R 11 and hydrogen; R g , when present, is R 11 ; and R h and R j , when present, are each independently selected from R 11 and hydrogen. [0261] In some embodiments, the compound is a compound according to Formula IIIK, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIL, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIM, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIN, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIP, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIQ, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound according to Formula IIIR, or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. [0262] In some embodiments, the present disclosure provides a compound of Formula IIIK or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIL or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIM or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIN or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIP or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIQ or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments, the present disclosure provides a compound of Formula IIIR or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0263] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, Q is selected from CR h R j , NR g , and O. In some embodiments, Q is CR h R j . In some embodiments, Q is CR h R j and R h and R j are each hydrogen. In some embodiments, Q is CR h R j , R h is hydrogen, and R j is R 11 . In some embodiments, Q is CR h R j and R h and R j are each R 11 . In some embodiments, Q is CR h R j , R h is hydrogen, and R j is selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is NR g . In some embodiments, Q is NR g and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is NR g and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is O. In some embodiments, Q is S or SO 2 . In some embodiments, Q is S. In some embodiments, Q is SO 2 . [0264] In some embodiments for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, each R e and R f is independently selected from R 11 and hydrogen, and each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, each R e and R f is independently selected from R 11 and hydrogen, and each R 11 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, each R e and R f is independently selected from R 11 and hydrogen, and each R 11 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R e and R f is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with –OH or –CN). In some embodiments, each R e and R f is hydrogen. In some embodiments, each R e is hydrogen. In some embodiments, each R f is hydrogen. It will be appreciated that when R e or R f is =O, the other R e or R f on the same carbon atom is absent, such that the carbon has proper valency. [0265] In some embodiments for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, R h and R j , when present, are each independently selected from R 11 and hydrogen, and each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R h and R j , when present, are each independently selected from R 11 and hydrogen, and each R 11 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, at least one of R h and R j is -OR 12 or C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 (e.g., C 1-6 alkyl that is unsubstituted or substituted with – OH or –CN). In some embodiments, R h is hydrogen and R j is R 11 . In some embodiments, R h and R j are each hydrogen. It will be appreciated that when R h or R j is =O, the R h or R j on the same carbon atom is absent, such that the carbon has proper valency. [0266] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, R g , when present, is R 11 , and R 11 is selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R g , when present, is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, R g , when present, is selected from -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . [0267] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, Q is O, and each R e and R f is hydrogen. In some embodiments, Q is O, and at least one R e or R f is R 11 . In some embodiments, Q is O, and at least one R e or R f is R 11 , wherein each R 11 is independently selected from deuterium, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is O, and at least one R e or R f is R 11 , wherein each R 11 is independently selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0268] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, Q is NR g ; each R e and R f is hydrogen; and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is NR g ; at least one R e or R f is R 11 ; and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is NR g ; at least one R e or R f is R 11 ; and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is NR g ; at least one R e or R f is R 11 , wherein each R 11 is independently selected from deuterium, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is NR g ; at least one R e or R f is R 11 , wherein each R 11 is independently selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R g is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . [0269] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, Q is CR h R j ; each R e and R f is hydrogen; and R h and R j are each independently selected from R 11 and hydrogen. In some embodiments, Q is CR h R j ; each R e and R f is hydrogen; and R h and R j are each hydrogen. In some embodiments, Q is CR h R j ; at least one R e or R f is R 11 , wherein each R 11 is independently selected from deuterium, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R h and R j are each independently selected from R 11 and hydrogen. In some embodiments, Q is CR h R j ; at least one R e or R f is R 11 , wherein each R 11 is independently selected from deuterium, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 ; and R h and R j are each hydrogen. In some embodiments, Q is CR h R j ; at least one R e or R f is independently selected from deuterium, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 ; R h is hydrogen; and R j is R 11 . In some embodiments, Q is CR h R j ; at least one R e or R f is independently selected from deuterium, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 ; R h is hydrogen; and R j is selected from deuterium, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0270] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, and IIIR, Q is SO 2 and each R e and R f is hydrogen. In some embodiments, Q is SO 2 and at least one R e or R f is R 11 . In some embodiments, Q is SO 2 , and at least one R e or R f is R 11 , wherein each R 11 is independently selected from deuterium, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q is SO 2 , and at least one R e or R f is R 11 , wherein each R 11 is independently selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0271] In some embodiments, for a compound according to any one of Formulas IIIK, IIIL, IIIM, IIIN, , [0272] In some embodiments, the compound is a compound according to Formula IIIS: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; Q 1 is selected from NR g1 , O, SR h 2, and CR i R j ; Q 2 is selected from NR g2 , O, SR h 2, and CR i R j ; R g1 and R g2 , when present, are independently selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R h is absent or, when present, is independently selected from =O, =N(R 14 ), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R i and R j , when present, are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R e1 , R e2 , R e3 , and R e4 are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein (i) an R e2 and an R e3 optionally join together to form a 5-6 membered ring; or (ii) when Q 2 is NR g2 , R g2 and an R e3 , together with the atoms to which they are attached, optionally join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R 11 , wherein each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . [0273] In some embodiments, the present disclosure provides a compound of Formula IIIS or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0274] In some embodiments, for a compound according to Formula IIIS, Q 1 and Q 2 are each CR i R j , wherein each R i and R j are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 and Q 2 are each CR i R j , and each R i and R j are independently selected from hydrogen, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 and Q 2 are each CR i R j , wherein at least one R i or R j is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 and Q 2 are each CR i R j , and each R i and R j are hydrogen. In some embodiments, Q 1 and Q 2 are each CR i R j , each R i and R j are hydrogen, and at least one R e1 , R e2 , R e3 , or R e4 is selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 and Q 2 are each CR i R j , wherein at least one R i or R j is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R e1 , R e2 , R e3 , and R e4 is hydrogen. In some embodiments, Q 1 and Q 2 are each CR i R j , and an R e2 and an R e3 join together to form a 5-6 membered ring. [0275] In some embodiments, for a compound according to Formula IIIS, Q 1 is CR i R j and Q 2 is NR g2 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 , and R g2 and an R e3 , together with the atoms to which they are attached, join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R 11 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 , and R g2 and an R e3 , together with the atoms to which they are attached, join together to form a 5-membered heteroaryl that is unsubstituted or substituted with one or more R 11 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 , and R g2 and an R e3 , together with the atoms to which they are attached, join together to form a 5-membered heteroaryl comprising two nitrogen atoms that is unsubstituted or substituted with one or more R 11 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 ; R g2 and an R e3 , together with the atoms to which they are attached, join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R 11 ; and R i and R j are each hydrogen. In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 ; R g2 and an R e3 , together with the atoms to which they are attached, join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R 11 ; and R i and/or R j is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 , and R g2 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 ; R g2 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R i and R j are each hydrogen. In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 ; R g2 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 ; and R i and/or R j is selected from deuterium, - OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is CR i R j and Q 2 is NR g2 , and R e2 and an R e3 join together to form a 5-6 membered ring. [0276] In some embodiments, for a compound according to Formula IIIS, Q 2 is CR i R j and Q 1 is NR g1 . In some embodiments, Q 2 is CR i R j and Q 1 is NR g1 , and R g1 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 2 is CR i R j and Q 1 is NR g1 ; R g1 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 ; and R i and R j are each hydrogen. In some embodiments, Q 2 is CR i R j and Q 1 is NR g1 ; R g1 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R i and/or R j is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 2 is CR i R j and Q 1 is NR g1 , and an R e2 and an R e3 join together to form a 5-6 membered ring. [0277] In some embodiments, for a compound according to Formula IIIS, Q 1 is CR i R j and Q 2 is O. In some embodiments, Q 1 is CR i R j and Q 2 is O, wherein R i and R j are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is CR i R j and Q 2 is O, wherein R i and R j are independently selected from hydrogen, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is CR i R j and Q 2 is O, and an R e2 and an R e3 join together to form a 5-6 membered ring. [0278] In some embodiments, for a compound according to Formula IIIS, Q 2 is CR i R j and Q 1 is O. In some embodiments, Q 2 is CR i R j and Q 1 is O, wherein R i and R j are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 2 is CR i R j and Q 1 is O, wherein R i and R j are independently selected from hydrogen, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 2 is CR i R j and Q 1 is O, and an R e2 and an R e3 join together to form a 5-6 membered ring. [0279] In some embodiments, for a compound according to Formula IIIS, Q 1 is CR i R j and Q 2 is SR h 2. In some embodiments, Q 1 is CR i R j and Q 2 is SR h 2; R i and R j are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R h is =O. In some embodiments, Q 1 is CR i R j and Q 2 is SR h 2; R i and R j are independently selected from hydrogen, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R h is =O. In some embodiments, Q 1 is CR i R j and Q 2 is SR h 2; and an R e2 and an R e3 join together to form a 5-6 membered ring. In some embodiments, Q 1 is CR i R j and Q 2 is SR h 2; each R h is =O; and an R e2 and an R e3 join together to form a 5-6 membered ring. [0280] In some embodiments, for a compound according to Formula IIIS, Q 2 is CR i R j and Q 1 is SR h 2. In some embodiments, Q 2 is CR i R j and Q 1 is SR h 2; R i and R j are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R h is =O. In some embodiments, Q 2 is CR i R j and Q 1 is SR h 2; R i and R j are independently selected from hydrogen, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R h is =O. In some embodiments, Q 2 is CR i R j and Q 1 is SR h 2; and an R e2 and an R e3 join together to form a 5-6 membered ring. In some embodiments, Q 2 is CR i R j and Q 1 is SR h 2; each R h is =O; and an R e2 and an R e3 join together to form a 5-6 membered ring. [0281] In some embodiments, for a compound according to Formula IIIS, Q 1 is NR g1 and Q 2 is SR h 2. In some embodiments, Q 1 is NR g1 and Q 2 is SR h 2; each R h is =O; and R g1 is selected from hydrogen, -C(O)(C 1- 6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is NR g1 and Q 2 is SR h 2; each R h is =O; and R g1 is selected from hydrogen, -C(O)(C 1- 6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 1 is NR g1 and Q 2 is SR h 2; each R h is =O; R g1 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and an R e2 and an R e3 join together to form a 5-6 membered ring. [0282] In some embodiments, for a compound according to Formula IIIS, Q 2 is NR g2 and Q 1 is SR h 2. In some embodiments, Q 2 is NR g2 and Q 1 is SR h 2; each R h is =O; and R g2 is selected from hydrogen, -C(O)(C 1- 6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 2 is NR g2 and Q 1 is SR h 2; each R h is =O; and R g2 is selected from hydrogen, -C(O)(C 1- 6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, Q 2 is NR g2 and Q 1 is SR h 2; each R h is =O; R g2 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and an R e2 and an R e3 join together to form a 5-6 membered ring. [0283] In some embodiments, for a compound according to Formula has a , ,

[0285] In all of the preceding embodiments for a compound according to Formula IIIS, it will be appreciated that when an R e , R g , R i , R j , or R 11 is =O, another substitutent that would otherwise be on the same carbon atom is absent, such that the carbon has proper valency. [0286] In some embodiments, the compound is a compound according to Formula IIIT:

or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 , and; dashed lines represent single or double bonds, such that the ring containing Q 1 , Q 2 , Q 3 , and Q 4 is aromatic; Q 1 , Q 2 , Q 3 , and Q 4 are independently selected from C, N, O, and S, wherein at least one of Q 1 , Q 2 , Q 3 , and Q 4 is N; each R e and R f is independently selected from R 11 and hydrogen; and each R g is absent or is independently selected from R 11 and hydrogen. [0287] In some embodiments, the present disclosure provides a compound of Formula IIIT or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0288] In some embodiments, for a compound according to Formula IIIT, Q 1 is C. In some embodiments, Q 1 and Q 2 are C. In some embodiments, Q 1 and Q 2 are C, and Q 3 and Q 4 are N. In some embodiments, Q 1 is C, Q 2 -R g is CH, Q 3 -R g is N, and Q 4 -R g is NH. In some embodiments, Q 1 is C, Q 2 -R g is CH, Q 3 -R g is N, and Q 4 -R g is N(C 1-6 alkyl). [0289] In some embodiments, for a compound according to Formula IIIT, Q 1 is N. In some embodiments, Q 1 and Q 2 are N. In some embodiments, Q 1 and Q 2 are N, and Q 3 and Q 4 are C. In some embodiments, Q 1 is N, Q 2 -R g is N, Q 3 -R g is CH, and Q 4 -R g is CH. In some embodiments, Q 1 is N, Q 2 -R g is N, Q 3 -R g is CC(O)N(R 14 ) 2 , and Q 4 -R g is CH. In some embodiments, Q 1 is N, Q 2 -R g is N, Q 3 -R g is CH, and Q 4 -R g is CC(O)N(R 14 ) 2 . In some embodiments, Q 1 , Q 2 , and Q 3 are N, and Q 4 is C. In some embodiments, Q 1 is N, Q 2 -R g and Q 3 -R g are N, and Q 4 -R g is CH. In some embodiments, Q 1 , Q 3 , and Q 4 are N, and Q 2 is C. In some embodiments, Q 1 is N, Q 3 -R g and Q 4 -R g are N, and Q 2 -R g is CH. In some embodiments, Q 1 , Q 2 , and Q 4 are N, and Q 3 is C. In some embodiments, Q 1 is N, Q 2 -R g and Q 4 -R g are N, and Q 3 -R g is CH. In some embodiments, Q 1 is N, Q 2 -R g and Q 4 -R g are N, and Q 3 -R g is CC(O)N(R 14 ) 2 . [0290] In some embodiments, for a compound according to Formula IIIT, each R g is hydrogen or is absent. In some embodiments, at least one R g is R 11 . [0291] In some embodiments, for a compound according to Formula has a , [0292] In some embodiments, for a compound according to Formula IIIT, at least one R g is R 11 . In some embodiments, the at least one R g is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 . In some embodiments, the at least one R g is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, the at least one R g is selected from deuterium, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, the at least one R g is selected from -OR 12 , -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, the at least one R g is selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . [0293] In some embodiments, for a compound according to Formula structure selected from:

. [0294] In all of the preceding embodiments for a compound according to Formula IIIT, it will be appreciated that when an R e , R f , or R g is =O, another substitutent that would otherwise be on the same carbon atom is absent, such that the carbon has proper valency. Similarly, an R g substituent on Q 2 , Q 3 , or Q 4 may be absent to ensure that a corresponding nitrogen atom has proper valency. [0295] In some embodiments, for a compound according to any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1- 6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, R 24 is halogen (e.g., fluoro). In some embodiments, R 26 is deuterium. [0296] In some embodiments, for a compound according to any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 6 is selected from: , , , , , , any of which [0297] In some embodiments, for a compound according to any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 6 is selected from:

[0298] In some embodiments, for a compound according to any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 6 is selected from: . [0299] In some embodiments, for a compound according to any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 6 is . [0300] In some embodiments, for a compound according to any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is a pyridine substituted with one or more R 15 . In some embodiments, at least one R 15 is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, at least one R 15 , any of which is optionally substituted with one or more R 15 . In some embodiments, R 6 has the structure . [0301] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from -OR 8 , wherein R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl. In some embodiments, R 8 is a heterocycle or an alkylheterocycle, wherein any heterocycle contains 4-8 members and is substituted with one or more R a or R b . In some embodiments, R 8 is a heterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is an alkylheterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is –CH 2 (heterocycle), where the heterocycle is unsubstituted or substituted with one or more R a or R b . In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is a 4-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is an 8- membered bicyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a halogen (e.g., F). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a C 1-6 alkyl (e.g., methyl). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a -OR 12 (e.g., -OCH 3 ). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a 3-6 membered carbocycle (e.g., a cyclopropane). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is deuterium. [0302] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is a halogen. In some embodiments, R a1 and/or R a2 is F. In some embodiments, R a1 and/or R a2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is methyl. In some embodiments, R a1 and/or R a2 is -OC 1-6 alkyl. In some embodiments, R a1 and/or R a2 is H. In some embodiments, R b1 and/or R b2 is H. In some embodiments, R b1 and/or R b2 is a halogen. In some embodiments, R b1 and/or R b2 is F. In some embodiments, R b1 and/or R b2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b1 and/or R b2 is methyl. In some embodiments, each of R a1 and R b1 is F. In some embodiments, R a2 and/or R b2 is D. In some embodiments, R a2 and R b2 join together to form a 3-6 membered carbocycle (e.g., cyclopropane), which carbocycle is optionally substituted with one or more R 13 . In some embodiments, R a1 and R b1 join together to form a 3-6 membered carbocycle (e.g., cyclopropane). In some embodiments, R 1 is selected from: [0303] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. In some embodiments, R 1 is selected from: . [0304] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from: . [0305] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from: . In some embodiments, R a is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R 1 is selected from: . [0306] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and wherein an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1- 6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, one R a or R b is selected from halogen, C 1-6 alkyl, and -OR 12 , and the other R a and R b groups are H. In some embodiments, one R a or R b is halogen (e.g., F). In some embodiments, two R a groups, two R b groups, or an R a and an R b are halogen (e.g., F). In some embodiments, one R a or R b is -OR 12 (e.g., -OCH 3 or –OCHF 2 ). In some embodiments, one R a or R b is C 1-6 alkyl (e.g., methyl). In some embodiments, two R a groups, two R b groups, or an R a and an R b are C 1-6 alkyl (e.g., methyl). In some embodiments, R c is selected from –CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , and –CH 2 CH 2 CN. In some embodiments, an R a and R b join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, R 1 is selected from: , [0307] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from: . [0308] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 1 is selected from:   [0309] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 11 is independently selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R 11 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, heterocycle, or heteroaryl is unsubstituted or substituted with one or more R 20 . [0310] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 5 is a halogen (e.g., F or Cl). In some embodiments, R 5 is Cl. In some embodiments, R 5 is F. In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-2 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted, such as methyl or ethyl. In some embodiments, R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more halogens, such as one or more fluorines. In some embodiments, R 5 is -CF 3 . In some embodiments, R 5 is -CHF 2 . In some embodiments, R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and -CH 2 CH 3 . In some embodiments, R 5 is selected from –CH 3 , -CH 2 CH 3 , - CF 2 H, -CF 3 , -CF 2 CH 3 , and -CH 2 CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more R 13 , wherein each R 13 is independently selected from -OR 14 , -CN, and -N(R 14 ) 2 . In some embodiments, R 5 is -CH 2 CN. [0311] In some embodiments, for a compound of any one of Formulas III, III’, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, R 7 is Cl. In some embodiments, R 7 is F. [0312] In some embodiments, for a compound of any one of Formulas III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, and IIIT, the compound is a not a compound included in Table 2, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. Table 2.

[0313] In another aspect, the present disclosure provides a compound represented by Formula IV: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, phenyl, -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 3-6 membered heterocycle or 5-6 membered heteroaryl is unsubstituted or substituted with one or more =O, R 12 , or R 13 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle. [0314] In some embodiments, the present disclosure provides a compound of Formula IV or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0315] In some embodiments, the present disclosure provides a compound of Formula IV, wherein: R 1 is selected from -OR 8 ; R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 10 ; R 4 is H; R 5 is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, phenyl, -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), and halogen, wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 3-6 membered heterocycle or 5-6 membered heteroaryl is unsubstituted or substituted with one or more =O, R 12 , or R 13 ; each R 12 is independently selected from C 1-6 alkyl and H, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , and -CN; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle. [0316] In some embodiments, the present disclosure provides a compound of Formula IV-a: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R 2 and R 3 are as defined for Formula IV above and described in classes and subclasses herein, both singly and in combination. In some embodiments, the present disclosure provides a compound of Formula IV-a, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0317] In some embodiments, the compound is a compound according to Formula IVA: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle; and each R i and R h is independently selected from H and R 10 . [0318] In some embodiments, the present disclosure provides a compound of Formula IVA or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0319] In some embodiments, for a compound according to Formula IVA, each R i and R h is independently selected from H and R 10 , and each each R 10 is independently selected from -OR 14 , =O, -CN, -NH(C 1-6 alkyl), -N(C 1-6 alkyl) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 . In some embodiments, each R i and R h is independently selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, each R i and R h is hydrogen. It will be appreciated that when R h or R i is =O, the R h or R i on the same carbon atom is absent, such that the carbon has proper valency. [0320] In some embodiments, for a compound according to Formula IVA, R 14 is H. [0321] In some embodiments, for a compound according to Formula IV or IVA, R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1- 6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, R 24 is halogen (e.g., fluoro). In some embodiments, R 26 is deuterium. [0322] In some embodiments, for a compound according to Formula IV or IVA, R 6 is selected from:

any of which is substituted with one or more R 15 . [0323] In some embodiments, for a compound according to Formula IV or IVA, R 6 is selected from:

. [0325] In some embodiments, for a compound according to Formula I [0326] In some embodiments, the compound is a compound according to Formula IVB: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 10 ; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, phenyl, -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 3-6 membered heterocycle or 5-6 membered heteroaryl is unsubstituted or substituted with one or more =O, R 12 , or R 13 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . [0327] In some embodiments, the present disclosure provides a compound of Formula IVB or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0328] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from -OR 8 , wherein R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl. In some embodiments, R 8 is a heterocycle or an alkylheterocycle, wherein any heterocycle contains 4-8 members and is substituted with one or more R a or R b . In some embodiments, R 8 is a heterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is an alkylheterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is -CH 2 (heterocycle), where the heterocycle is unsubstituted or substituted with one or more R a or R b . In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is a 4-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is an 8- membered bicyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a halogen (e.g., F). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a C 1-6 alkyl (e.g., methyl). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a -OR 12 (e.g., -OCH 3 ). [0329] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. In some embodiments, R 1 is selected from: . [0330] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from: , , , , , . [0331] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from: . In some embodiments, R a is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R 1 is selected from: . [0332] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and wherein an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, one R a or R b is selected from halogen, C 1-6 alkyl, and -OR 12 , and the other R a and R b groups are H. In some embodiments, one R a or R b is halogen (e.g., F). In some embodiments, two R a groups, two R b groups, or an R a and an R b are halogen (e.g., F). In some embodiments, one R a or R b is -OR 12 (e.g., -OCH 3 or – OCHF 2 ). In some embodiments, one R a or R b is C 1-6 alkyl (e.g., methyl). In some embodiments, two R a groups, two R b groups, or an R a and an R b are C 1-6 alkyl (e.g., methyl). In some embodiments, R c is selected from –CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , and –CH 2 CH 2 CN. In some embodiments, an R a and R b join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, R 1 is selected from: , [0333] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from: . [0334] In some embodiments, for a compound of any one of Formulas IV, IVA, or IVB, R 1 is selected from:   [0335] In some embodiments, the compound is a compound according to Formula IVC, (IVC),  or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 10 ; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen, -CN, and H; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 3-6 membered heterocycle, a 5-6 membered heteroaryl, phenyl, S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 3-6 heterocycle or 5-6 membered heteroaryl is unsubstituted or substituted with one or more =O, R 12 , or R 13 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . [0336] In some embodiments, the present disclosure provides a compound of Formula IVC or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0337] In some embodiments, for a compound according to Formula IVC, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. [0338] In some embodiments, for a compound according to Formula IVB or IVC, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, X is C-CN, Y is S, R 23 is - N(R 12 ) 2 , and R 24 is a halogen (e.g., F). In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). In some embodiments, R 26 is deuterium. [0339] In some embodiments, for a compound according to any one of Formulas IV, IV-a, IVA, IVB, or IVC, R 2 is H. In some embodiments, R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is selected from C 1-6 alkyl that is unsubstituted. In some embodiments, R 2 is selected from C 1-6 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is selected from C 1-2 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is selected from C 1-2 alkyl that is unsubstituted. In some embodiments, R 2 is selected from C 1-2 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl. In some embodiments, R 2 is a 3-6 membered carbocycle (e.g., a cyclopropane). [0340] In some embodiments, for a compound according to any one of Formula IV, IV-a, IVB, and IVC, R 3 is selected from C 1-6 alkyl that is unsubstituted. In some embodiments, R 3 is selected from C 1-6 alkyl that is substituted with one or more R 10 . In some embodiments, R 3 is selected from C 1-6 alkyl that is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 5-6 membered heteroaryl, -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 5-6 membered heteroaryl is unsubstituted or substituted with one or more R 13 . In some embodiments, R 3 is selected from C 1-6 alkyl that is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, - NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2- 6 alkenyl. In some embodiments, R 3 is selected from C 1-3 alkyl that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is selected from C 1-3 alkyl that is unsubstituted or is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 5-6 membered heteroaryl, -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 5-6 membered heteroaryl is unsubstituted or substituted with one or more R 13 . In some embodiments, R 3 is selected from C 1-3 alkyl that is unsubstituted or is substituted with one or more R 10 , wherein each R 10 is independently selected from - OR 14 , =O, -CN, -NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1- 6 alkyl and C 2-6 alkenyl. In some embodiments, R 3 is selected from C 1-3 alkyl that is unsubstituted. In some embodiments, R 3 is selected from C 1-3 alkyl that is substituted with one or more R 10 . In some embodiments, R 3 is selected from C 1-3 alkyl that is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 5-6 membered heteroaryl, -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 5-6 membered heteroaryl is unsubstituted or substituted with one or more R 13 . In some embodiments, R 3 is selected from C 1-3 alkyl that is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2-6 alkenyl. In some embodiments, R 3 is C 2-3 alkyl that is unsubstituted or is substituted with one or more R 10 . In some embodiments, R 3 is C 2-3 alkyl that is unsubstituted or is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 5-6 membered heteroaryl, -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 5-6 membered heteroaryl is unsubstituted or substituted with one or more R 13 . In some embodiments, R 3 is C 2-3 alkyl that is unsubstituted or is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2-6 alkenyl. In some embodiments, R 3 is C 2-3 alkyl that is unsubstituted. In some embodiments, R 3 is C 2-3 alkyl that is substituted with one or more R 10 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, -NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2- 6 alkenyl. In some embodiments, R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein the one or more R 10 are selected from -OR 14 , -CN, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein the one or more R 10 are selected from -OR 14 and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein the one or more R 10 are halogen. In some embodiments, R 3 is C 2-3 alkyl that is substituted with one or more F. In some embodiments, R 3 is C 1-3 alkyl that is substituted with a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more =O, R 12 , or R 13 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with a 5-6 membered heteroaryl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 3 is C 1-3 alkyl that is substituted with an oxazole, isoxazole, pyridine, pyrazine, pyridazine, or pyrimidine that is unsubstituted or substituted with one or more =O, R 12 , or R 13 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with a pyridine that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with a pyridine that is substituted with one or more R 13 . In some embodiments, R 3 is C 2-3 alkyl that is substituted with - N(R 14 )C(O)(C 1-6 alkyl). In some embodiments, R 3 is C 2-3 alkyl that is substituted with -S(O) 2 (C 1-6 alkyl). In some embodiments, R 3 is C 1-3 alkyl that is substituted with a 3-6 membered heterocycle (e.g., oxetane). In some embodiments, R 3 is C 1-3 alkyl that is substituted with a phenyl. [0341] In some embodiments, for a compound according to any one of Formula IV, IV-a, IVB, and IVC, the moiety is selected from: , any of which is optionally further substituted with one or more R 10 . [0342] In some embodiments, for a compound according to any one of Formula IV, IVA, IVB, and IVC, R 5 is H. In some embodiments, R 5 is a halogen (e.g., F or Cl). In some embodiments, R 5 is Cl. In some embodiments, R 5 is F. In some embodiments, R 5 is -CN. In some embodiments, R 5 is -OR 12 , wherein R 12 is selected from C 1-6 alkyl and H. In some embodiments, R 5 is -OCH 3 . In some embodiments, R 5 is -OCF 3 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-2 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted, such as methyl or ethyl. In some embodiments, R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more halogens, such as one or more fluorines. In some embodiments, R 5 is -CF 3 . In some embodiments, R 5 is -CHF 2 . In some embodiments, R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and -CH 2 CH 3 . In some embodiments, R 5 is selected from –CH 3 , -CH 2 CH 3 , -CF 2 H, -CF 3 , -CF 2 CH 3 , and -CH 2 CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more R 13 , wherein each R 13 is independently selected from –OR 14 , -CN, and -N(R 14 ) 2 . In some embodiments, R 5 is -CH 2 CN. In some embodiments, R 5 is a 3-6 membered heterocycle. In some embodiments, R 5 is a 5-6 membered heteroaryl, such as a furan. [0343] In some embodiments, for a compound according to any one of Formula IV, IVA, IVB, and IVC, R 7 is H. In some embodiments, R 7 is a halogen (e.g., F or Cl). In some embodiments, R 7 is Cl. In some embodiments, R 7 is F. In some embodiments, R 7 is -CN. [0344] In some embodiments, for a compound of any one of Formulas IV, IVA, IVB, and IVC, the compound is a not a compound included in Table 3, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof.

Table 3. [0345] In another aspect, the present disclosure provides a compound represented by Formula V: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R m is selected from hydrogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0346] In some embodiments, the present disclosure provides a compound of Formula V or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0347] In some embodiments, the present disclosure provides a compound of Formula V, wherein: R 1 is selected from -OR 8 ; R m is selected from hydrogen and C 1-6 alkyl; R 4 is H; R 5 is C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is H; each R 13 is halogen; each R 15 is independently selected from halogen, -N(R 12 ) 2 , and -CN; and R a and R b are each independently selected from halogen, and H. [0348] In some embodiments, the present disclosure provides a compound of Formula V-a: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R m is as defined for Formula V above and described in classes and subclasses herein, both singly and in combination. In some embodiments, the present disclosure provides a compound of Formula V-a, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0349] In some embodiments, for a compound according to Formula V or V-a, R m is hydrogen. In some embodiments, R m is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R m is C 1-6 alkyl that is unsubstituted. In some embodiments, R m is methyl that is unsubstituted. In some embodiments, R m is C 1-6 alkyl that is substituted with one or more R 13 . [0350] In some embodiments, the compound is a compound according to Formula VA: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0351] In some embodiments, the present disclosure provides a compound of Formula VA or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0352] In some embodiments, the compound is a compound according to Formula VB: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R m is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . [0353] In some embodiments, the present disclosure provides a compound of Formula VB or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0354] In some embodiments, for a compound according to any one of Formulas V, VA, and VB, R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1- 6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, R 24 is halogen (e.g., fluoro). In some embodiments, R 26 is deuterium. [0355] In some embodiments, for a compound according to any one of Formulas V, VA, and VB, R 6 is selected from: , , , , , , any of which [0356] In some embodiments, for a compound according to any one of Formulas V, VA, and VB, R 6 is selected from: selected from:

. [0358] In some embodiments, for a compound according to any one of Formulas V, VA, and VB, R 6 is . [0359] In some embodiments, for a compound according to any one of Formulas V, VA, and VB, R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is a pyridine substituted with one or more R 15 . In some embodiments, at least one R 15 is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, at least one R 15 , any of which is optionally substituted with one or more R 15 . In some embodiments, R 6 has the structure . [0360] In some embodiments, the compound is a compound according to Formula VC: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein: R 1 is selected from R m is selected from hydrogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . [0361] In some embodiments, the present disclosure provides a compound of Formula VC or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0362] In some embodiments, for a compound of Formula VC, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and R 24 is a halogen (e.g., F). In some embodiments, X is C-CN, Y is S, R 23 is -N(R 12 ) 2 , and one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). In some embodiments, R 26 is deuterium. [0363] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from -OR 8 , wherein R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl. In some embodiments, R 8 is a heterocycle or an alkylheterocycle, wherein any heterocycle contains 4-8 members and is substituted with one or more R a or R b . In some embodiments, R 8 is a heterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is an alkylheterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is –CH 2 (heterocycle), where the heterocycle is unsubstituted or substituted with one or more R a or R b . In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is a 4-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is an 8- membered bicyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a halogen (e.g., F). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a C 1-6 alkyl (e.g., methyl). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a -OR 12 (e.g., -OCH 3 ). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a 3-6 membered carbocycle (e.g., a cyclopropane). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is deuterium. [0364] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is a halogen. In some embodiments, R a1 and/or R a2 is F. In some embodiments, R a1 and/or R a2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is methyl. In some embodiments, R a1 and/or R a2 is -OC 1-6 alkyl. In some embodiments, R a1 and/or R a2 is H. In some embodiments, R b1 and/or R b2 is H. In some embodiments, R b1 and/or R b2 is a halogen. In some embodiments, R b1 and/or R b2 is F. In some embodiments, R b1 and/or R b2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b1 and/or R b2 is methyl. In some embodiments, each of R a1 and R b1 is F. In some embodiments, R a2 and/or R b2 is D. In some embodiments, R a2 and R b2 join together to form a 3-6 membered carbocycle (e.g., cyclopropane), which carbocycle is optionally substituted with one or more R 13 . In some embodiments, R a1 and R b1 join together to form a 3-6 membered carbocycle (e.g., cyclopropane). In some embodiments, R 1 is selected from: , [0365] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. In some embodiments, R 1 is selected from: . [0366] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from: . [0367] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from: . In some embodiments, R a is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R 1 is selected from: [0368] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and wherein an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1- 6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, one R a or R b is selected from halogen, C 1-6 alkyl, and -OR 12 , and the other R a and R b groups are H. In some embodiments, one R a or R b is halogen (e.g., F). In some embodiments, two R a groups, two R b groups, or an R a and an R b are halogen (e.g., F). In some embodiments, one R a or R b is -OR 12 (e.g., -OCH 3 or –OCHF 2 ). In some embodiments, one R a or R b is C 1-6 alkyl (e.g., methyl). In some embodiments, two R a groups, two R b groups, or an R a and an R b are C 1-6 alkyl (e.g., methyl). In some embodiments, R c is selected from –CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , and –CH 2 CH 2 CN. In some embodiments, an R a and R b join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, R 1 is selected from:

[0369] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from: . [0370] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 1 is selected from:   [0371] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 5 is a halogen (e.g., F or Cl). In some embodiments, R 5 is Cl. In some embodiments, R 5 is F. In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-2 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted, such as methyl or ethyl. In some embodiments, R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more halogens, such as one or more fluorines. In some embodiments, R 5 is -CF 3 . In some embodiments, R 5 is -CHF 2 . In some embodiments, R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and -CH 2 CH 3 . In some embodiments, R 5 is selected from –CH 3 , -CH 2 CH 3 , - CF 2 H, -CF 3 , -CF 2 CH 3 , and -CH 2 CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more R 13 , wherein each R 13 is independently selected from -OR 14 , -CN, and -N(R 14 ) 2 . In some embodiments, R 5 is -CH 2 CN. [0372] In some embodiments, for a compound of any one of Formulas V, VA, VB, and VC, R 7 is Cl. In some embodiments, R 7 is F. [0373] In another aspect, the present disclosure provides a compound represented by Formula VI: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from H and halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, - C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, a 5-6 membered aryl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , a 3-6 membered carbocycle, and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; R e is selected from R f is selected from H, halogen, and C 1-6 alkyl; R g and R h are independently selected from H and C 1-6 alkyl; and R j is selected from C 1-6 alkyl, provided that R e is not . [0374] In some embodiments, the present disclosure provides a compound of Formula VI, or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0375] In some embodiments, the present disclosure provides a compound of Formula VI, wherein: R 1 is selected from -OR 8 ; R 2 is C 1-6 alkyl; R 4 is H; R 5 is C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is halogen; R 8 is an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is H; each R 13 is halogen; each R 15 is independently selected from halogen, -N(R 12 ) 2 , and -CN; each R 20 is -OC 1-6 alkyl; R a and R b are each independently selected from halogen and H; each R d is independently selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; R f is selected from H, halogen, and C 1-6 alkyl; R g and R h are independently selected from H and C 1-6 alkyl; and R j is selected from C 1-6 alkyl, provided that R e is not . [0376] In some embodiments, the present disclosure provides a compound of Formula VI-a: or a salt (e.g., pharmaceutically acceptable salt), ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, wherein R 2 , R d , and R e are as defined for Formula VI above and described in classes and subclasses herein, both singly and in combination. In some embodiments, the present disclosure provides a compound of Formula VI-a, or a salt (e.g., pharmaceutically acceptable salt) thereof. [0377] In some embodiments, for a compound according to Formula VI or VI-a, R e is selected from . In some embodiments, R g and R h are H, and R f is not H. In some embodiments, R g is H, and at least one of R h and R f is not H. In some embodiments, R f is H, and at least one of R g and R h is not H. [0378] In some embodiments, for a compound according to Formula some embodiments, R j is C 1-3 alkyl. [0379] In some embodiments, for a compound according to Formula . [0380] In some embodiments, for a compound according to Formula VI or VI-a, each R d is H. In some embodiments, at least one R d is not H. In some embodiments, at least one R d is selected from C 1-6 alkyl that is substituted with one or more R 20 (e.g., one or more –OC 1-6 alkyl). In some embodiments, at least one R d is selected from C 1-6 alkyl. In some embodiments, one R d is selected from C 1-6 alkyl and each other R d is H. [0381] In some embodiments, for a compound according to Formula VI, R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is a pyridine substituted with one or more R 15 . In some embodiments, at least one R 15 is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, at least one R 15 is -N(R 12 ) 2 . In , any of which is optionally substituted with one or more R 15 . In some embodiments, [0382] In some embodiments, for a compound according to Formula VI, R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . In some embodiments, R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1- 6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . In some embodiments, X is C-CN and Y is S. In some embodiments, X is C-CN and Y is O. In some embodiments, X is N and Y is S. In some embodiments, X is N and Y is O. In some embodiments, X is C-CN, Y is S, and R 23 is -N(R 12 ) 2 . In some embodiments, X is C-CN, Y is S, and R 23 is -NH 2 . In some embodiments, R 24 is halogen (e.g., fluoro). In some embodiments, R 26 is deuterium. [0383] In some embodiments, for a compound according to Formula VI, R 6 is selected from: any of which [0384] In some embodiments, for a compound according to Formula VI, R 6 is selected from:

[0385] In some embodiments, for a compound according to Formula VI, R 6 is selected from: . [0386] In some embodiments, for a compound according to Formula [0387] In some embodiments, for a compound of Formula VI or VI-a, R 2 is H. In some embodiments, R 2 is a C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is a C 1- 6 alkyl that is unsubstituted. In some embodiments, R 2 is a C 1-6 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is a C 1-2 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R 2 is a C 1-2 alkyl that is unsubstituted. In some embodiments, R 2 is a C 1-2 alkyl that is substituted with one or more R 13 . In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl. In some embodiments, R 2 is a 3-6 membered carbocycle (e.g., cyclopropane). [0388] In some embodiments, for a compound of Formula VI, R 1 is selected from -OR 8 , wherein R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl. In some embodiments, R 8 is a heterocycle or an alkylheterocycle, wherein any heterocycle contains 4-8 members and is substituted with one or more R a or R b . In some embodiments, R 8 is a heterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is an alkylheterocycle that is unsubstituted or substituted with one or more R a or R b . In some embodiments, R 8 is –CH 2 (heterocycle), where the heterocycle is unsubstituted or substituted with one or more R a or R b . In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is a 4-6 membered monocyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is an 8- membered bicyclic heterocycle having 1-2 heteroatoms independently selected from N, O, and S. In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a halogen (e.g., F). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a C 1-6 alkyl (e.g., methyl). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a -OR 12 (e.g., -OCH 3 ). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is a 3-6 membered carbocycle (e.g., a cyclopropane). In some embodiments, a heterocycle or a heterocycle of an alkylheterocycle is substituted with one or more R a or R b , wherein the one or more R a or R b is deuterium. [0389] In some embodiments, for a compound according to Formula VI, R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b2 are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a1 and R b1 and/or R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is a halogen. In some embodiments, R a1 and/or R a2 is F. In some embodiments, R a1 and/or R a2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a1 and/or R a2 is methyl. In some embodiments, R a1 and/or R a2 is -OC 1- 6 alkyl. In some embodiments, R a1 and/or R a2 is H. In some embodiments, R b1 and/or R b2 is H. In some embodiments, R b1 and/or R b2 is a halogen. In some embodiments, R b1 and/or R b2 is F. In some embodiments, R b1 and/or R b2 is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b1 and/or R b2 is methyl. In some embodiments, each of R a1 and R b1 is F. In some embodiments, R a2 and/or R b2 is D. In some embodiments, R a2 and R b2 join together to form a 3-6 membered carbocycle (e.g., cyclopropane), which carbocycle is optionally substituted with one or more R 13 . In some embodiments, R a1 and R b1 join together to form a 3-6 membered carbocycle (e.g., cyclopropane). In some embodiments, R 1 is selected from: , , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is a halogen. In some embodiments, R a is F. In some embodiments, R a is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R a is -OC 1-6 alkyl. In some embodiments, R a is H. In some embodiments, R b is H. In some embodiments, R b is a halogen. In some embodiments, R b is F. In some embodiments, R b is C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . In some embodiments, R b is methyl. In some embodiments, each of R a and R b is F. In some embodiments, each of R a and R b is methyl. In some embodiments, R 1 is selected from: . [0391] In some embodiments, for a compound of Formula VI, R 1 is selected from: . [0392] In some embodiments, for a compound of Formula VI, R 1 is selected from: . In some embodiments, R a is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R a is methyl. In some embodiments, R 1 is selected from: [0393] In some embodiments, for a compound of Formula VI, R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and wherein an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, each R a and R b is independently selected from halogen, C 1- 6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . In some embodiments, one R a or R b is selected from halogen, C 1-6 alkyl, and -OR 12 , and the other R a and R b groups are H. In some embodiments, one R a or R b is halogen (e.g., F). In some embodiments, two R a groups, two R b groups, or an R a and an R b are halogen (e.g., F). In some embodiments, one R a or R b is -OR 12 (e.g., -OCH 3 or –CHF 2 ). In some embodiments, one R a or R b is C 1- 6 alkyl (e.g., methyl). In some embodiments, two R a groups, two R b groups, or an R a and an R b are C 1-6 alkyl (e.g., methyl). In some embodiments, R c is selected from –CH 3 , -CH 2 CH 2 F, -CH 2 CHF 2 , and –CH 2 CH 2 CN. In some embodiments, an R a and R b join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R b attached to the same carbon atom join together to form a 3-6 membered carbocycle, such as a cyclopropane. In some embodiments, an R a and R c join together to form a 3-6 membered heterocycle. In some embodiments, R 1 is selected from: [0394] In some embodiments, for a compound of Formula VI, R 1 is selected from: . [0395] In some embodiments, for a compound of Formula VI, R 1 is selected from: .  [0396] In some embodiments, for a compound of Formula VI, R 5 is H. In some embodiments, R 5 is a halogen (e.g., F or Cl). In some embodiments, R 5 is Cl. In some embodiments, R 5 is F. In some embodiments, R 5 is -CN. In some embodiments, R 5 is -OR 12 , wherein R 12 is selected from C 1-6 alkyl and H. In some embodiments, R 5 is -OCH 3 . In some embodiments, R 5 is -OCF 3 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-2 alkyl that is unsubstituted or substituted with one or more R 13 . In some embodiments, R 5 is selected from C 1-6 alkyl that is unsubstituted, such as methyl or ethyl. In some embodiments, R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more halogens, such as one or more fluorines. In some embodiments, R 5 is -CF 3 . In some embodiments, R 5 is -CHF 2 . In some embodiments, R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and -CH 2 CH 3 . In some embodiments, R 5 is selected from –CH 3 , -CH 2 CH 3 , -CF 2 H, -CF 3 , -CF 2 CH 3 , and -CH 2 CN. In some embodiments, R 5 is C 1-6 alkyl that is substituted with one or more R 13 , wherein each R 13 is independently selected from -OR 14 , -CN, and -N(R 14 ) 2 . In some embodiments, R 5 is -CH 2 CN. In some embodiments, R 5 is a 3-6 membered heterocycle. In some embodiments, R 5 is a 5-6 membered heteroaryl, such as a furan. [0397] In some embodiments, for a compound of Formula VI, R 7 is Cl. In some embodiments, R 7 is F. In some embodiments, R 7 is a halogen. In some embodiments, R 7 is H [0398] In some embodiments, for a compound of Formula VI, the compound is a not a compound included in Table 4, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. Table 4. [0399] Also provided herein are embodiments wherein any embodiment described herein may be combined with any one or more of these embodiments, provided the combination is not mutually exclusive. As used herein, two embodiments are “mutually exclusive” when one is defined to be something which is different than the other. For example, an embodiment wherein two groups combine to form a ring is mutually exclusive with an embodiment in which one group is ethyl and the other group is hydrogen. Similarly, an embodiment wherein one group is CH 2 is mutually exclusive with an embodiment wherein the same group is NH. [0400] In some embodiments of any of the preceding aspects, the compound is a compound included in Table 5, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound included in Table 5, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments of any of the preceding aspects, the compound is a compound included in Table 6, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound included in Table 6, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments of any of the preceding aspects, the compound is a compound included in Table 7, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound included in Table 7, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments of any of the preceding aspects, the compound is a compound included in Table 8, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound included in Table 8, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments of any of the preceding aspects, the compound is a compound included in Table 9, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound included in Table 9, or a salt (e.g., a pharmaceutically acceptable salt) thereof. In some embodiments of any of the preceding aspects, the compound is a compound included in Table 10, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the compound is a compound included in Table 10, or a salt (e.g., a pharmaceutically acceptable salt) thereof. [0401] Also provided herein is a compound selected from Table 5, Table 6, Table 7, Table 8, Table 9, or Table 10 or any of the Examples provided herein, or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the present disclosure provides a compound selected from Table 5, Table 6, Table 7, Table 8, Table 9, or Table 10 or any of the Examples provided herein, or a salt thereof. [0402] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of interacting with a residue at the 12 and/or 13 and/or 61 position of the KRAS protein (e.g., a glutamine, histidine, cysteine, valine, aspartic acid, serine, alanine, arginine, or glycine residue). In some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of non-covalently interacting with a residue at the 12 and/or 13 and/or 61 position of the KRAS protein (e.g., a glutamine, histidine, cysteine, valine, aspartic acid, serine, alanine, arginine, or glycine residue), such as via one or more van der Waals, hydrogen bonding, ionic, or other interactions. [0403] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12C mutation relative to KRAS having other residues at the 12 position of the P loop, such as arginine (R), glycine (G), valine (V), serine (S), alanine (A), and aspartic acid (D). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G12C mutation relative to KRAS having other residues at the 12 position of the P loop, such as arginine (R), glycine (G), valine (V), serine (S), alanine (A), and aspartic acid (D). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12C mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100- fold, or greater binding selectivity for KRAS having a G12C mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12C mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12C mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G12C mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G12C mutation and one or more additional mutations, such as a mutation at codon 13 (to, e.g., D or C) or codon 61. [0404] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12R mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), valine (V), serine (S), alanine (A), and aspartic acid (D). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G12R mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), valine (V), serine (S), alanine (A), and aspartic acid (D). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12R mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100- fold, or greater binding selectivity for KRAS having a G12R mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12R mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12R mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G12R mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G12R mutation and one or more additional mutations, such as a mutation at codon 13 (to, e.g., D or C) or codon 61. [0405] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12V mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), serine (S), alanine (A), and aspartic acid (D). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G12V mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), serine (S), alanine (A), and aspartic acid (D). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12V mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100- fold, or greater binding selectivity for KRAS having a G12V mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12V mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12V mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G12V mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G12V mutation and one or more additional mutations, such as a mutation at codon 13 (to, e.g., D or C) or codon 61. [0406] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12S mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), alanine (A), and aspartic acid (D). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G12S mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), alanine (A), and aspartic acid (D). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12S mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12S mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12S mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12S mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G12S mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G12S mutation and one or more additional mutations, such as a mutation at codon 13 (to, e.g., D or C) or codon 61. [0407] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12A mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), serine (S), and aspartic acid (D). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G12A mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), serine (S), and aspartic acid (D). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12A mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100- fold, or greater binding selectivity for KRAS having a G12A mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12A mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12A mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G12A mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G12A mutation and one or more additional mutations, such as a mutation at codon 13 (to, e.g., D or C) or codon 61. [0408] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12D mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), serine (S), and alanine (A). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G12D mutation relative to KRAS having other residues at the 12 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), serine (S), and alanine (A). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12D mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100- fold, or greater binding selectivity for KRAS having a G12D mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G12D mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G12D mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G12D mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G12D mutation and one or more additional mutations, such as a mutation at codon 13 (to, e.g., D or C) or codon 61. [0409] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G13D mutation relative to KRAS having other residues at the 13 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), serine (S), and alanine (A). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a G13D mutation relative to KRAS having other residues at the 13 position of the P loop, such as cysteine (C), glycine (G), arginine (R), valine (V), serine (S), and alanine (A). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G13D mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100- fold, or greater binding selectivity for KRAS having a G13D mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a G13D mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a G13D mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a G13D mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a G13D mutation and one or more additional mutations, such as a mutation at codon 12 (to, e.g., D, C, A, S, V, or R) or codon 61. [0410] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a Q61H mutation relative to KRAS having other residues at the 61 position of the P loop, such as glutamine (Q). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater selectivity for KRAS having a Q61H mutation relative to KRAS having other residues at the 61 position of the P loop, such as glutamine (Q). In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a Q61H mutation relative to wild-type KRAS. For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a Q61H mutation relative to wild-type KRAS. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, binds selectively to KRAS having a Q61H mutation relative to other forms of RAS (e.g., HRAS and NRAS). For example, in some embodiments, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, demonstrates at least 1.5, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100-fold, or greater binding selectivity for KRAS having a Q61H mutation relative to another form of RAS (e.g., HRAS or NRAS), such as an HRAS or NRAS protein having a Q61H mutation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of binding to a KRAS protein having a Q61H mutation and one or more additional mutations, such as a mutation at codon 12 (to, e.g., D, C, A, S, V, or R) or codon 13 (to, e.g., D). [0411] In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of selectively binding a KRAS protein in an active (GTP-bound) conformation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of selectively binding a KRAS protein in an inactive (GDP-bound) conformation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, is capable of selectively binding a KRAS protein in both active (GTP-bound) and inactive (GDP-bound) conformations. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, has higher selectivity for a KRAS protein in its active (GTP-bound) conformation than in its inactive (GDP-bound) conformation. In some embodiments of any of the preceding aspects, a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, has higher selectivity for a KRAS protein in its inactive (GDP-bound) conformation than in its active (GTP-bound) conformation. Compositions [0412] The present disclosure also provides a composition (e.g., a pharmaceutical composition) comprising a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, a provided composition comprises a compound provided herein, or a pharmaceutically acceptable salt thereof. For example, the present disclosure provides a pharmaceutical composition comprising a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, together with a pharmaceutically acceptable carrier. In some embodiments, a provided pharmaceutical composition comprises a compound provided herein or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier. [0413] In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the oral pharmaceutical formulation is selected from a tablet and a capsule. [0414] In some embodiments, the pharmaceutical composition is formulated for parenteral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. [0415] While it may be possible for certain compounds provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II- a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, to be administered as the raw chemical, compounds may additionally or alternatively be provided in a pharmaceutical formulation. Accordingly, provided herein are pharmaceutical formulations which comprise one or more compounds disclosed herein (e.g., a compound of any any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration selected. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art. The pharmaceutical compositions disclosed herein may be manufactured in any suitable manner known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes. [0416] A pharmaceutical formulation provided herein can be suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal, and topical (including dermal, buccal, sublingual, and intraocular) administration. The most suitable route may depend on, for example, the condition and disorder of the subject to which the pharmaceutical formulation will be administered. A pharmaceutical formulation can be provided in a unit dosage form. A pharmaceutical formulation can be prepared by any suitable method. A method of preparing a pharmaceutical formulation may comprise bringing a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof (“active ingredient”) in contact with one or more pharmaceutically acceptable carriers (e.g., accessory ingredients). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. [0417] Pharmaceutical formulations of compounds provided herein (e.g., compounds of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II- a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a in any available form (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s) etc.)) may be provided as discrete units. For example, a formulation suitable for oral administration may be provided as capsules, cachets, and/or tablets containing a predetermined amount of the compound in any suitable form (e.g., the active ingredient); as a solution or suspension in a solvent (e.g., aqueous or non-aqueous solvent); as an emulsion (e.g., an oil-in-water liquid emulsion or water-in- oil liquid emulsion); or as a powder or granules. The active ingredient may additionally or alternatively be provided as a bolus, electuary, or paste. [0418] Pharmaceutical preparations suitable for oral administration include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by, for example, compression or molding, optionally with one or more accessory ingredients, such as one or more pharmaceutically acceptable excipients. Compressed tablets may be prepared by, for example, compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by, for example, molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration. The push-fit capsules can contain the active ingredients in admixture with, for example, one or more fillers such as lactose, one or more binders such as one or more starches, and/or one or more lubricants such as talc or magnesium stearate and, optionally, one or more stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers and other elements may also be added. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain a gum, gelling agent, polymer, solvent, or combination thereof. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses. [0419] A pharmaceutical composition comprising a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.), may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules, vials, or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing, and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, prior (e.g., immediately prior) to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. [0420] A pharmaceutical composition comprising a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.), may be formulated as a solution for injection, which solution may be an aqueous or non-aqueous (oily) sterile solution and may comprise one or more antioxidants, thickening agents, suspending agents, buffers, solutes, and/or bacteriostats. The addition of one or more such additives may render the formulation isotonic with the blood of the intended recipient (e.g., subject or patient). Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. [0421] In addition to the formulations described elsewhere herein, the compounds provided herein (e.g., compounds of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a in any suitable form (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.)), may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. [0422] A pharmaceutical composition comprising a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a) or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) that is suitable for buccal or sublingual administration may take the form of tablets, lozenges, pastilles, or gels. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth. A pharmaceutical composition comprising a compound provided herein or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) that is suitable for rectal administration may be formulated as a suppository or retention enema and may comprise a medium such as, for example, cocoa butter, polyethylene glycol, or other glycerides. [0423] Certain compounds provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a) or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) may be formulated for non-systemic administration, such as topical administration. This includes the application of a compound disclosed herein, or a form thereof, externally to the epidermis or the buccal cavity and the instillation of such a compound, or a form thereof, into the ear, eye, and nose, such that the compound, or a form thereof, does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal, and intramuscular administration. [0424] Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments, or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation. [0425] For administration by inhalation, compounds (e.g., compounds of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a) or forms thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) may be conveniently delivered from an insufflator, nebulizer pressurized packs, or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds provided herein may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator. [0426] Preferred unit dosage formulations are those containing an effective dose, as described herein, or an appropriate fraction thereof, of the active ingredient (e.g., a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof). [0427] It should be understood that in addition to the ingredients particularly described elsewhere herein, the formulations described herein may include other useful agents having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents. [0428] Compounds (e.g., compounds of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a) or forms thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day. The dose range for adult humans is generally from 5 mg to 2 g/day. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg. [0429] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Methods [0430] The present disclosure also provides a method of modulating KRAS (e.g., KRAS having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) comprising contacting KRAS with a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. For example, the present disclosure may provide a method of altering a cell phenotype, cell proliferation, KRAS activity, biochemical output produced by active or inactive KRAS, expression of KRAS, and/or binding of KRAS with a natural binding partner. Any such feature may be monitored and may be altered upon contacting KRAS with a compound provided herein, or a form thereof. A method of modulating KRAS (e.g., KRAS having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) may be a mode of treatment of a disease, disorder, or condition (e.g., a cancer), a biological assay, a cellular assay, a biochemical assay, etc. In some embodiments, a method of modulating KRAS (e.g., KRAS having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) comprises contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, where the KRAS protein is in the active (GTP-bound) conformation. In some embodiments, a method of modulating KRAS (e.g., KRAS having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) comprises contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, where the KRAS protein is in the inactive (GDP-bound) conformation. In some embodiments, contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, comprises incubating the KRAS protein with the compound or form thereof. In some embodiments, contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, comprises contacting a cell containing the KRAS protein with the compound or form thereof. In some embodiments, the cell is in a subject. In some embodiments, the subject is a human. In some embodiments, the subject is a human having a disease, disorder, or condition such as a cancer, such as a cancer characterized by a KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS. [0431] The present disclosure also provides methods of treating a disease, disorder, or condition in a subject in need thereof using a compound provided herein, (e.g., a compound of any one of Formulas I, I- a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. For example, the present disclosure provides a method comprising providing (e.g., administering) to a subject (e.g., patient) in need thereof an effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. The present disclosure also provides methods of treating a disease, disorder, or condition in a subject in need thereof using a pharmaceutical composition comprising a compound provided herein, (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. For example, the present disclosure provides a method comprising providing (e.g., administering) to a subject (e.g., patient) in need thereof a pharmaceutical composition comprising an effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof. In some embodiments, the subject is known to have (e.g., has previously been diagnosed with) a disease, disorder, or condition such as a cancer. The disease, disorder, or condition may be a KRAS- mediated disease, such as a cancer characterized by a KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS. In some embodiments, the compound administered to the subject in need thereof according to the methods described herein is a compound described in an embodiment, example, figure, or table herein, or a stereoisomer(s) or pharmaceutically acceptable salt thereof. [0432] The present disclosure also provides a compound as provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, for use as a medicament, such as a medicament for the treatment of a disease, disorder, or condition (e.g., a cancer). The present disclosure also provides a compound as provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, for use in the manufacture of a medicament for the treatment of a disease, disorder, or condition (e.g., a cancer) in a subject in need thereof. [0433] The present disclosure also provides the use of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, for the treatment of a disease, disorder, or condition (e.g., a cancer, as described herein, such as a cancer characterized by a KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) in a subject in need thereof. [0434] The present disclosure also provides the use of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, in the manufacture of a medicament for treating a disease, disorder, or condition (e.g., a cancer, as described herein, such as a cancer characterized by a KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) in a subject in need thereof. [0435] The present disclosure also provides a method of inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) (e.g., in a subject in need thereof) comprising contacting KRAS with a compound as provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient. In some embodiments, a method of inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) comprises contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, where the KRAS protein is in the active (GTP-bound) conformation. In some embodiments, a method of inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) comprises contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, where the KRAS protein is in the inactive (GDP-bound) conformation. In some embodiments, contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, comprises incubating the KRAS protein with the compound or form thereof. In some embodiments, contacting a KRAS protein with a compound provided herein, or a salt, ester, tautomer, zwitterionic form, or stereoisomer(s) thereof, comprises contacting a cell containing the KRAS protein with the compound or form thereof. In some embodiments, the cell is in a subject. In some embodiments, the subject is a human. In some embodiments, the subject is a human having a disease, disorder, or condition such as a cancer, such as a cancer characterized by a KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS. [0436] The present disclosure also provides a compound as provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, for use in inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) (e.g., in a subject in need thereof). The present disclosure also provides a compound as provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, for use in the manufacture of a medicament for inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild- type KRAS) in a subject in need thereof. [0437] The present disclosure also provides the use of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, for inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) in a subject in need thereof. [0438] The present disclosure also provides the use of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, or a pharmaceutical composition comprising any of the foregoing compounds and a pharmaceutically acceptable excipient, in the manufacture of a medicament for inhibiting KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) in a subject in need thereof. [0439] The present disclosure also provides a method comprising administering a therapeutically effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof to a subject (e.g., patient) (e.g., a subject in need thereof), thereby ameliorating, reducing, eliminating, ceasing, delaying the progression of, or improving one or more symptoms of the subject, such as one or more symptoms of a disease, disorder, or condition (e.g., a cancer). In some embodiments, the subject has a cancer characterized by a mutant KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS). [0440] In some embodiments, administering a therapeutically effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, slows or prevents growth of a tumor. In some embodiments, administering a therapeutically effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, results in shrinkage of a tumor (e.g., tumor regression). In some embodiments, administering a therapeutically effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, results in at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% regression of a tumor, such as for a period of one or more weeks (e.g., at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks), a period of one or more months (e.g., at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months), or a period of one or more years (e.g., at least about 1, 2, 3, or more years). In some embodiments, administering a therapeutically effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, stabilizes a tumor. In some embodiments, administering a therapeutically effective amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a salt, ester, tautomer, prodrug, zwitterionic form, or stereoisomer(s) thereof, stabilizes a tumor for a period of one or more weeks (e.g., at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more weeks), a period of one or more months (e.g., at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months), or a period of one or more years (e.g., at least about 1, 2, 3, or more years). In some embodiments, the subject has a cancer characterized by a mutant KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS). [0441] In some embodiments of any of the methods, uses, and medicaments provided herein, the disease, disorder, or condition is a cancer. In some embodiments of any of the methods, uses, and medicaments provided herein, the cancer is pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), lung cancer (e.g., non-small cell lung cancer), colorectal cancer (CRC), endometrial cancer, uterine carcinosarcoma, Ewing sarcoma, osteosarcoma, Rhabdomyosarcoma, adrenocortical carcinoma, neuroblastoma, Wilm tumor, retinoblastoma, skin cancer, breast cancer, prostate cancer, head and neck cancer, or ovarian cancer. In some embodiments, the cancer is pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), lung cancer (e.g., non-small cell lung cancer adenocarcinoma), or colorectal cancer (CRC). In some embodiments, the cancer is pancreatic cancer (e.g., pancreatic ductal adenocarcinoma). In some embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer adenocarcinoma). In some embodiments, the cancer is colorectal cancer (CRC). In some embodiments, the cancer is or comprises a solid tumor. [0442] In some embodiments of any of the methods, uses, and medicaments provided herein, the disease, disorder, or condition is related to KRAS, such as a disorder associated with a mutation of KRAS or dysregulation of KRAS. In some embodiments, the disease, disorder, or condition is related to the KRAS gene, such as a disease, disorder, or condition associated with a mutation of the KRAS gene or dysregulation of the KRAS gene. Mutation or dysregulation of KRAS or KRAS may include mutation or dysregulation of human K-Ras4a and/or human K-Ras4b. In some embodiments, the disease, disorder, or condition is related to the KRAS (e.g., human K-Ras4a or K-Ras4b) signaling pathway activity, such as a disease, disorder, or condition related to aberrant KRAS signaling pathway activity. In some embodiments, the disease, disorder, or condition is related to mutation or dysregulation of human K-Ras4b. In some embodiments, the disease, disorder, or condition is related to aberrant K-Ras4b signaling pathway activity. In some embodiments, the disease, disorder, or condition is related to mutation or dysregulation of human K-Ras4a. In some embodiments, the disease, disorder, or condition is related to aberrant K-Ras4a signaling pathway activity. Administration and Combination Therapy [0443] The compounds provided herein (e.g., compounds of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a) and forms thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.), or compositions (e.g., pharmaceutical compositions) comprising the same, can be administered in various modes (e.g., orally, topically, or by injection). The amount of active ingredient (e.g., a compound provided herein in any suitable form thereof) administered to a subject (e.g., patient) will be the responsibility of an attendant medical provider. The specific dose level for a given subject (e.g., patient) will depend on a variety of factors including, for example, the activity of the active ingredient administered; the physical attributes of the subject (e.g., age, weight, height, body mass index, general health, co-morbidities, sex, etc.); other characteristics of the subject (e.g., diet, level of exercise, national origin, ethnicity, etc.); time of administration; route of administration; rate of excretion; drug combination; the disease, disorder, or condition being treated; and the severity of the disease, disorder, or condition being treated. [0444] In some embodiments, a compound provided herein (e.g., a compound of any one of Formulas I, I- a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) is administered in combination with an additional agent, such as an additional therapeutic agent. For example, if a subject experiences a side effect such as hypertension upon receiving a compound provided herein, or a form thereof, it may be appropriate to administer an additional agent that is effective in managing the side effect, such as an anti-hypertensive agent. In another example, the therapeutic effectiveness of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof, may be enhanced by administration of an adjuvant, which adjuvant may itself have only minimal therapeutic benefit, but in combination with another therapeutic agent may provide an enhanced overall therapeutic benefit to a subject. In a further example, the therapeutic benefit of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof, may be enhanced by administration of the compound, or a form thereof, and an additional agent (which may comprise an additional therapeutic regimen) that also provides a therapeutic benefit. For example, a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof, may be administered in combination with an additional agent that may be effective in the treatment of a disease, disorder, or condition such as a cancer. Generally, the combination of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof, and one or more additional agents (e.g., therapeutic agents) may enhance the overall benefit experienced by the subject upon either component individually. In some embodiments, the effect may be additive. In some embodiments, the effect may be synergistic. [0445] In some embodiments, a compound provided herein (e.g., a compound of any one of Formulas I, I- a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.) is administered in combination with an anti-cancer agent (e.g., chemotherapeutic agent). An anti-cancer agent may be, for example, an alkylating agent, an antimitotic, a checkpoint inhibitor, an anti-metabolite, a plant alkaloid, a terpenoid, a cytotoxic agent, an antibiotic, a topoisomerase inhibitor, an aromatase inhibitor, an angiogenesis inhibitor, an anti-steroid, an anti-androgen, an mTOR inhibitor, monoclonal antibodies, or a tyrosine kinase inhibitor. An alkylating agent may be, for example, armustine, chlorambucil (LEUKERAN), cisplatin (PLATIN), carboplatin (PARAPLATIN), oxaliplatin (ELOXATIN), streptozocin (ZANOSAR), busulfan (MYLERAN), dacarbazine, ifosfamide, lomustine (CCNU), melphalan (ALKERAN), procarbazine (MATULAN), temozolomide (TEMODAR), thiotepa, or cyclophosphamide (ENDOXAN). An anti-metabolite may be, for example, cladribine (LEUSTATIN), mercaptopurine (PURINETHOL), thioguanine, pentostatin (NIPENT), cytosine arabinoside (cytarabine, ARA-C), gemcitabine (GEMZAR), fluorouracil (5-FU, CARAC), capecitabine (XELODA), leucovorin (FUSILEY), methotrexate (RHEUMATREX), or raltitrexed. An antimitotic may be, for example, a taxane such as docetaxel (TAXITERE) or paclitaxel (ABRAXANE, TAXOL), or a vinca alkaloid such as vincristine (ONCOVIN), vinblastine, vindesine, or vinorelbine (NAVELBINE). A checkpoint inhibitor may be an anti-PD-1 or anti-PD-L1 antibody such as pembrolizumab (KEYTRUDA), nivolumab (OPDIVO), MEDI4736, or MPDL3280A; anti-CTLA-4 antibody ipilimumab (YERVOY); or an agent that targets LAG3 (lymphocyte activation gene 3 protein), KIR (killer cell immunoglobulin-like receptor), 4-1BB (tumor necrosis factor receptor superfamily member 9), TIM3 (T-cell immunoglobulin and mucin-domain containing-3), or 0X40 (tumor necrosis factor receptor superfamily member 4). A topoisomerase inhibitor may be, for example, camptothecin (CTP), irinotecan (CAMPTOSAR), topotecan (HYCAMTIN), teniposide (VUMON), or etoposide (EPOSIN). A cytotoxic antibiotic may be, for example, actinomycin D (dactinomycin, COSMEGEN), bleomycin (BLENOXANE) doxorubicin (ADRIAMYCIN), daunorubicin (CERUBIDINE), epirubicin (ELLENCE), fludarabine (FLUDARA), idarubicin, mitomycin (MITOSOL), mitoxantrone (NOYANTRONE), or plicamycin. An aromatase inhibitor may be, for example, aminoglutethimide, anastrozole (ARIMIDEX), letrozole (FEMARA), vorozole (RIYIZOR), or exemestane (AROMASIN). An angiogenesis inhibitor may be, for example, genistein, sunitinib (SUTENT), or bevacizumab (AYASTIN). An anti-steroid or anti-androgen may be, for example, aminoglutethimide (CYTADREN), bicalutamide (CASODEX), cyproterone, flutamide (EULEXIN), or nilutamide (NILANDRON). A tyrosine kinase inhibitor may be, for example, imatinib (GLEEVEC), erlotinib (TARCEVA), afatinib (GILOTRIF), lapatinib (TYKERB), sorafenib (NEXAVAR), or axitinib (INLYTA). An mTOR inhibitor may be, for example, everolimus, temsirolimus (TORISEL), or sirolimus. Monoclonal antibody may be, for example, trastuzumab (HERCEPTIN) or rituximab (RITUXAN). Additional examples of agents that may be useful in combination with a compound provided herein, or an alternative form thereof, include, but are not limited to, amsacrine; Bacillus Calmette-Guerin (B-C-G) vaccine; buserelin (ETILAMIDE); chloroquine (ARALEN); clodronate, pamidronate, and other bisphosphonates; colchicine; demethoxyviridin; dichloroacetate; estramustine; filgrastim (NEUPOGEN); fludrocortisone (FLORINEF); goserelin (ZOLADEX); interferon; leucovorin; leuprolide (LUPRON); levamisole; lonidamine; mesna; metformin; mitotane (o,r'-DDD, LYSODREN); nocodazole; octreotide (SANDOSTATIN); perifosine; porfimer (particularly in combination with photo- and radiotherapy); suramin; tamoxifen; titanocene dichloride; tretinoin; anabolic steroids such as fluoxymesterone (HALOTESTIN); estrogens such as estradiol, diethylstilbestrol (DES), and dienestrol; progestins such as medroxyprogesterone acetate (MPA) and megestrol; and testosterone. [0446] Two or more therapeutic agents, one of which is a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a) or a form thereof, may be administered in any order or may be administered simultaneously. If administered simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (such as, for example, as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not administered simultaneously, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks. [0447] Accordingly, in another aspect, the present disclosure provides a method for treating a disease, disorder, or condition (e.g., a cancer) in a subject (e.g., a human or animal subject) in need of such treatment comprising administering to the subject an amount of a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a), or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.), in combination with at least one additional agent for the treatment of the disease, disorder, or condition. In a related aspect, the present disclosure provides a composition (e.g., pharmaceutical composition) comprising a compound provided herein (e.g., a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V- a, VA, VB, VC, VI, and VI-a), or a form thereof (e.g., salt, ester, tautomer, prodrug, zwitterionic form, stereoisomer(s), etc.), and at least one additional agent for use in the treatment of a disease, disorder, or condition (e.g., a cancer). [0448] In some embodiments, a method provided herein is used to treat a disease, disorder, or condition (e.g., a cancer) comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a or a pharmaceutically acceptable salt thereof, wherein the disease, disorder, or condition is a cancer that has developed a resistance to one or more chemotherapeutic drugs and/or ionizing radiation. In some embodiments, a method provided herein is used to treat a disease, disorder, or condition (e.g., a cancer) comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Formulas I, I-a, IA, IA1, IA2, IB, IB1, IB2, IC, IC1, IC2, ID, ID1, ID2, IE, IE1, IE2, IF, IF1, IF2, II, II’, II-a, IIA, IIA1, IIB, IIB1, IIC, IIC1, IID, IID1, IIE, IIE1, IIF, IIF1, IIG, IIG1, IIH, IIH1, IIJ, IIJ1, IIK, IIK1, IIL, IIL1, IIM, IIM1, IIN, IIN1, IIP, IIP1, IIQ, IIQ1, IIR, IIR1, IIS, IIS1, IIT, IIT1, IIU, IIU1, IIV, IIV1, IIW, IIW1, IIX, IIX1, IIY, IIY1, IIZ, IIZ1, IIAA, IIAA1, III, III’, III-a, IIIA, IIIA1, IIIB, IIIC, IIIC1, IIID, IIIE, IIIF, IIIG, IIIH, IIIJ, IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, IIIR, IIIS, IIIT, IV, IV-a, IVA, IVB, IVC, V, V-a, VA, VB, VC, VI, and VI-a or a pharmaceutically acceptable salt thereof, in combination with an additional agent, wherein the disease, disorder, or condition is a cancer that has developed a resistance to one or more chemotherapeutic drugs and/or ionizing radiation. [0449] The compounds, compositions, and methods disclosed herein are useful for the treatment of a disease, disorder, or condition, such as a cancer. In certain embodiments, the disease is one of dysregulated cellular proliferation, including cancer. The cancer may be hormone-dependent or hormone-resistant, such as in the case of breast cancers. In certain embodiments, the cancer is or comprises a solid tumor. In other embodiments, the cancer is a lymphoma or leukemia. In certain embodiments, the cancer is a drug resistant phenotype of a cancer disclosed herein or otherwise known. Tumor invasion, tumor growth, tumor metastasis, and angiogenesis may also be treated using the compositions and methods disclosed herein. In some embodiments, the compounds, compositions, and methods provided herein are also useful in the treatment of precancerous neoplasias. [0450] Cancers that may be treated by the methods disclosed herein include, but are not limited to, pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, breast cancer, ovarian cancer, endometrial cancer, lung cancer, and prostate cancer; cancers of the oral cavity and pharynx (lip, tongue, mouth, larynx, pharynx), esophagus, stomach, small intestine, large intestine, colon, rectum, liver and biliary passages; pancreas, bone, connective tissue, skin, cervix, uterus, corpus endometrium, testis, bladder, kidney and other urinary tissues, including renal cell carcinoma (RCC); cancers of the eye, brain, spinal cord, and other components of the central and peripheral nervous systems, as well as associated structures such as the meninges; and thyroid and other endocrine glands. The term “cancer” also encompasses cancers that do not necessarily form solid tumors, including Hodgkin’s disease, non-Hodgkin’s lymphomas, multiple myeloma, and hematopoietic malignancies including leukemias (Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Acute Myelogenous Leukemia (AML),) and lymphomas including lymphocytic, granulocytic and monocytic lymphomas. Additional types of cancers which may be treated using the compounds and methods provided herein include, but are not limited to, adenocarcinoma, angiosarcoma, astrocytoma, acoustic neuroma, anaplastic astrocytoma, basal cell carcinoma, blastoglioma, chondrosarcoma, choriocarcinoma, chordoma, craniopharyngioma, cutaneous melanoma, cystadenocarcinoma, endotheliosarcoma, embryonal carcinoma, ependymoma, Ewing's tumor, epithelial carcinoma, fibrosarcoma, gastric cancer, genitourinary tract cancers, glioblastoma multiforme, head and neck cancer, hemangioblastoma, hepatocellular carcinoma, hepatoma, Kaposi's sarcoma, large cell carcinoma, leiomyosarcoma, leukemias, liposarcoma, lymphatic system cancer, lymphomas, lymphangiosarcoma, lymphangioendotheliosarcoma, medullary thyroid carcinoma, medulloblastoma, meningioma mesothelioma, myelomas, myxosarcoma neuroblastoma, neurofibrosarcoma, oligodendroglioma, osteogenic sarcoma, epithelial ovarian cancer, papillary carcinoma, papillary adenocarcinomas, paraganglioma, parathyroid tumors, pheochromocytoma, pinealoma, plasmacytomas, retinoblastoma, rhabdomyosarcoma, sebaceous gland carcinoma, seminoma, skin cancers, melanoma, small cell lung carcinoma, non-small cell lung carcinoma, squamous cell carcinoma, sweat gland carcinoma, synovioma, thyroid cancer, uveal melanoma, and Wilm’s tumor. Additional diseases and disorders that may be treated by the methods disclosed herein include, but are not limited to, diseases or disorders related to KRAS, such as diseases or disorders associated with a mutation of KRAS (e.g., KRAS protein having a Q61H, G12C, G12D, G12V, G12S, G12A, G12R, or G13D mutation, or wild-type KRAS) or dysregulation of KRAS, and diseases or disorders related to the KRAS gene, such as diseases or disorders associated with a mutation of the KRAS gene or dysregulation of the KRAS gene. [0451] In some embodiments, the compounds, compositions, and methods provided herein are useful in the prevention and/or reduction of tumor invasion, growth, and/or metastasis. [0452] The compounds, compositions, and methods provided herein may be useful in the treatment of humans as well as in the veterinary treatment of non-human animals including companion animals, exotic animals, and farm animals (e.g., as described herein), including mammals, rodents, and the like. For example, the compounds, compositions, and methods provided herein may be useful in the treatment of horses, dogs, or cats. Exemplary Embodiments [0453] The following numbered embodiments, while non-limiting, are exemplary of certain aspects of the present disclosure: A1. A compound represented by Formula I: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 3-11 membered carbocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A2. The compound of embodiment A1, wherein R 3 is a 3-6 membered carbocycle that is unsubstituted or is substituted with one or more R 10 . A3. The compound of embodiment A2, wherein R 3 is a 3-6 membered carbocycle that is substituted with 1-4 R 10 . A4. The compound of embodiment A2, wherein R 3 is a cyclopropane that is substituted with 0-4 R 10 . A5. The compound of embodiment A2, wherein R 3 is a cyclobutane that is substituted with 0-4 R 10 . A6. The compound of embodiment A2, wherein R 3 is a cyclopentane that is substituted with 0-4 R 10 . A7. The compound of embodiment A2, wherein R 3 is a cyclohexane that is substituted with 0-4 R 10 . A8. The compound of any one of embodiments A1-A3, wherein R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 A9. The compound of any one of embodiments A1-A8, wherein R 3 is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. A10. The compound of any one of embodiments A1-A9, wherein R 3 is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl. A11. The compound of any one of embodiments A1-A10, wherein the compound is a compound according to Formula IA, Formula IB, or Formula IC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A12. The compound of embodiment A11, wherein the compound is a compound according to Formula IA, or a salt (e.g., pharmaceutically acceptable salt) thereof. A13. The compound of embodiment A11, wherein the compound is a compound according to Formula IB, or a salt (e.g., pharmaceutically acceptable salt)thereof. A14. The compound of embodiment A11, wherein the compound is a compound according to Formula IC, or a salt (e.g., pharmaceutically acceptable salt)thereof. A15. The compound of any one of embodiments A11-A14, wherein at least one R d is selected from - OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A16. The compound of embodiment A15, wherein at least one R d is selected from -OR 12 and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A17. The compound of any one of embodiments A1-A16, wherein R 6 is selected from: , wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 .

A18. The compound of any one of embodiments A1-A17, wherein R 6 is selected from: , any of which is substituted with one or more R 15 . A19. The compound of any one of embodiments A1-A18, wherein R 6 is selected from: , A20. The compound of any one of embodiments A1-A19, wherein R 6 is selected from: , , A21. The compound of any one of embodiments A1-A20, wherein the compound is a compound according to Formula IA1, IB1, or IC1: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A22. The compound of embodiment A21, wherein the compound is a compound according to Formula IA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A23. The compound of embodiment A21, wherein the compound is a compound according to Formula IB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A24. The compound of embodiment A21, wherein the compound is a compound according to Formula IC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A25. The compound of any one of embodiments A21-A24, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . A26. The compound of any one of embodiments A21-A25, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). A27. The compound of any one of embodiments A1-A26, wherein R 1 is selected from -OR 8 . A28. The compound of embodiment A27, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . A29. The compound of embodiment A28, wherein R 1 is selected from: , A30. The compound of embodiment A27, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein the C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A31. The compound of embodiment A27, wherein R 1 is selected from: , A32. The compound of any one of embodiments A1-A26, wherein R 1 is selected from A33. The compound of any one of embodiments A1-A32, wherein the compound is a compound according to Formula IA2, IB2, or IC2:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A34. The compound of embodiment A33, wherein the compound is a compound according to Formula IA2, or a salt (e.g., pharmaceutically acceptable salt) thereof. A35. The compound of embodiment A33, wherein the compound is a compound according to Formula IB2, or a salt (e.g., pharmaceutically acceptable salt) thereof. A36. The compound of embodiment A33, wherein the compound is a compound according to Formula IC2, or a salt (e.g., pharmaceutically acceptable salt) thereof. A37. The compound of any one of embodiments A33-A36, wherein R a is a halogen (e.g., F). A38. The compound of any one of embodiments A33-A37, wherein R b is H. A39. The compound of any one of embodiments A21-A38, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . A40. The compound of any one of embodiments A21-A39, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). A41. The compound of any one of embodiments A1-A40, wherein R 2 is H. A42. The compound of any one of embodiments A1-A40, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . A43. The compound of embodiment A42, wherein R 2 is selected from C 1-2 alkyl. A44. The compound of any one of embodiments A1-A43, wherein R 5 is H. A45. The compound of any one of embodiments A1-A43, wherein R 5 is a halogen (e.g., F or Cl). A46. The compound of any one of embodiments A1-A43, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . A47. The compound of embodiment A46, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. A48. The compound of embodiment A47, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . A49. The compound of embodiment A48, wherein R 5 is –CF 3 . A50. The compound of any one of embodiments A1-A49, wherein R 7 is H. A51. The compound of any one of embodiments A1-A49, wherein R 7 is a halogen (e.g., F or Cl). A52. The compound of any one of embodiments A1-A49, wherein R 7 is -CN. A53. A compound represented by Formula II’: or a salt (e.g., pharmaceutically acceptable salt)thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-6 membered heterocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A54. A compound represented by Formula II: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-6 membered heterocycle that is unsubstituted or substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A55. The compound of embodiment A53 or A54, wherein R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N. A56. The compound of embodiment A55, wherein R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . A57. The compound of any one of embodiments A53-A56, wherein R 3 is a pyrrolidine that is substituted with 0-4 R 10 , provided that the nitrogen atom is substituted with R 10 . A58. The compound of any one of embodiments A53-A56, wherein R 3 is an oxetane or thietane that is substituted with 0-4 R 10 . A59. The compound of any one of embodiments A53-A56, wherein R 3 is a tetrahydrofuran or tetrahydrothiopene that is substituted with 0-4 R 10 . A60. The compound of any one of embodiments A53-A59, wherein R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1- 6 alkyl substituted with -OH. A61. The compound of any one of embodiments A53-A60, wherein R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl. A62. The compound of any one of embodiments A53-A61, wherein the compound is a compound according to Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, or IIK: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkyl)CN, -C(O)(C 1-6 alkyl)OH, -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 . A63. The compound of embodiment A62, wherein the compound is a compound according to Formula IIA, or a salt (e.g., pharmaceutically acceptable salt) thereof. A64. The compound of embodiment A62, wherein the compound is a compound according to Formula IIB, or a salt (e.g., pharmaceutically acceptable salt) thereof. A65. The compound of embodiment A62, wherein the compound is a compound according to Formula IIC, or a salt (e.g., pharmaceutically acceptable salt)thereof. A66. The compound of embodiment A62, wherein the compound is a compound according to Formula IID, or a salt (e.g., pharmaceutically acceptable salt) thereof. A67. The compound of embodiment A62, wherein the compound is a compound according to Formula IIE, or a salt (e.g., pharmaceutically acceptable salt) thereof. A68. The compound of embodiment A62, wherein the compound is a compound according to Formula IIF, or a salt (e.g., pharmaceutically acceptable salt) thereof. A69. The compound of embodiment A62, wherein the compound is a compound according to Formula IIG, or a salt (e.g., pharmaceutically acceptable salt) thereof. A70. The compound of embodiment A62, wherein the compound is a compound according to Formula IIH, or a salt (e.g., pharmaceutically acceptable salt) thereof. A71. The compound of embodiment A62, wherein the compound is a compound according to Formula IIJ, or a salt (e.g., pharmaceutically acceptable salt) thereof. A72. The compound of embodiment A62, wherein the compound is a compound according to Formula IIK, or a salt (e.g., pharmaceutically acceptable salt) thereof. A73. The compound of any one of embodiments A62, A65, and A67, wherein the compound is a compound according to Formula IIC or IIE, wherein each R f is =O. A74. The compound of any one of embodiments A62, A63, A66, A69, and A70, wherein the compound is a compound according to Formula IIA IID, IIG, or IIH, wherein R e is C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . A75. The compound of any one of embodiments A53-A74, wherein R 6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . any of which is substituted with one or more R 15 . A77. , ,

A78. The compound of any one of embodiments A53-A75, wherein R 6 is selected from: , A79. The compound of any one of embodiments A53-A78, wherein the compound is a compound according to Formula IIA1, IIB1, IIC1, IID1, IIE1, IIF1, IIG1, IIH1, IIJ1, or IIK1:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A80. The compound of embodiment A79, wherein the compound is a compound according to Formula IIA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A81. The compound of embodiment A79, wherein the compound is a compound according to Formula IIB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A82. The compound of embodiment A79, wherein the compound is a compound according to Formula IIC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A83. The compound of embodiment A79, wherein the compound is a compound according to Formula IID1, or a salt (e.g., pharmaceutically acceptable salt) thereof. A84. The compound of embodiment A79, wherein the compound is a compound according to Formula IIE1, or a salt (e.g., pharmaceutically acceptable salt)thereof. A85. The compound of embodiment A79, wherein the compound is a compound according to Formula IIF1, or a salt (e.g., pharmaceutically acceptable salt)thereof. A86. The compound of embodiment A79, wherein the compound is a compound according to Formula IIG1, or a salt (e.g., pharmaceutically acceptable salt)thereof. A87. The compound of embodiment A79, wherein the compound is a compound according to Formula IIH1, or a salt (e.g., pharmaceutically acceptable salt)thereof. A88. The compound of embodiment A79, wherein the compound is a compound according to Formula IIJ1, or a salt (e.g., pharmaceutically acceptable salt)thereof. A89. The compound of embodiment A79, wherein the compound is a compound according to Formula IIK1, or a salt (e.g., pharmaceutically acceptable salt)thereof. A90. The compound of any one of embodiments A79-A89, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . A91. The compound of any one of embodiments A79-A90, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). A92. The compound of any one of embodiments A79, A82, A84, A90, and A91, wherein the compound is a compound according to Formula IIC1 or IIE1, wherein each R f is =O. A93. The compound of any one of embodiments A79, A80, A83, A86, A87, A90, and A91, wherein the compound is a compound according to Formula IIA1, IID1, IIG1, or IIH1, wherein R e is C 1- 6 alkyl that is unsubstituted or substituted with one or more R 20 . A94. The compound of any one of embodiments A62-A93, wherein each R d is H. A95. The compound of any one of embodiments A62-A93, wherein at least one R d is selected from - OR 12 and a C 1-6 alkyl substituted with -OH. A96. The compound of any one of embodiments A53-A95, wherein R 2 is H. A97. The compound of any one of embodiments A53-A95, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . A98. The compound of embodiment A97, wherein R 2 is selected from C 1-2 alkyl. A99. The compound of any one of embodiments A53-A98, wherein R 1 is selected from -OR 8 . A100. The compound of embodiment A99, wherein R 1 is selected from: R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . A101. The compound of embodiment A100, wherein R 1 is selected from: , A102. The compound of embodiment A99, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein the C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A103. The compound of embodiment A102, wherein R 1 is selected from: , A104. The compound of any one of embodiments A53-A98, wherein R 1 is selected from A105. The compound of any one of embodiments A53-A104, wherein R 5 is H. A106. The compound of any one of embodiments A53-A104, wherein R 5 is a halogen (e.g., F or Cl). A107. The compound of any one of embodiments A53-A104, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . A108. The compound of embodiment A107, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. A109. The compound of embodiment A108, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . A110. The compound of embodiment A109, wherein R 5 is –CF 3 . A111. The compound of any one of embodiments A53-A110, wherein the compound is a not a compound included in Table 1.  A112. A compound represented by Formula III’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-9 membered heterocycle that is unsubstituted or is substituted with one or more R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A113. A compound represented by Formula III: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-9 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A114. The compound of embodiment A112 or A113, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle. A115. The compound of embodiment A114, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. A116. The compound of embodiment A115, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 11 . A117. The compound of any one of embodiments A112-A116, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a pyrrolidine that is substituted with 0-4 R 11 . A118. The compound of any one of embodiments A112-A116, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form an azetidine that is substituted with 0-4 R 11 . A119. The compound of any one of embodiments A112-A116, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperidine that is substituted with 0-4 R 11 . A120. The compound of any one of embodiments A112-A116, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperazine that is substituted with 0-4 R 11 . A121. The compound of any one of embodiments A112-A116, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a morpholine or thiomorpholine that is substituted with 0-4 R 11 . A122. The compound of any one of embodiments A112-A121, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle substituted with one or more R 11 , wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. A123. The compound of any one of embodiments A112-A121, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-6 membered heterocycle substituted with one or more R 11 , wherein at least one R 11 is an unsubstituted C 1-6 alkyl. A124. The compound of embodiment A112 or A113, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle . A125. The compound of embodiment A124, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. A126. The compound of embodiment A125, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the bridged heterocycle is substituted with 1-4 R 11 . A127. The compound of any one of embodiments A124-A126, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperidine that is substituted with 0-4 R 11 . A128. The compound of any one of embodiments A124-A126, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperazine that is substituted with 0-4 R 11 . A129. The compound of any one of embodiments A124-A126, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged morpholine or thiomorpholine that is substituted with 0-4 R 11 . A130. The compound of any one of embodiments A124-A129, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. A131. The compound of any one of embodiments A124-A130, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , wherein at least one R 11 is an unsubstituted C 1-6 alkyl. A132. The compound of embodiment A112 or A113, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle. A133. The compound of embodiment A132, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-9 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , wherein the one or more R 11 are independently selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . A134. The compound of any one of embodiments A112-A133, wherein the compound is a compound according to Formula IIIA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f and R g are each independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , or R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A135. The compound of embodiment A134, wherein each R e , R f , and R g is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A136. The compound of embodiment A134, wherein each R e , R f , and R g is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . A137. The compound of embodiment A134, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A138. The compound of embodiment A137, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted. A139. The compound of embodiment A137, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . A140. The compound of any one of embodiments A137-A139, wherein R f and R g join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A141. The compound of embodiment A140, wherein R f and R g join together to form a cyclopropane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A142. The compound of any one of embodiments A137-A139, wherein R f and R g join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A143. The compound of embodiment A142, wherein R f and R g join together to form an oxetane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A144. The compound of any one of embodiments A112-A133, wherein the compound is a compound according to Formula IIIB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A145. The compound of embodiment A144, wherein each R e is hydrogen. A146. The compound of any one of embodiments A112-A133, wherein the compound is a compound according to Formula IIIC: (IIIC), or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A147. The compound of embodiment A146, wherein each R e is hydrogen. A148. The compound of any one of embodiments A112-A133, wherein the compound is a compound according to Formula IIID: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: Q is selected from CR h R j , NR g , O, S, and SO 2 ; each R e and R f is independently selected from R 11 and hydrogen, wherein an R e and an R f can optionally join together to form a 4-6 membered ring, or a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring, or a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; R g , when present, is R 11 ; and R h and R j , when present, are independently selected from R 11 and hydrogen, or can optionally join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A149. The compound of embodiment A148, wherein Q is O, S, or SO 2 . A150. The compound of embodiment A149, wherein Q is O. A151. The compound of embodiment A148, wherein Q is NR g . A152. The compound of embodiment A148, wherein Q is CR h R j . A153. The compound of embodiment A148, wherein the compound is a compound according to Formula IIIE: or a salt (e.g., pharmaceutically acceptable salt) thereof. A154. The compound of embodiment A153, wherein R h and R j are independently selected from R 11 and hydrogen. A155. The compound of embodiment A153, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A156. The compound of embodiment A155, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted. A157. The compound of embodiment A153, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . A158. The compound of embodiment A153, wherein R h and R j join together to form a 3-4 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . A159. The compound of embodiment A158, wherein R h and R j join together to form a cyclobutane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A160. The compound of embodiment A153, wherein R h and R j join together to form a 3-4 membered heterocycle that is unsubstituted or substituted with one or more substitutents selected from - OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . A161. The compound of embodiment A148, wherein the compound is a compound according to Formula IIIF, IIIG, or IIIH: or a salt (e.g., pharmaceutically acceptable salt) thereof. A162. The compound of embodiment A161, wherein the compound is a compound of Formula IIIF or a salt (e.g., a pharmaceutically acceptable salt) thereof. A163. The compound of embodiment A161, wherein the compound is a compound of Formula IIIG or a salt (e.g., a pharmaceutically acceptable salt) thereof. A164. The compound of embodiment A161, wherein the compound is a compound of Formula IIIH or a salt (e.g., a pharmaceutically acceptable salt) thereof. A165. The compound of any one of embodiments A161-A164, wherein each R e and R f is independently selected from R 11 and hydrogen. A166. The compound of any one of embodiments A161-A164, wherein an R e and an R f join together to form a 4-6 membered ring. A167. The compound of embodiment A148, wherein the compound is a compound according to Formula IIIJ:

or a salt (e.g., pharmaceutically acceptable salt) thereof. A168. The compound of embodiment A167, wherein each R e and R f is independently selected from R 11 and hydrogen. A169. The compound of embodiment A167, wherein an R e and an R f join together to form a 4-6 membered ring. A170. The compound of any one of embodiments A148-A169, wherein the compound is a compound according to Formula IIIK, Formula IIIL, Formula IIIM, Formula IIIN, Formula IIIP, Formula IIIQ, or Formula IIIR: or a salt (e.g., pharmaceutically acceptable salt) wherein: each R e and R f is independently selected from R 11 and hydrogen; R g , when present, is R 11 ; and R h and R j , when present, are independently selected from R 11 and hydrogen. A171. The compound of embodiment A170, wherein the compound is a compound of Formula IIIK or a salt (e.g., a pharmaceutically acceptable salt) thereof. A172. The compound of embodiment A170, wherein the compound is a compound of Formula IIIL or a salt (e.g., a pharmaceutically acceptable salt) thereof. A173. The compound of embodiment A170, wherein the compound is a compound of Formula IIIM or a salt (e.g., a pharmaceutically acceptable salt) thereof. A174. The compound of embodiment A170, wherein the compound is a compound of Formula IIIN or a salt (e.g., a pharmaceutically acceptable salt) thereof. A175. The compound of embodiment A170, wherein the compound is a compound of Formula IIIP or a salt (e.g., a pharmaceutically acceptable salt) thereof. A176. The compound of embodiment A170, wherein the compound is a compound of Formula IIIQ or a salt (e.g., a pharmaceutically acceptable salt) thereof. A177. The compound of embodiment A170, wherein the compound is a compound of Formula IIIR or a salt (e.g., a pharmaceutically acceptable salt) thereof. A178. The compound of any one of embodiments A170-A177, wherein Q is selected from CR h R j , NR g , and O. A179. The compound of embodiment A178, wherein Q is CR h R j . A180. The compound of embodiment A179, wherein R h and R j are independently selected from R 11 and hydrogen. A181. The compound of embodiment A178, wherein Q is NR g . A182. The compound of embodiment A178, wherein Q is O. A183. The compound of any one of embodiments A170-A177, wherein Q is S or SO 2 . A184. The compound of any one of embodiments A112-A183, wherein R 6 is selected from: , wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A185. The compound of any one of embodiments A112-A183, wherein R 6 is selected from: , any of which is substituted with one or more R 15 . A186. The compound of any one of embodiments A112-A183, wherein R 6 is selected from: A187. The compound of any one of embodiments A112-A183, wherein R 6 is selected from: , A188. The compound of any one of embodiments A112-A187, wherein R 1 is selected from -OR 8 . A189. The compound of embodiment A188, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . A190. The compound of embodiment A189, wherein R 1 is selected from: , . A191. The compound of embodiment A188, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein the C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A192. The compound of embodiment A191, wherein R 1 is selected from: , A193. The compound of any one of embodiments A112-A187, wherein R 1 is selected from A194. The compound of any one of embodiments A112-A193, wherein each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . A195. The compound of any one of embodiments A112-A194, wherein R 5 is a halogen (e.g., F or Cl). A196. The compound of any one of embodiments A112-A194, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . A197. The compound of embodiment A196, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. A198. The compound of embodiment A197, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . A199. The compound of embodiment A198, wherein R 5 is –CF 3 . A200. The compound of any one of embodiments A112-A199, wherein the compound is a not a compound included in Table 2.  A201. A compound represented by Formula IV: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A202. The compound of embodiment A201, wherein the compound is a compound according to Formula IVA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R i and R h are independently selected from H and R 10 . A203. The compound of embodiment A202, wherein each R i and R h are independently selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A204. The compound of embodiment A202 or A203, wherein R 14 is H. A205. The compound of any one of embodiments A201-A204, wherein R 6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A206. The compound of any one of embodiments A201-A205, wherein R 6 is selected from: any of which is substituted with one or more R 15 . A207. The compound of any one of embodiments A201-A206, wherein R 6 is selected from: A209. The compound of any one of embodiments A201-A208, wherein the compound is a compound according to Formula IVB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A210. The compound of any one of embodiments A201-A209, wherein R 1 is selected from -OR 8 . A211. The compound of embodiment A210, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . A212. The compound of embodiment A211, wherein R 1 is selected from: , A213. The compound of embodiment A210, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein the C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 . A214. The compound of embodiment A213, wherein R 1 is selected from: , , , A215. The compound of any one of embodiments A201-A209, wherein R 1 is selected from A216. The compound of any one of embodiments A201-A215, wherein the compound is a compound according to Formula IVC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . A217. The compound of embodiment A216, wherein R a is a halogen (e.g., F). A218. The compound of embodiment A216 or A217, wherein R b is H. A219. The compound of any one of embodiments A209-A218, wherein X is C-CN, Y is S, and R 23 is selected from -N(R 12 ) 2 . A220. The compound of any one of embodiments A209-A219, wherein at least one of R 24 , R 25 , and R 26 is a halogen (e.g., F). A221. The compound of any one of embodiments A201 and A209-A221, wherein R 3 is selected from C 1-3 alkyl that is unsubstituted or is substituted with one or more R 10 . A222. The compound of embodiment A221, wherein R 3 is selected from C 1-6 alkyl that is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, -CN, - NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2-6 alkenyl. A223. The compound of embodiment A221, wherein R 3 is C 2-3 alkyl that is unsubstituted or is substituted with one or more R 10 . A224. The compound of embodiment A223, wherein R 3 is C 2-3 alkyl that is unsubstituted or is substituted with one or more R 10 , wherein each R 10 is independently selected from -OR 14 , =O, - CN, -NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2-6 alkenyl. A225. The compound of embodiment A224, wherein R 3 is C 2-3 alkyl that is unsubstituted. A226. The compound of embodiment A224, wherein R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein the one or more R 10 are selected from -OR 14 , -CN, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A227. The compound of embodiment A226, wherein R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein the one or more R 10 are selected from -OR 14 and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . A228. The compound of any one of embodiments A223, A226, and A227, wherein R 3 is C 2-3 alkyl that is substituted with one or more R 10 , wherein the one or more R 10 are halogen. A229. The compound of embodiment A228, wherein R 3 is C 2-3 alkyl that is substituted with one or more F. A230. The compound of any one of embodiments A201 and A209-A221, wherein the moiety is A231. The compound of any one of embodiments A201-A230, wherein R 2 is selected from H and C 1- 6 alkyl that is unsubstituted. A232. The compound of embodiment A231, wherein R 2 is H A233. The compound of any one of embodiments A201-A230, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 A234. The compound of embodiment A233, wherein R 2 is selected from C 1-2 alkyl that is unsubstituted. A235. The compound of any one of embodiments A201-A234, wherein R 5 is H. A236. The compound of any one of embodiments A201-A234, wherein R 5 is a halogen (e.g., F or Cl). A237. The compound of any one of embodiments A201-A234, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . A238. The compound of embodiment A237, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. A239. The compound of embodiment A238, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . A240. The compound of embodiment A239, wherein R 5 is –CF 3 . A241. The compound of any one of embodiments A201-A240, wherein R 7 is H. A242. The compound of any one of embodiments A201-A240, wherein R 7 is a halogen (e.g., F or Cl). A243. The compound of any one of embodiments A201-A240, wherein R 7 is -CN. A244. The compound of any one of embodiments A201-A243, wherein the compound is a not a compound included in Table 3.  A245. A compound shown in Table 5, or a salt (e.g., pharmaceutically acceptable salt) thereof. A246. A pharmaceutical composition comprising a compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof, and a pharmaceutically acceptable excipient. A247. A compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use as a medicament. A248. The compound of embodiment A247, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. A249. The compound of embodiment A248, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of wild-type KRAS. A250. The compound of embodiment A248, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. A251. The compound of any one of embodiments A247-A250, wherein the medicament is useful in the prevention or treatment of a cancer. A252. The compound of embodiment A251, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A253. A compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use in the treatment of a disease, disorder, or condition. A254. The compound of embodiment A253, wherein the disease, disorder, or condition is a cancer. A255. The compound of embodiment A254, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A256. The compound of any one of embodiments A245-A255, wherein the compound is used in the treatment of a disease, disorder, or condition in a subject in need thereof. A257. A compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use in the manufacture of a medicament. A258. The compound of embodiment A257, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. A259 The compound of embodiment A258, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of wild-type KRAS. A260 The compound of embodiment A258, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. A261. The compound of any one of embodiments A257-A260, wherein the medicament is useful in the treatment of a cancer. A262. The compound of embodiment A261, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A263. A method, comprising administering a therapeutically effective amount of a compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof, to a subject in need thereof. A264. The method of embodiment A263, wherein the subject has a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. A265. The method of embodiment A264, wherein the disease, disorder, or condition is ameliorated by the inhibition of wild-type KRAS. A266. The compound of embodiment A264, wherein the disease, disorder, or condition is ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. A267. The method of any one of embodiments A263-A266, wherein the subject has a cancer. A268. The method of embodiment A267, wherein the subject was previously diagnosed with the cancer. A269. The method of embodiment A267, wherein the subject has previously undergone a treatment regimen for the cancer. A270. The method of embodiment A268, wherein the subject has previously entered remission from the cancer. A271. The method of any one of embodiments A259-A270, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A272. The method of any one of embodiments A263-A271, wherein the compound, or the salt thereof, is administered in combination with an additional therapeutic agent. A273. The use of a compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof, for the manufacture of a medicament for the treatment of a cancer. A274. The use of embodiment A273, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A275. A method, comprising contacting a KRAS protein with a compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof. A276. The method of embodiment A277, wherein contacting the KRAS protein with the compound modulates KRAS. A277. The method of embodiment A275 or A276, wherein the KRAS protein has a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation. A278. The method of embodiment A275 or A276, wherein the KRAS protein is a wild-type KRAS protein. A279. The method of any one of embodiments A275-A278, wherein the KRAS protein is in an active (GTP-bound) state. A280. The method of any one of embodiments A275-A278, wherein the KRAS protein is in an inactive (GDP-bound) state. A281. The method of any one of embodiments A275-A280, wherein the KRAS protein is located within a cell. A282. The method of embodiment A281, wherein the cell is located within a subject. A283. The method of embodiment A282, wherein the subject is a human. A284. The method of embodiment A282 or A283, wherein the subject has a cancer. A285. The method of embodiment A284, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A286. A method of inhibiting the function of a wild-type KRAS protein or a KRAS protein having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, comprising contacting the KRAS protein with a compound of any one of embodiments A1-A245, or a salt (e.g., pharmaceutically acceptable salt) thereof. A287. The method of embodiment A286, wherein the KRAS protein is a wild-type KRAS protein. A288. The method of embodiment A286, wherein the KRAS protein has a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation. A289. The method of embodiment A288, wherein the KRAS protein has a G12D, G12V, or G12R mutation. A290. The method of any one of embodiments A286-A289, wherein the KRAS protein is in an active (GTP-bound) state. A291. The method of any one of embodiments A286-A289, wherein the KRAS protein is in an inactive (GDP-bound) state. A292. The method of any one of embodiments A286-A291, wherein the KRAS protein is located within a cell. A293. The method of embodiment A292, wherein the cell is located within a subject. A294. The method of embodiment A293, wherein the subject is a human. A295. The method of embodiment A293 or A294, wherein the subject has a cancer. A296. The method of embodiment A295, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. A297. A compound capable of inhibiting a wild-type KRAS protein or a KRAS protein having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation in both its active (GTP-bound) and inactive (GDP-bound) state. A298. The compound of embodiment A297, wherein the compound: (i) has IC 50 ≤0.1 µM, 0.1 µM< IC 50 ≤1 µM, 1 µM< IC 50 ≤10 µM, or 10 µM< IC 50 in the assay of Biological Example 1 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS G12R (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS G12V (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS WT (amino acids 1- 169) GppNHp/ RAF1 RBD-3xFLAG (52-151); and/or 75 nM Avi-RAF1 RBD-3xFLAG; and/or (ii) has IC 50 ≤0.1 µM, 0.1 µM< IC 50 ≤1 µM, or IC 50 >1 µM in the assay of Biological Example 2 (e.g., cell-based pERK HTRF assay in GP2d (G12D) and SW620 (G12V) cell). A299. The compound of embodiment A298, wherein the compound: (i) has IC 50 ≤0.1 µM or 0.1 µM< IC 50 ≤1 µM in the assay of Biological Example 1 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS G12R (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS G12V (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS WT (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); and/or 75 nM Avi-RAF1 RBD-3xFLAG; and/or (ii) has IC 50 ≤0.1 µM or 0.1 µM< IC 50 ≤1 µM in the assay of Biological Example 2 (e.g., cell-based pERK HTRF assay in GP2d (G12D) and SW620 (G12V) cell). A300. The compound of any one of embodiments A297-A299, wherein the compound is capable of irreversibly binding the KRAS protein. A301. The compound of any one of embodiments A297-A299, wherein the compound is capable of reversibly binding the KRAS protein. A302. The compound of any one of embodiments A297-A301, wherein the compound is a compound according to any one of embodiments A1-A245. [0454] The following numbered embodiments, while non-limiting, are exemplary of certain aspects of the present disclosure: B1. A compound represented by Formula II’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-6 membered heterocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 , and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3- 6 membered carbocycle or heterocycle; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, a 3-6 membered carbocycle, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B2. A compound represented by Formula II: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-6 membered heterocycle that is unsubstituted or substituted with one or more R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl lis substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 , and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3- 6 membered carbocycle or heterocycle; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, a 3-6 membered carbocycle, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B3. The compound of embodiment B1 or B2, wherein R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N. B4. The compound of embodiment B3, wherein R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . B5. The compound of any one of embodiments B1-B4, wherein R 3 is a pyrrolidine that is substituted with 0-4 R 10 , provided that the nitrogen atom is substituted with R 10 . B6. The compound of any one of embodiments B1-B4, wherein R 3 is an oxetane or thietane that is substituted with 0-4 R 10 . B7. The compound of any one of embodiments B1-B4, wherein R 3 is a tetrahydrofuran or tetrahydrothiopene that is substituted with 0-4 R 10 . B8. The compound of any one of embodiments B1-B4, wherein R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1- 6 alkyl substituted with -OH. B9. The compound of any one of embodiments B1-B8, wherein R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl. B10. The compound of any one of embodiments B1-B9, wherein R 3 is selected from: , ,

optionally further substituted with one or more R 10 . B11. The compound of any one of embodiments B1-B10, wherein the compound is a compound according to Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, or IIZ:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle), - S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkyl)CN, -C(O)(C 1-6 alkyl)OH, -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1-6 alkyl), and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; and each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 . B12. The compound of embodiment B11, wherein the compound is a compound according to Formula IIA, or a salt (e.g., pharmaceutically acceptable salt) thereof. B13. The compound of embodiment B11, wherein the compound is a compound according to Formula IIB, or a salt (e.g., pharmaceutically acceptable salt) thereof. B14. The compound of embodiment B11, wherein the compound is a compound according to Formula IIC, or a salt (e.g., pharmaceutically acceptable salt)thereof. B15. The compound of embodiment B11, wherein the compound is a compound according to Formula IID, or a salt (e.g., pharmaceutically acceptable salt) thereof. B16. The compound of embodiment B11, wherein the compound is a compound according to Formula IIE, or a salt (e.g., pharmaceutically acceptable salt) thereof. B17. The compound of embodiment B11, wherein the compound is a compound according to Formula IIF, or a salt (e.g., pharmaceutically acceptable salt) thereof. B18. The compound of embodiment B11, wherein the compound is a compound according to Formula IIG, or a salt (e.g., pharmaceutically acceptable salt) thereof. B19. The compound of embodiment B11, wherein the compound is a compound according to Formula IIH, or a salt (e.g., pharmaceutically acceptable salt) thereof. B20. The compound of embodiment B11, wherein the compound is a compound according to Formula IIJ, or a salt (e.g., pharmaceutically acceptable salt) thereof. B21. The compound of embodiment B11, wherein the compound is a compound according to Formula IIK, or a salt (e.g., pharmaceutically acceptable salt) thereof. B22. The compound of embodiment B11, wherein the compound is a compound according to Formula IIL, or a salt (e.g., pharmaceutically acceptable salt) thereof. B23. The compound of embodiment B11, wherein the compound is a compound according to Formula IIM, or a salt (e.g., pharmaceutically acceptable salt) thereof. B24. The compound of embodiment B11, wherein the compound is a compound according to Formula IIN, or a salt (e.g., pharmaceutically acceptable salt)thereof. B25. The compound of embodiment B11, wherein the compound is a compound according to Formula IIP, or a salt (e.g., pharmaceutically acceptable salt) thereof. B26. The compound of embodiment B11, wherein the compound is a compound according to Formula IIQ, or a salt (e.g., pharmaceutically acceptable salt) thereof. B27. The compound of embodiment B11, wherein the compound is a compound according to Formula IIR, or a salt (e.g., pharmaceutically acceptable salt) thereof. B28. The compound of embodiment B11, wherein the compound is a compound according to Formula IIS, or a salt (e.g., pharmaceutically acceptable salt) thereof. B29. The compound of embodiment B11, wherein the compound is a compound according to Formula IIT, or a salt (e.g., pharmaceutically acceptable salt) thereof. B30. The compound of embodiment B11, wherein the compound is a compound according to Formula IIU, or a salt (e.g., pharmaceutically acceptable salt) thereof. B31. The compound of embodiment B11, wherein the compound is a compound according to Formula IIV, or a salt (e.g., pharmaceutically acceptable salt) thereof. B32. The compound of embodiment B11, wherein the compound is a compound according to Formula IIW, or a salt (e.g., pharmaceutically acceptable salt) thereof. B33. The compound of embodiment B11, wherein the compound is a compound according to Formula IIX, or a salt (e.g., pharmaceutically acceptable salt) thereof. B34. The compound of embodiment B11, wherein the compound is a compound according to Formula IIY, or a salt (e.g., pharmaceutically acceptable salt) thereof. B35. The compound of embodiment B11, wherein the compound is a compound according to Formula IIZ, or a salt (e.g., pharmaceutically acceptable salt) thereof. B36. The compound of any one of embodiments B1-B35, wherein R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . B37. The compound of embodiment B36, wherein R 6 is a pyridine substituted with one or more R 15 . B38. The compound of embodiment B37, wherein R 6 has the structure . B39. The compound of any one of embodiments B1-B35, wherein R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . B40. The compound of embodiment B39, wherein R 6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B41. The compound of embodiment B39 or B40, wherein R 6 is selected from: , , any of which is substituted with one or more R 15 . B42. The compound of any one of embodiments B39-B41, wherein R 6 is selected from: B43. The compound of any one of embodiments B39-B42, wherein R 6 is selected from:

. B44. The compound of any one of embodiments B1-B43, wherein the compound is a compound according to Formula IIA1, IIB1, IIC1, IID1, IIE1, IIF1, IIG1, IIH1, IIJ1, IIK1, IIL1, IIM1, IIN1, IIP1, IIQ1, IIR1, IIS1, IIT1, IIU1, IIV1, IIW1, IIX1, IIY1, or IIZ1:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle), - S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1-6 alkyl), and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B45. The compound of embodiment B44, wherein the compound is a compound according to Formula IIA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B46. The compound of embodiment B44, wherein the compound is a compound according to Formula IIB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B47. The compound of embodiment B44, wherein the compound is a compound according to Formula IIC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B48. The compound of embodiment B44, wherein the compound is a compound according to Formula IID1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B49. The compound of embodiment B44, wherein the compound is a compound according to Formula IIE1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B50. The compound of embodiment B44, wherein the compound is a compound according to Formula IIF1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B51. The compound of embodiment B44, wherein the compound is a compound according to Formula IIG1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B52. The compound of embodiment B44, wherein the compound is a compound according to Formula IIH1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B53. The compound of embodiment B44, wherein the compound is a compound according to Formula IIJ1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B54. The compound of embodiment B44, wherein the compound is a compound according to Formula IIK1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B55. The compound of embodiment B44, wherein the compound is a compound according to Formula IIL1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B56. The compound of embodiment B44, wherein the compound is a compound according to Formula IIM1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B57. The compound of embodiment B44, wherein the compound is a compound according to Formula IIN1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B58. The compound of embodiment B44, wherein the compound is a compound according to Formula IIP1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B59. The compound of embodiment B44, wherein the compound is a compound according to Formula IIQ1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B60. The compound of embodiment B44, wherein the compound is a compound according to Formula IIR1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B61. The compound of embodiment B44, wherein the compound is a compound according to Formula IIS1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B62. The compound of embodiment B44, wherein the compound is a compound according to Formula IIT1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B63. The compound of embodiment B44, wherein the compound is a compound according to Formula IIU1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B64. The compound of embodiment B44, wherein the compound is a compound according to Formula IIV1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B65. The compound of embodiment B44, wherein the compound is a compound according to Formula IIW1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B66. The compound of embodiment B44, wherein the compound is a compound according to Formula IIX1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B67. The compound of embodiment B44, wherein the compound is a compound according to Formula IIY1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B68. The compound of embodiment B44, wherein the compound is a compound according to Formula IIZ1, or a salt (e.g., pharmaceutically acceptable salt)thereof. B69. The compound of any one of embodiments B44-B68, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . B70. The compound of any one of embodiments B44-B69, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). B71. The compound of any one of embodiments B14, B16, B22, B23, B26, B28, B34, B35, B47, B49, B55, B56, B59, B61, B67, and B68, wherein each R f is =O. B72. The compound of any one of embodiments B14, B16, B22, B23, B26, B28, B34, B35, B47, B49, B55, B56, B59, B61, B67, and B68, wherein each R f is absent. B73. The compound of any one of embodiments B12, B15, B18, B19, B24, B27, B30, B31, B45, B48, B51, B52, B57, B60, B63, and B64, wherein R e is C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B74. The compound of any one of embodiments B12, B15, B18, B19, B24, B27, B30, B31, B45, B48, B51, B52, B57, B60, B63, and B64, wherein R e is -C(O)(3-6 membered carbocycle). B75. The compound of any one of embodiments B12-B74, wherein each R d is H. B76. The compound of any one of embodiments B12-B74, wherein at least one R d is selected from - OR 12 and a C 1-6 alkyl substituted with -OH. B77. The compound of any one of embodiments B1-B76, wherein R 2 is H. B78. The compound of any one of embodiments B1-B76, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . B79. The compound of embodiment B78, wherein R 2 is selected from C 1-2 alkyl. B80. The compound of any one of embodiments B1-B79, wherein R 1 is selected from -OR 8 . B81. The compound of embodiment B80, wherein R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b2 are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . B82. , B83. The compound of embodiment B80, wherein R 1 is selected from: R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . B84. The compound of embodiment B83, wherein R 1 is selected from: , B85. wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B86. The compound of embodiment B85, wherein R 1 is selected from: , B88. The compound of any one of embodiments B1-B87, wherein R 5 is H. B89. The compound of any one of embodiments B1-B87, wherein R 5 is a halogen (e.g., F or Cl). B90. The compound of any one of embodiments B1-B87, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B91. The compound of embodiment B90, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. B92. The compound of embodiment B91, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . B93. The compound of embodiment B92, wherein R 5 is -CF 3 . B94. The compound of any one of embodiments B1-B93, wherein the compound is a not a compound included in Table 1.  B95. A compound represented by Formula III’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B96. A compound represented by Formula III: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B97. The compound of embodiment B95 or B96, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle. B98. The compound of embodiment B97, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. B99. The compound of embodiment B98, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 11 . B100. The compound of any one of embodiments B95-B99, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a pyrrolidine that is substituted with 0-4 R 11 . B101. The compound of any one of embodiments B95-B99, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form an azetidine that is substituted with 0-4 R 11 . B102. The compound of any one of embodiments B95-B99, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperidine that is substituted with 0-4 R 11 . B103. The compound of any one of embodiments B95-B99, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperazine that is substituted with 0-4 R 11 . B104. The compound of any one of embodiments B95-B99, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a morpholine or thiomorpholine that is substituted with 0-4 R 11 . B105. The compound of any one of embodiments B95-B99, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N. B106. The compound of any one of embodiments B95-B105, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle substituted with one or more R 11 , wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. B107. The compound of any one of embodiments B95-B106, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle substituted with one or more R 11 , wherein at least one R 11 is an unsubstituted C 1-6 alkyl. B108. The compound of any one of embodiments B95-B105, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that is unsubstituted. B109. The compound of embodiment B95 or B96, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle. B110. The compound of embodiment B109, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. B111. The compound of embodiment B110, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the bridged heterocycle is substituted with 1-4 R 11 . B112. The compound of any one of embodiments B109-B111, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperidine that is substituted with 0-4 R 11 . B113. The compound of any one of embodiments B109-B111, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperazine that is substituted with 0-4 R 11 . B114. The compound of any one of embodiments B109-B111, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged morpholine or thiomorpholine that is substituted with 0-4 R 11 . B115. The compound of any one of embodiments B109-B114, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. B116. The compound of any one of embodiments B109-B115, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , wherein at least one R 11 is an unsubstituted C 1-6 alkyl. B117. The compound of any one of embodiments B109-B114, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle that is unsubstituted. B118. The compound of embodiment B95 or B96, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle. B119. The compound of embodiment B95 or B96, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings. 120. The compound of any one of embodiments B95-B107, B109-B116, B118, and B119, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is substituted with one or more R 11 , wherein the one or more R 11 are independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B121. The compound of embodiment B120, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is substituted with one or more R 11 , wherein the one or more R 11 are independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B122. The compound of any one of embodiments B95-B121, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a structure selected from: , , , , , , , , , , , ,

optionally further substituted with one or more R 11 . B123. The compound of any one of embodiments B95-B122, wherein the compound is a compound according to Formula IIIA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from deuterium, hydrogen, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f and R g are each independently selected from hydrogen, deuterium, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , or R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B124. The compound of embodiment B123, wherein each R e , R f , and R g is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B125. The compound of embodiment B123, wherein each R e , R f , and R g is independently selected from hydrogen, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B126. The compound of any one of embodiments B123-B125, wherein each R e is hydrogen. B127. The compound of any one of embodiments B123-B126, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B128. The compound of embodiment B127, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted. B129. The compound of embodiment B127, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B130. The compound of embodiment B127, wherein R f and R g join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B131. The compound of embodiment B130, wherein R f and R g join together to form a cyclopropane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B132. The compound of embodiment B127, wherein R f and R g join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B133. The compound of embodiment B132, wherein R f and R g join together to form an oxetane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B134. The compound of any one of embodiments B95-B122, wherein the compound is a compound according to Formula IIIB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B135. The compound of embodiment B134, wherein each R e is hydrogen. B136. The compound of any one of embodiments B95-B122, wherein the compound is a compound according to Formula IIIC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B137. The compound of embodiment B136, wherein each R e is hydrogen. B138. The compound of any one of embodiments B95-B122, wherein the compound is a compound according to Formula IIIC1: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f , R g , and R h are each independently selected from hydrogen, deuterium, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , optionally wherein (i) R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; or (ii) R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B139. The compound of embodiment B138, wherein each R e is hydrogen. B140. The compound of embodiment B138 or B139, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B141. The compound of embodiment B140, wherein R f and R g join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B142. The compound of embodiment B140, wherein R f and R g join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B143. The compound of embodiment B138 or B139, wherein R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B144. The compound of embodiment B143, wherein R g and R h join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B145. The compound of embodiment B143, wherein R g and R h join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . B146. The compound of any one of embodiments B95-B122, wherein the compound is a compound according to Formula IIID: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: Q is selected from CR h R j , NR g , O, S, and SO 2 ; each R e and R f is independently selected from R 11 and hydrogen, wherein: (i) an R e and an R f can optionally join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 ; R g , when present, is R 11 ; and R h and R j , when present, are independently selected from R 11 and hydrogen, or can optionally join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B147. The compound of embodiment B146, wherein Q is NR g . B148. The compound of embodiment B147, wherein R g is selected from -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B149. The compound of embodiment B146, wherein Q is O, S, or SO 2 . B150. The compound of embodiment B149, wherein Q is O. B151. The compound of embodiment B146, wherein Q is CR h R j . B152. The compound of embodiment B151, wherein the compound is a compound according to Formula IIIE: or a salt (e.g., pharmaceutically acceptable salt) thereof. B153. The compound of embodiment B152, wherein an R e and an R f join together to form a 4-6 membered ring. B154. The compound of embodiment B152 or B153, wherein R h and R j are independently selected from R 11 and hydrogen. B155. The compound of any one of embodiments B152-B154, wherein R h and/or R j is selected from deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B156. The compound of any one of embodiments B152-B154, wherein R h and R j are each hydrogen. B157. The compound of embodiment B152, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle. B158. The compound of embodiment B157, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted. B159. The compound of embodiment B157, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B160. The compound of any one of embodiments B157-B159, wherein no combination of one or more R e s and/or one or more R f s join together to form a ring. B161. The compound of any one of embodiments B157-B160, wherein each R e and R f is hydrogen. B162. The compound of embodiment B146, wherein the compound is a compound according to Formula IIIF, IIIG, or IIIH: or a salt (e.g., pharmaceutically acceptable salt) thereof. B163. The compound of embodiment B162, wherein the compound is a compound of Formula IIIF or a salt (e.g., a pharmaceutically acceptable salt) thereof. B164. The compound of embodiment B162, wherein the compound is a compound of Formula IIIG or a salt (e.g., a pharmaceutically acceptable salt) thereof. B165. The compound of embodiment B162, wherein the compound is a compound of Formula IIIH or a salt (e.g., a pharmaceutically acceptable salt) thereof. B166. The compound of any one of embodiments B162-B165, wherein each R e and R f is independently selected from R 11 and hydrogen. B167. The compound of any one of embodiments B162-B165, wherein an R e and an R f join together to form a 4-6 membered ring. B168. The compound of embodiment B146, wherein the compound is a compound according to Formula IIIJ: or a salt (e.g., pharmaceutically acceptable salt) thereof. B169. The compound of embodiment B168, wherein each R e and R f is independently selected from R 11 and hydrogen. B170. The compound of embodiment B168, wherein an R e and an R f join together to form a 4-6 membered ring. B171. The compound of any one of embodiments B146-B170, wherein the compound is a compound according to Formula IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, or IIIR: or a salt (e.g., pharmaceutically acceptable salt) wherein: each R e and R f is independently selected from R 11 and hydrogen; R g , when present, is R 11 ; and R h and R j , when present, are independently selected from R 11 and hydrogen. B172. The compound of embodiment B171, wherein the compound is a compound of Formula IIIK or a salt (e.g., a pharmaceutically acceptable salt) thereof. B173. The compound of embodiment B171, wherein the compound is a compound of Formula IIIL or a salt (e.g., a pharmaceutically acceptable salt) thereof. B174. The compound of embodiment B171, wherein the compound is a compound of Formula IIIM or a salt (e.g., a pharmaceutically acceptable salt) thereof. B175. The compound of embodiment B171, wherein the compound is a compound of Formula IIIN or a salt (e.g., a pharmaceutically acceptable salt) thereof. B176. The compound of embodiment B171, wherein the compound is a compound of Formula IIIP or a salt (e.g., a pharmaceutically acceptable salt) thereof. B177. The compound of embodiment B171, wherein the compound is a compound of Formula IIIQ or a salt (e.g., a pharmaceutically acceptable salt) thereof. B178. The compound of embodiment B171, wherein the compound is a compound of Formula IIIR or a salt (e.g., a pharmaceutically acceptable salt) thereof. B179. The compound of any one of embodiments B171-B178, wherein Q is selected from CR h R j , NR g , and O. B180. The compound of embodiment B179, wherein Q is CR h R j . B181. The compound of embodiment B180, wherein R h and R j are independently selected from R 11 and hydrogen. B182. The compound of embodiment B181, wherein R h and/or R j is selected from -OR 12 , =O, =N(R 14 ), - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B183. The compound of embodiment B181, wherein R h and R j are each hydrogen. B184. The compound of embodiment B179, wherein Q is NR g . B185. The compound of embodiment B184, wherein R g is selected from -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B186. The compound of embodiment B179, wherein Q is O. B187. The compound of any one of embodiments B171-B178, wherein Q is S or SO 2 . B188. The compound of any one of embodiments B171-B187, wherein each R e and R f is independently selected from R 11 and hydrogen. B189. The compound of embodiment B188, wherein R e and/or R f is selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B190. The compound of embodiment B188, wherein each R e and R f is hydrogen. B191. The compound of any one of embodiments B146-B170, wherein the compound is a compound according to Formula IIIS: or a salt (e.g., pharmaceutically acceptable salt) wherein: Q 1 is selected from NR g1 , O, SR h 2, and CR i R j ; Q 2 is selected from NR g2 , O, SR h 2, and CR i R j ; R g1 and R g2 , when present, are independently selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R h is absent or, when present, is independently selected from =O, =N(R 14 ), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R i and R j , when present, are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R e1 , R e2 , R e3 , and R e4 are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein (i) an R e2 and an R e3 optionally join together to form a 5-6 membered ring; or (ii) when Q 2 is NR g2 , R g2 and an R e3 , together with the atoms to which they are attached, optionally join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R 11 , wherein each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B192. The compound of embodiment B191, wherein Q 1 and Q 2 are each CR i R j . B193. The compound of embodiment B192, wherein at least one R e1 , R e2 , R e3 , or R e4 is selected from - OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B194. The compound of embodiment B193, wherein each R e1 , R e2 , R e3 , and R e4 is hydrogen. B195. The compound of embodiment B192, wherein an R e2 and an R e3 join together to form a 5-6 membered ring. B196. The compound of embodiment B191, wherein Q 1 is CR i R j and Q 2 is NR g2 . B197. The compound of embodiment B196, wherein R g2 and an R e3 , together with the atoms to which they are attached, join together to form a 5-membered heterocycle or heteroaryl that is unsubstituted or substituted with one or more R 11 . B198. The compound of embodiment B196, wherein R g2 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B199. The compound of embodiment B191, wherein Q 2 is CR i R j and Q 1 is NR g1 . B200. The compound of embodiment B199, wherein R g1 is selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B201. The compound of embodiment B199 or B200, wherein each R e1 , R e2 , R e3 , and R e4 is hydrogen. B202. The compound of embodiment B191, wherein (i) Q 1 is CR i R j and Q 2 is O or (ii) Q 2 is CR i R j and Q 1 is O. B203. The compound of embodiment B202, wherein each R e1 , R e2 , R e3 , and R e4 is hydrogen. B204. The compound of embodiment B202, wherein an R e2 and an R e3 join together to form a 5-6 membered ring. B205. The compound of embodiment B191, wherein (i) Q 1 is CR i R j and Q 2 is SR h 2 or (ii) Q 2 is CR i R j and Q 1 is SR h 2. B206. The compound of embodiment B205, wherein each R e1 , R e2 , R e3 , and R e4 is hydrogen. B207. The compound of embodiment B205, wherein an R e2 and an R e3 join together to form a 5-6 membered ring. B208. The compound of any one of embodiments B205-B207, wherein each R h is =O. B209. The compound of any one of embodiments B192-B208, wherein each R i and R j are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B210. The compound of embodiment B209, wherein each R i and R j are hydrogen. B211. The compound of embodiment B191, wherein (i) NR g1 and Q 2 is SR h 2 or (ii) NR g2 and Q 1 is SR h 2. B212. The compound of embodiment B211, wherein each R e1 , R e2 , R e3 , and R e4 is hydrogen. B213. The compound of embodiment B211, wherein an R e2 and an R e3 join together to form a 5-6 membered ring. B214. The compound of any one of embodiments B211-B213, wherein each R h is =O. B215. The compound of any one of embodiments B146-B170, wherein the compound is a compound according to Formula IIIT: or a salt (e.g., pharmaceutically acceptable salt) wherein: dashed lines represent single or double bonds, such that the ring containing Q 1 , Q 2 , Q 3 , and Q 4 is aromatic; Q 1 , Q 2 , Q 3 , and Q 4 are independently selected from C and N, wherein at least one of Q 1 , Q 2 , Q 3 , and Q 4 is N; each R e and R f is independently selected from R 11 and hydrogen; and each R g is absent or is independently selected from R 11 and hydrogen. B216. The compound of embodiment B215, wherein Q 1 is C. B217. The compound of embodiment B216, wherein Q 2 is C, Q 3 is N, and Q 4 is N. B218. The compound of embodiment B215, wherein Q 1 is N. B219. The compound of embodiment B218, wherein Q 2 is N, and Q 3 and Q 4 are C. B220. The compound of embodiment B218, wherein Q 2 and Q 3 are N, and Q 4 is C. B221. The compound of embodiment B218, wherein Q 3 and Q 4 are N, and Q 2 is C. B222. The compound of embodiment B218, wherein Q 2 and Q 4 are N, and Q 3 is C. B223. The compound of any one of embodiments B215-B222, wherein each R g is hydrogen or is absent. B224. The compound of any one of embodiments B95-B223, wherein R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . B225. The compound of embodiment B224, wherein R 6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B226. The compound of embodiment B224 or B225, wherein R 6 is selected from: any of which is substituted with one or more R 15 . B227. The compound of any one of embodiments B224-B226, wherein R 6 is selected from: . B228. The compound of any one of embodiments B224-B227, wherein R 6 is selected from: . B229. The compound of any one of embodiments B95-B223, wherein R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . B230. The compound of embodiment B229, wherein R 6 is a pyridine substituted with one or more R 15 . B231. The compound of embodiment B230, wherein R 6 has the structure .  B232. The compound of any one of embodiments B95-B231, wherein R 1 is selected from -OR 8 . B233. The compound of embodiment B232, wherein R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b2 are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . , B235. The compound of embodiment B232, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . B236. The compound of embodiment B235, wherein R 1 is selected from: , B237. The compound of embodiment B232, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B239. The compound of any one of embodiments B95-B231, wherein R 1 is selected from B240. The compound of any one of embodiments B95-B239, wherein each R 11 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . B241. The compound of any one of embodiments B95-B240, wherein R 5 is a halogen (e.g., F or Cl). B242. The compound of any one of embodiments B95-B240, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B243. The compound of embodiment B242, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. B244. The compound of embodiment B243, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . B245. The compound of embodiment B244, wherein R 5 is –CF 3 . B246. The compound of any one of embodiments B95-B245, wherein the compound is a not a compound included in Table 2.  B247. A compound represented by Formula I: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 3-11 membered carbocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle. B248. The compound of embodiment B247, wherein R 3 is a 3-6 membered carbocycle that is unsubstituted or is substituted with one or more R 10 . B249. The compound of embodiment B248, wherein R 3 is a 3-6 membered carbocycle that is substituted with 1-4 R 10 . B250. The compound of embodiment B248, wherein R 3 is a cyclopropane that is substituted with 0-4 R 10 . B251. The compound of embodiment B248, wherein R 3 is a cyclobutane that is substituted with 0-4 R 10 . B252. The compound of embodiment B248, wherein R 3 is a cyclopentane that is substituted with 0-4 R 10 . B253. The compound of embodiment B248, wherein R 3 is a cyclohexane that is substituted with 0-4 R 10 . B254. The compound of any one of embodiments B247-B249, wherein R 3 is a spirocycle that is unsubstituted or is substituted with one or more R 10 . B255. The compound of any one of embodiments B247-B249, wherein R 3 is a bridged carbocycle that is unsubstituted or is substituted with one or more R 10 . B256. The compound of any one of embodiments B247-B255, wherein R 3 is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. B257. The compound of any one of embodiments B247-B256, wherein R 3 is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl. B258. The compound of any one of embodiments B247-B257, wherein the compound is a compound according to Formula IA, IB, IC, ID, IE, or IF: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B259. The compound of embodiment B258, wherein the compound is a compound according to Formula IA, or a salt (e.g., pharmaceutically acceptable salt) thereof. B260. The compound of embodiment B258, wherein the compound is a compound according to Formula IB, or a salt (e.g., pharmaceutically acceptable salt)thereof. B261. The compound of embodiment B258, wherein the compound is a compound according to Formula IC, or a salt (e.g., pharmaceutically acceptable salt)thereof. B262. The compound of embodiment B258, wherein the compound is a compound according to Formula ID, or a salt (e.g., pharmaceutically acceptable salt) thereof. B263. The compound of embodiment B258, wherein the compound is a compound according to Formula IE, or a salt (e.g., pharmaceutically acceptable salt)thereof. B264. The compound of embodiment B258, wherein the compound is a compound according to Formula IF, or a salt (e.g., pharmaceutically acceptable salt)thereof. B265. The compound of any one of embodiments B258-B264, wherein at least one R d is selected from - OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B266. The compound of embodiment B265, wherein at least one R d is selected from -OR 12 and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B267. The compound of any one of embodiments B247-B266, wherein R 6 is selected from: , wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B268. The compound of any one of embodiments B247-B267, wherein R 6 is selected from: any of which is substituted with one or more R 15 . B269. The compound of any one of embodiments B247-B268, wherein R 6 is selected from: B270. The compound of any one of embodiments B247-B269, wherein R 6 is selected from: B271. The compound of any one of embodiments B247-B270, wherein the compound is a compound according to Formula IA1, IB1, IC1, ID1, IE1, or IF1: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B272. The compound of embodiment B271, wherein the compound is a compound according to Formula IA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B273. The compound of embodiment B271, wherein the compound is a compound according to Formula IB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B274. The compound of embodiment B271, wherein the compound is a compound according to Formula IC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B275. The compound of embodiment B271, wherein the compound is a compound according to Formula ID1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B276. The compound of embodiment B271, wherein the compound is a compound according to Formula IE1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B277. The compound of embodiment B271, wherein the compound is a compound according to Formula IF1, or a salt (e.g., pharmaceutically acceptable salt) thereof. B278. The compound of any one of embodiments B271-B277, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . B279. The compound of any one of embodiments B271-B278, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). B280. The compound of any one of embodiments B247-B279, wherein R 1 is selected from -OR 8 . B281. The compound of embodiment B280, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . B282. The compound of embodiment B281, wherein R 1 is selected from: , B283. The compound of embodiment B280, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle. B284. The compound of embodiment B283, wherein R 1 is selected from: , B285. The compound of any one of embodiments B247-B279, wherein R 1 is selected from B286. The compound of any one of embodiments B247-B285, wherein the compound is a compound according to Formula IA2, IB2, IC2, ID2, IE2, or IF2:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; each R d is independently selected from H, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B287. The compound of embodiment B286, wherein the compound is a compound according to Formula IA2, or a salt (e.g., pharmaceutically acceptable salt) thereof. B288. The compound of embodiment B286, wherein the compound is a compound according to Formula IB2, or a salt (e.g., pharmaceutically acceptable salt) thereof. B289. The compound of embodiment B286, wherein the compound is a compound according to Formula IC2, or a salt (e.g., pharmaceutically acceptable salt) thereof. B290. The compound of embodiment B286, wherein the compound is a compound according to Formula ID2, or a salt (e.g., pharmaceutically acceptable salt) thereof. B291. The compound of embodiment B286, wherein the compound is a compound according to Formula IE2, or a salt (e.g., pharmaceutically acceptable salt) thereof. B292. The compound of embodiment B286, wherein the compound is a compound according to Formula IF2, or a salt (e.g., pharmaceutically acceptable salt) thereof. B293. The compound of any one of embodiments B286-B292, wherein R a is a halogen (e.g., F). B294. The compound of any one of embodiments B286-B293, wherein R b is H. B295. The compound of any one of embodiments B286-B294, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . B296. The compound of any one of embodiments B286-B295, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). B297. The compound of any one of embodiments B247-B296, wherein R 2 is H. B298. The compound of any one of embodiments B247-B296, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . B299. The compound of embodiment B298, wherein R 2 is selected from C 1-2 alkyl. B300. The compound of any one of embodiments B247-B299, wherein R 5 is H. B301. The compound of any one of embodiments B247-B299, wherein R 5 is a halogen (e.g., F or Cl). B302. The compound of any one of embodiments B247-B299, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B303. The compound of embodiment B302, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. B304. The compound of embodiment B303, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . B305. The compound of embodiment B304, wherein R 5 is -CF 3 . B306. The compound of any one of embodiments B247-B305, wherein R 7 is H. B307. The compound of any one of embodiments B247-B305, wherein R 7 is a halogen (e.g., F or Cl). B308. The compound of any one of embodiments B247-B305, wherein R 7 is -CN. B309. A compound represented by Formula IV: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a bicyclic heteroaryl substituted with one or more R 15 ; R 7 is selected from halogen, -CN, and H; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 14 , =O, -CN, -N(R 14 ) 2 , a 3-6 membered carbocycle, a 5-6 membered heteroaryl, -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and any 5- 6 membered heteroaryl is unsubstituted or substituted with one or more R 13 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle. B310. The compound of embodiment B309, wherein the compound is a compound according to Formula IVA:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R i and R h are independently selected from H and R 10 . B311. The compound of embodiment B310, wherein each R i and R h are independently selected from H and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B312. The compound of embodiment B310 or B311, wherein R 14 is H. B313. The compound of any one of embodiments B309-B312, wherein R 6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B314. The compound of any one of embodiments B309-B313, wherein R 6 is selected from: any of which is substituted with one or more R 15 . B315. The compound of any one of embodiments B309-B314, wherein R 6 is selected from: B316. The compound of any one of embodiments B309-B315, wherein R 6 is selected from: B317. The compound of embodiment B309, wherein the compound is a compound according to Formula IVB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B318. The compound of any one of embodiments B309-B317, wherein R 1 is selected from -OR 8 . B319. The compound of embodiment B318, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . B320. The compound of embodiment B321, wherein R 1 is selected from: , B321. The compound of embodiment B318, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 , and wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle. B323. The compound of any one of embodiments B309-B317, wherein R 1 is selected from B324. The compound of any one of embodiments B309-B323, wherein the compound is a compound according to Formula IVC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B325. The compound of embodiment B324, wherein R a is a halogen (e.g., F). B326. The compound of embodiment B324 or B325, wherein R b is H. B327. The compound of any one of embodiments B317-B326, wherein X is C-CN, Y is S, and R 23 is selected from -N(R 12 ) 2 . B328. The compound of any one of embodiments B317-B327, wherein at least one of R 24 , R 25 , and R 26 is a halogen (e.g., F). B329. The compound of any one of embodiments B309 and B317-B328, wherein R 3 is selected from C 1- 3 alkyl that is unsubstituted or is substituted with one or more R 10 . B330. The compound of embodiment B329, wherein each R 10 is independently selected from -OR 14 , =O, -CN, -NH(R 16 ), -N(R 16 ) 2 , a 3-6 membered carbocycle, C 1-6 alkyl, and halogen, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 , and wherein each R 16 is independently selected from C 1-6 alkyl and C 2-6 alkenyl. B331. The compound of embodiment B330, wherein each R 10 is independently selected from -OR 14 , - CN, C 1-6 alkyl, and halogen, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . B332. The compound of embodiment B331, wherein each R 10 is independently selected from halogen. B333. The compound of embodiment B329, wherein R 3 is selected from C 1-3 alkyl that is unsubstituted. B334. The compound of any one of embodiments B309 and B317-B333, wherein the moiety is

of which is optionally further substituted with one or more R 10 . B335. The compound of any one of embodiments B309-B334, wherein R 2 is H. B336. The compound of any one of embodiments B309-B334, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . B337. The compound of embodiment B336, wherein R 2 is selected from C 1-2 alkyl that is unsubstituted. B338. The compound of any one of embodiments B309-B337, wherein R 5 is H. B339. The compound of any one of embodiments B309-B337, wherein R 5 is a halogen (e.g., F or Cl). B340. The compound of any one of embodiments B309-B337, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B341. The compound of embodiment B340, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. B342. The compound of embodiment B341, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . B343. The compound of embodiment B342, wherein R 5 is –CF 3 . B344. The compound of any one of embodiments B309-B343, wherein R 7 is H. B345. The compound of any one of embodiments B309-B343, wherein R 7 is a halogen (e.g., F or Cl). B346. The compound of any one of embodiments B309-B343, wherein R 7 is -CN. B347. The compound of any one of embodiments B309-B346, wherein the compound is a not a compound included in Table 3.  B348. A compound represented by Formula V: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R m is selected from hydrogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B349. The compound of embodiment B348, wherein R m is hydrogen. B350. The compound of embodiment B348 or B349, wherein the compound is a compound according to Formula VA: or a salt (e.g., pharmaceutically acceptable salt) thereof. B351. The compound of embodiment B348, wherein the compound is a compound according to Formula VB: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R m is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B352. The compound of embodiment B348 or B351, wherein R m is C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B353. The compound of embodiment B352, wherein R m is C 1-6 alkyl that is unsubstituted. B354. The compound of any one of embodiments B348-B353, wherein R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . B355. The compound of embodiment B354, wherein R 6 is selected from: , wherein X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from - N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B356. The compound of embodiment B355, wherein X is C-CN; Y is S; and R 23 is -N(R 12 ) 2 . B357. The compound of embodiment B355 or B356, wherein at least one of R 24 , R 25 , and R 26 is halogen. B358. The compound of any one of embodiments B348-B353, wherein R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . B359. The compound of embodiment B358, wherein R 6 is a pyridine substituted with one or more R 15 . B360. The compound of embodiment B359, wherein R 6 has the structure . B361. The compound of any one of embodiments B348-B360, wherein the compound is a compound according to Formula VC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, -OR 12 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . B362. The compound of embodiment B361, wherein X is C-CN, Y is S, and R 23 is selected from - N(R 12 ) 2 . B363. The compound of embodiment B361 or B362, wherein at least one of R 24 , R 25 , and R 26 is halogen. B364. The compound of any one of embodiments B348-B363, wherein R 1 is selected from -OR 8 . B365. The compound of embodiment B364, wherein R 1 is selected from: wherein R a1 , R a2 , R b1 , and R b2 are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 .

, B367. The compound of embodiment B364, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . B368. The compound of embodiment B367, wherein R 1 is selected from: , . B369. The compound of embodiment B364, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . B370. The compound of embodiment B369, wherein R 1 is selected from: , B372. The compound of any one of embodiments B348-B371, wherein R 5 is a halogen (e.g., F or Cl). B373. The compound of any one of embodiments B348-B371, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . B374. The compound of embodiment B373, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. B375. The compound of embodiment B374, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . B376. The compound of embodiment B375, wherein R 5 is –CF 3 . B377. A compound shown in Table 5, or a salt (e.g., pharmaceutically acceptable salt) thereof. B378. A compound shown in Table 6, or a salt (e.g., pharmaceutically acceptable salt) thereof. B379. A compound shown in Table 7, or a salt (e.g., pharmaceutically acceptable salt) thereof. B380. A pharmaceutical composition comprising a compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof, and a pharmaceutically acceptable excipient. B381. A compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use as a medicament. B382. The compound of embodiment B381, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. B383. The compound of embodiment B382, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of wild-type KRAS. B384. The compound of embodiment B382, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. B385. The compound of any one of embodiments B381-B384, wherein the medicament is useful in the prevention or treatment of a cancer. B386. The compound of embodiment B385, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B387. A compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use in the treatment of a disease, disorder, or condition. B388. The compound of embodiment B387, wherein the disease, disorder, or condition is a cancer. B389. The compound of embodiment B388, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B390. The compound of any one of embodiments B387-B389, wherein the compound is used in the treatment of a disease, disorder, or condition in a subject in need thereof. B391. A compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof, for use in the manufacture of a medicament. B392. The compound of embodiment B391, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. B393. The compound of embodiment B392, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of wild-type KRAS. B394. The compound of embodiment B392, wherein the medicament is useful in the prevention or treatment of a disease, disorder, or condition ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. B395. The compound of any one of embodiments B391-B394, wherein the medicament is useful in the treatment of a cancer. B396. The compound of embodiment B395, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B397. A method, comprising administering a therapeutically effective amount of a compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof, to a subject in need thereof. B398. The method of embodiment B397, wherein the subject has a disease, disorder, or condition ameliorated by the inhibition of KRAS having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, or wild-type KRAS. B399. The method of embodiment B398, wherein the disease, disorder, or condition is ameliorated by the inhibition of wild-type KRAS. B400. The method of embodiment B398, wherein the disease, disorder, or condition is ameliorated by the inhibition of KRAS having a G12D, G12R, or G12V mutation. B401. The method of any one of embodiments B397-B400, wherein the subject has a cancer. B402. The method of embodiment B401, wherein the subject was previously diagnosed with the cancer. B403. The method of embodiment B401, wherein the subject has previously undergone a treatment regimen for the cancer. B404. The method of embodiment B402 or B403, wherein the subject has previously entered remission from the cancer. B405. The method of any one of embodiments B401-B404, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B406. The method of any one of embodiments B397-B405, wherein the compound, or the salt thereof, is administered in combination with an additional therapeutic agent. B407. The use of a compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof, for the manufacture of a medicament for the treatment of a cancer. B408. The use of embodiment B407, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B409. A method, comprising contacting a KRAS protein with a compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof. B410. The method of embodiment B409, wherein contacting the KRAS protein with the compound modulates KRAS. B411. The method of embodiment B409 or B410, wherein the KRAS protein has a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation. B412. The method of embodiment B409 or B410, wherein the KRAS protein is a wild-type KRAS protein. B413. The method of any one of embodiments B409-B412, wherein the KRAS protein is in an active (GTP-bound) state. B414. The method of any one of embodiments B409-B412, wherein the KRAS protein is in an inactive (GDP-bound) state. B415. The method of any one of embodiments B409-B414, wherein the KRAS protein is located within a cell. B416. The method of embodiment B415, wherein the cell is located within a subject. B417. The method of embodiment B416, wherein the subject is a human. B418. The method of embodiment B416 or B417, wherein the subject has a cancer. B419. The method of embodiment B418, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B420. A method of inhibiting the function of a wild-type KRAS protein or a KRAS protein having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation, comprising contacting the KRAS protein with a compound of any one of embodiments B1-B379, or a salt (e.g., pharmaceutically acceptable salt) thereof. B421. The method of embodiment B420, wherein the KRAS protein is a wild-type KRAS protein. B422. The method of embodiment B420, wherein the KRAS protein has a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation. B423. The method of embodiment B422, wherein the KRAS protein has a G12D, G12V, or G12R mutation. B424. The method of any one of embodiments B420-B423, wherein the KRAS protein is in an active (GTP-bound) state. B425. The method of any one of embodiments B420-B423, wherein the KRAS protein is in an inactive (GDP-bound) state. B426. The method of any one of embodiments B420-B425, wherein the KRAS protein is located within a cell. B427. The method of embodiment B426, wherein the cell is located within a subject. B428. The method of embodiment B427, wherein the subject is a human. B429. The method of embodiment B427 or B428, wherein the subject has a cancer. B430. The method of embodiment B429, wherein the cancer is selected from the group consisting of pancreatic cancer, colorectal cancer, and lung cancer. B431. A compound capable of inhibiting a wild-type KRAS protein or a KRAS protein having a Q61H, G13D, G12D, G12V, G12C, G12S, G12A, or G12R mutation in both its active (GTP-bound) and inactive (GDP-bound) state. B432. The compound of embodiment B431, wherein the compound: (i) has IC 50 ≤0.1 µM, 0.1 µM< IC 50 ≤1 µM, 1 µM< IC 50 ≤10 µM, or 10 µM< IC 50 in the assay of Biological Example 1 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS G12R (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS G12V (amino acids 1-169) GppNHp/ RAF1 RBD-3xFLAG (52-151); 50 nM Avi-KRAS WT (amino acids 1- 169) GppNHp/ RAF1 RBD-3xFLAG (52-151); and/or 75 nM Avi-RAF1 RBD-3xFLAG; and/or (ii) has IC 50 ≤0.1 µM, 0.1 µM< IC 50 ≤1 µM, or IC 50 >1 µM in the assay of Biological Example 2 (e.g., cell-based pERK HTRF assay in GP2d (G12D) and SW620 (G12V) cell). B433. The compound of embodiment B432, wherein the compound: (i) has IC 50 ≤0.1 µM or 0.1 µM< IC 50 ≤1 µM in the assay of Biological Example 1 (e.g., a protein:protein interaction (PPI) Homogenous Time Resolved Fluorescence (HTRF) analysis of 50 nM Avi-KRAS G12D (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS G12R (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS G12V (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); 50 nM Avi-KRAS WT (amino acids 1-169) GppNHp/ RAF1 RBD- 3xFLAG (52-151); and/or 75 nM Avi-RAF1 RBD-3xFLAG; and/or (ii) has IC 50 ≤0.1 µM or 0.1 µM< IC 50 ≤1 µM in the assay of Biological Example 2 (e.g., cell-based pERK HTRF assay in GP2d (G12D) and SW620 (G12V) cell). B434. The compound of any one of embodiments B431-B433, wherein the compound is capable of irreversibly binding the KRAS protein. B435. The compound of any one of embodiments B431-B433, wherein the compound is capable of reversibly binding the KRAS protein. B436. The compound of any one of embodiments B431-B435, wherein the compound is a compound according to any one of embodiments B1-B379. [0455] The following numbered embodiments, while non-limiting, are exemplary of certain aspects of the present disclosure: C1. A compound represented by Formula II’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R 10 ; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -C(O)(3-7 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -S(O) 2 (C 1-6 alkyl), halogen, a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 , and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, - C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . C2. A compound represented by Formula II: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 is selected from H, C 1-6 alkyl, and a 3-6 membered carbocycle, wherein any C 1-6 alkyl is unsubstituted or is substituted with one or more R 13 ; R 3 is selected from a 4-9 membered heterocycle that is unsubstituted or substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 , or (ii) the heterocycle does not comprise an –NH- moiety; R 4 is H; R 5 is selected from H, halogen, -CN, -OR 12 , a 3-6 membered heterocycle, a 5-6 membered heteroaryl, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl lis substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 10 is independently selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -C(O)(3-7 membered heterocycle), -C(O)(5-6 membered heteroaryl), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -S(O) 2 (C 1-6 alkyl), halogen, a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 , and wherein two R 10 s optionally join together to form, together with the atom(s) to which they are attached, a 3-6 membered carbocycle or heterocycle; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from a 3-6 membered carbocycle, a 3-6 membered heterocycle, C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl is optionally deuterated; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, =O, -CN, -NH 2 , -NHC 1-6 alkyl, - C(O)(C 1-6 alkyl), a 3-6 membered carbocycle, phenyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . C3. The compound of embodiment C1 or C2, wherein R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N. C4. The compound of embodiment C3, wherein R 3 is a 4-6 membered heterocycle that includes 1 heteroatom selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 10 , provided that when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 . C5. The compound of any one of embodiments C1-C4, wherein R 3 is a pyrrolidine that is substituted with 0-4 R 10 , provided that the nitrogen atom is substituted with R 10 . C6. The compound of any one of embodiments C1-C4, wherein R 3 is an oxetane or thietane that is substituted with 0-4 R 10 . C7. The compound of any one of embodiments C1-C4, wherein R 3 is a tetrahydrofuran or tetrahydrothiopene that is substituted with 0-4 R 10 . C8. The compound of any one of embodiments C1-C4, wherein R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is selected from -OR 12 and a C 1- 6 alkyl substituted with -OH. C9. The compound of any one of embodiments C1-C8, wherein R 3 is a 4-6 membered heterocycle that is substituted with one or more R 10 , wherein at least one R 10 is an unsubstituted C 1-6 alkyl. C10. The compound of any one of embodiments C1-C9, wherein R 3 is selected from: ,

C11. The compound of embodiment C1 or C2, wherein R 3 is a 7-9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 . C12. The compound of embodiment C11, wherein R 3 is a 7-9 membered heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 , provided that (i) when the heterocycle contains a nitrogen atom, the nitrogen atom is substituted with R 10 or (ii) the heterocycle does not comprise an –NH- moiety. C13. The compound of embodiment C11 or C12, wherein R 3 is a 7-9 membered bridged heterocycle that includes one or more heteroatoms selected from O, S, and N, wherein the bridged heterocycle is unsubstituted or is substituted with one or more R 10 . C14. The compound of embodiment C11 or C12, wherein R 3 is a 7-9 membered heterocycle comprising a fused ring system that includes one or more heteroatoms selected from O, S, and N, wherein the heterocycle is unsubstituted or is substituted with one or more R 10 . C15. The compound of any one of embodiments C1, C2, or C11-C14, wherein R 3 is selected from: , , any of which is optionally further substituted with one or more R 10 . C16. The compound of any one of embodiments C1-C15, wherein the compound is a compound according to Formula IIA, IIB, IIC, IID, IIE, IIF, IIG, IIH, IIJ, IIK, IIL, IIM, IIN, IIP, IIQ, IIR, IIS, IIT, IIU, IIV, IIW, IIX, IIY, or IIZ:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle), - S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkyl)CN, -C(O)(C 1-6 alkyl)OH, -C(O)(C 1-6 alkyl), - C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), -C(O)(3- 7 membered heterocycle), -C(O)(5-6 membered heteraryl), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -S(O) 2 (C 1-6 alkyl), a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; and each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 . C17. The compound of embodiment C16, wherein the compound is a compound according to Formula IIA, or a salt (e.g., pharmaceutically acceptable salt) thereof. C18. The compound of embodiment C16, wherein the compound is a compound according to Formula IIB, or a salt (e.g., pharmaceutically acceptable salt) thereof. C19. The compound of embodiment C16, wherein the compound is a compound according to Formula IIC, or a salt (e.g., pharmaceutically acceptable salt)thereof. C20. The compound of embodiment C16, wherein the compound is a compound according to Formula IID, or a salt (e.g., pharmaceutically acceptable salt) thereof. C21. The compound of embodiment C16, wherein the compound is a compound according to Formula IIE, or a salt (e.g., pharmaceutically acceptable salt) thereof. C22. The compound of embodiment C16, wherein the compound is a compound according to Formula IIF, or a salt (e.g., pharmaceutically acceptable salt) thereof. C23. The compound of embodiment C16, wherein the compound is a compound according to Formula IIG, or a salt (e.g., pharmaceutically acceptable salt) thereof. C24. The compound of embodiment C16, wherein the compound is a compound according to Formula IIH, or a salt (e.g., pharmaceutically acceptable salt) thereof. C25. The compound of embodiment C16, wherein the compound is a compound according to Formula IIJ, or a salt (e.g., pharmaceutically acceptable salt) thereof. C26. The compound of embodiment C16, wherein the compound is a compound according to Formula IIK, or a salt (e.g., pharmaceutically acceptable salt) thereof. C27. The compound of embodiment C16, wherein the compound is a compound according to Formula IIL, or a salt (e.g., pharmaceutically acceptable salt) thereof. C28. The compound of embodiment C16, wherein the compound is a compound according to Formula IIM, or a salt (e.g., pharmaceutically acceptable salt) thereof. C29. The compound of embodiment C16, wherein the compound is a compound according to Formula IIN, or a salt (e.g., pharmaceutically acceptable salt)thereof. C30. The compound of embodiment C16, wherein the compound is a compound according to Formula IIP, or a salt (e.g., pharmaceutically acceptable salt) thereof. C31. The compound of embodiment C16, wherein the compound is a compound according to Formula IIQ, or a salt (e.g., pharmaceutically acceptable salt) thereof. C32. The compound of embodiment C16, wherein the compound is a compound according to Formula IIR, or a salt (e.g., pharmaceutically acceptable salt) thereof. C33. The compound of embodiment C16, wherein the compound is a compound according to Formula IIS, or a salt (e.g., pharmaceutically acceptable salt) thereof. C34. The compound of embodiment C16, wherein the compound is a compound according to Formula IIT, or a salt (e.g., pharmaceutically acceptable salt) thereof. C35. The compound of embodiment C16, wherein the compound is a compound according to Formula IIU, or a salt (e.g., pharmaceutically acceptable salt) thereof. C36. The compound of embodiment C16, wherein the compound is a compound according to Formula IIV, or a salt (e.g., pharmaceutically acceptable salt) thereof. C37. The compound of embodiment C16, wherein the compound is a compound according to Formula IIW, or a salt (e.g., pharmaceutically acceptable salt) thereof. C38. The compound of embodiment C16, wherein the compound is a compound according to Formula IIX, or a salt (e.g., pharmaceutically acceptable salt) thereof. C39. The compound of embodiment C16, wherein the compound is a compound according to Formula IIY, or a salt (e.g., pharmaceutically acceptable salt) thereof. C40. The compound of embodiment C16, wherein the compound is a compound according to Formula IIZ, or a salt (e.g., pharmaceutically acceptable salt) thereof. C41. The compound of any one of embodiments C1-C15, wherein the compound is a compound according to Formula IIAA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein any 3-6 membered carbocycle, is unsubstituted or substituted with one or more R 12 or R 20 ; and (i) R q1 , R q2 , and R p2 are each independently selected from R d , and R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d ; or (ii) R p1 , R p2 , and R q2 are each independently selected from R d , and R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d . C42. The compound of any one of embodiments C1-C41, wherein R 6 is a monocyclic heteroaryl that is substituted with one or more R 15 . C43. The compound of embodiment C42, wherein R 6 is a pyridine substituted with one or more R 15 . C44. The compound of embodiment C43, wherein R 6 has the structure . C45. The compound of any one of embodiments C1-C41, wherein R 6 is a bicyclic heteroaryl that is substituted with one or more R 15 . C46. The compound of embodiment C45, wherein R 6 is selected from: X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . C47. The compound of embodiment C45 or C46, wherein R 6 is selected from: , , , , , , , C48. The compound of any one of embodiments C45-C47, wherein R 6 is selected from:

. C49. The compound of any one of embodiments C45-C48, wherein R 6 is selected from: C50. The compound of any one of embodiments C1-C49, wherein the compound is a compound according to Formula IIA1, IIB1, IIC1, IID1, IIE1, IIF1, IIG1, IIH1, IIJ1, IIK1, IIL1, IIM1, IIN1, IIP1, IIQ1, IIR1, IIS1, IIT1, IIU1, IIV1, IIW1, IIX1, IIY1, or IIZ1:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle), - S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; R e , if present, is selected from -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)O(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)OR 14 , -C(O)(3-6 membered carbocycle), - C(O)(3-7 membered heterocycle), -C(O)(5-6 membered heteraryl), -C(O)O(3-6 membered heterocycle), -C(O)O(C 1-6 alkylene)(3-6 membered heterocycle), -S(O) 2 (C 1- 6 alkyl), a 3-6 membered carbocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle, 5-6 membered heteroaryl, or 3-6 membered heterocycle is unsubstituted or substituted with one or more R 12 or R 20 ; each R f is optionally absent and, if present, is selected from =O, -NH 2 , -NHC 1-6 alkyl, and -N(C 1- 6 alkyl) 2 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 . C51. The compound of embodiment C50, wherein the compound is a compound according to Formula IIA1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C52. The compound of embodiment C50, wherein the compound is a compound according to Formula IIB1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C53. The compound of embodiment C50, wherein the compound is a compound according to Formula IIC1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C54. The compound of embodiment C50, wherein the compound is a compound according to Formula IID1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C55. The compound of embodiment C50, wherein the compound is a compound according to Formula IIE1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C56. The compound of embodiment C50, wherein the compound is a compound according to Formula IIF1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C57. The compound of embodiment C50, wherein the compound is a compound according to Formula IIG1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C58. The compound of embodiment C50, wherein the compound is a compound according to Formula IIH1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C59. The compound of embodiment C50, wherein the compound is a compound according to Formula IIJ1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C60. The compound of embodiment C50, wherein the compound is a compound according to Formula IIK1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C61. The compound of embodiment C50, wherein the compound is a compound according to Formula IIL1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C62. The compound of embodiment C50, wherein the compound is a compound according to Formula IIM1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C63. The compound of embodiment C50, wherein the compound is a compound according to Formula IIN1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C64. The compound of embodiment C50, wherein the compound is a compound according to Formula IIP1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C65. The compound of embodiment C50, wherein the compound is a compound according to Formula IIQ1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C66. The compound of embodiment C50, wherein the compound is a compound according to Formula IIR1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C67. The compound of embodiment C50, wherein the compound is a compound according to Formula IIS1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C68. The compound of embodiment C50, wherein the compound is a compound according to Formula IIT1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C69. The compound of embodiment C50, wherein the compound is a compound according to Formula IIU1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C70. The compound of embodiment C50, wherein the compound is a compound according to Formula IIV1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C71. The compound of embodiment C50, wherein the compound is a compound according to Formula IIW1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C72. The compound of embodiment C50, wherein the compound is a compound according to Formula IIX1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C73. The compound of embodiment C50, wherein the compound is a compound according to Formula IIY1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C74. The compound of embodiment C50, wherein the compound is a compound according to Formula IIZ1, or a salt (e.g., pharmaceutically acceptable salt) thereof. C75. The compound of any one of embodiments C1-C49, wherein the compound is a compound according to Formula IIAA1:

or a salt (e.g., a pharmaceutically acceptable salt) thereof, wherein: each R d is independently selected from H, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OH, -C(O)(C 1-6 alkyl), -C(O)(3-6 membered carbocycle), -C(O)N(R 14 ) 2 , - S(O) 2 (C 1-6 alkyl), halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , and wherein any 3-6 membered carbocycle is unsubstituted or substituted with one or more R 12 or R 20 ; X is selected from N and C-CN; Y is selected from O and S; R 23 is selected from -N(R 12 ) 2 , C 1-6 alkyl, and C 1-6 alkyl-N(R 14 ) 2 , wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 24 , R 25 , and R 26 are independently selected from H, deuterium, halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; and (i) R q1 , R q2 , and R p2 are each independently selected from R d , and R e and R p1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d ; or (ii) R p1 , R p2 , and R q2 are each independently selected from R d , and R e and R q1 , together with the atoms to which they are attached, form a 5-6 membered heterocycle that is unsubstituted or is substituted with one or more R d . C76. The compound of any one of embodiments C50-C75, wherein X is C-CN, Y is S, and R 23 is - N(R 12 ) 2 . C77. The compound of any one of embodiments C50-C76, wherein one or more of R 24 , R 25 , and R 26 is a halogen (e.g., F). C78. The compound of any one of embodiments C19, C21, C27, C28, C31, C33, C39, C40, C53, C55, C61, C62, C65, C67, C73, and C74, wherein each R f is =O. C79. The compound of any one of embodiments C19, C21, C27, C28, C31, C33, C39, C40, C53, C55, C61, C62, C65, C67, C73, and C74, wherein each R f is absent. C80. The compound of any one of embodiments C17, C20, C23, C24, C32, C35, C36, C41, C51, C54, C57, C58, C63, C66, C69, C70, and C75, wherein R e is C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . C81. The compound of any one of embodiments C17, C20, C23, C24, C32, C35, C36, C41, C51, C54, C57, C58, C63, C66, C69, C70, and C75, wherein R e is -C(O)(3-6 membered carbocycle). C82. The compound of any one of embodiments C17-C81, wherein each R d is H. C83. The compound of any one of embodiments C17-C81, wherein at least one R d is selected from - OR 12 and a C 1-6 alkyl substituted with -OH. C84. The compound of any one of embodiments C1-C83, wherein R 2 is H. C85. The compound of any one of embodiments C1-C83, wherein R 2 is selected from C 1-6 alkyl that is unsubstituted or is substituted with one or more R 13 . C86. The compound of embodiment C85, wherein R 2 is selected from C 1-2 alkyl. C87. The compound of any one of embodiments C1-C83, wherein R 2 is selected from a 3-6 membered carbocycle. C88. The compound of any one of embodiments C1-C87, wherein R 1 is selected from -OR 8 . C89. The compound of embodiment C88, wherein R 1 is selected from: , wherein R a1 , R a2 , R b1 , and R b2 are each independently selected from deuterium, halogen, C 1-6 alkyl, -OR 12 , and H, wherein R a2 and R b2 can optionally join together to form a 3-6 membered carbocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle is unsubstituted or is substituted with one or more R 13 . C90. The compound of embodiment C89, wherein R 1 is selected from: C91. The compound of embodiment C88, wherein R 1 is selected from: , wherein R a and R b are each independently selected from halogen, C 1-6 alkyl, -OR 12 , and H, wherein any C 1- 6 alkyl is unsubstituted or is substituted with one or more R 13 . C93. The compound of embodiment C88, wherein R 1 is selected from: wherein each R a and R b is independently selected from halogen, C 1-6 alkyl, -OR 12 , and H; and R c is selected from C 1-6 alkyl, wherein an R a and R b or R c optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . C94. The compound of embodiment C93, wherein R 1 is selected from: , , , C95. The compound of any one of embodiments C1-C87, wherein R 1 is selected from C96. The compound of any one of embodiments C1-C95, wherein R 5 is H. C97. The compound of any one of embodiments C1-C95, wherein R 5 is a halogen (e.g., F or Cl). C98. The compound of any one of embodiments C1-C95, wherein R 5 is selected from C 1-6 alkyl that is unsubstituted or substituted with one or more R 13 . C99. The compound of embodiment C98, wherein R 5 is selected from C 1-6 alkyl that is substituted with one or more halogens or -CN. C100. The compound of embodiment C99, wherein R 5 is selected from -CF 2 H, -CF 3 , -CH 2 CN, and - CH 2 CH 3 . C101. The compound of embodiment C100, wherein R 5 is -CF 3 . C102. The compound of any one of embodiments C1-C101, wherein the compound is a not a compound included in Table 1.  C103. A compound represented by Formula III’: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -C(O)(3-6 membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . C104. A compound represented by Formula III: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: R 1 is selected from R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is unsubstituted or is substituted with one or more R 11 , provided that when the heterocycle contains an additional nitrogen atom, the additional nitrogen atom is substituted with R 11 ; R 4 is H; R 5 is selected from halogen and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; R 6 is a monocyclic or bicyclic heteroaryl, wherein the heteroaryl is substituted with one or more R 15 ; R 7 is selected from halogen; R 8 is selected from a heterocycle and an alkylheterocycle, wherein any heterocycle comprises 4-8 members and is unsubstituted or is substituted with one or more R a or R b , and wherein an alkyl moiety of any alkylheterocycle is selected from C 1-6 alkyl; each R 11 is independently selected from deuterium, O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - membered carbocycle or heterocycle), -S(O) 2 (C 1-6 alkyl 14 l), -N(R )C(O)(C 1- 6 alkylene)OR 14 , halogen, -CN, a 3-6 membered carbocycle or heterocycle, and C 1-6 alkyl, wherein any C 1-6 alkyl, carbocycle, or heterocycle is unsubstituted or substituted with one or more R 20 ; each R 12 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H, wherein any C 1-6 alkyl or C 2-6 alkenyl is unsubstituted or substituted with one or more R 13 ; each R 13 is independently selected from -OR 14 , -CN, -N(R 14 ) 2 , and halogen; each R 14 is independently selected from C 1-6 alkyl, C 2-6 alkenyl, and H; each R 15 is independently selected from deuterium, halogen, -N(R 12 ) 2 , -CN, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 13 ; each R 20 is independently selected from -OH, -OC 1-6 alkyl, -CN, -NH 2 , -NHC 1-6 alkyl, and halogen; R 27 is a 3-6 membered heterocycle including one or more heteroatoms selected from N, O, and S, wherein the heterocycle is unsubstituted or substituted with one or more R 28 ; each R 28 is independently selected from C 1-6 alkyl and halogen; and R a and R b are each independently selected from deuterium, halogen, C 1-6 alkyl, a 3-6 membered carbocycle, -OR 12 , and H, wherein an R a and R b optionally join together to form a 3-6 membered carbocycle or heterocycle, and wherein any C 1-6 alkyl or 3-6 membered carbocycle or heterocycle is unsubstituted or is substituted with one or more R 13 . C105. The compound of embodiment C103 or C104, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle. C106. The compound of embodiment C105, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. C107. The compound of embodiment C106, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the heterocycle is substituted with 1-4 R 11 . C108. The compound of any one of embodiments C103-C107, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a pyrrolidine that is substituted with 0-4 R 11 . C109. The compound of any one of embodiments C103-C107, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form an azetidine that is substituted with 0-4 R 11 . C110. The compound of any one of embodiments C103-C107, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperidine that is substituted with 0-4 R 11 . C111. The compound of any one of embodiments C103-C107, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a piperazine that is substituted with 0-4 R 11 . C112. The compound of any one of embodiments C103-C107, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a morpholine or thiomorpholine that is substituted with 0-4 R 11 . C113. The compound of any one of embodiments C103-C107, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-membered heterocycle that includes 1-3 heteroatoms selected from O, S, and N. C114. The compound of any one of embodiments C103-C113, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle substituted with one or more R 11 , wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. C115. The compound of any one of embodiments C103-C114, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle substituted with one or more R 11 , wherein at least one R 11 is an unsubstituted C 1-6 alkyl. C116. The compound of any one of embodiments C103-C113, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-7 membered heterocycle that is unsubstituted. C117. The compound of embodiment C103 or C104, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle. C118. The compound of embodiment C117, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N. C119. The compound of embodiment C118, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 7-9 membered bridged heterocycle that includes 1 or 2 heteroatoms selected from O, S, and N, wherein the bridged heterocycle is substituted with 1-4 R 11 . C120. The compound of any one of embodiments C117-C119, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperidine that is substituted with 0-4 R 11 . C121. The compound of any one of embodiments C117-C119, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged piperazine that is substituted with 0-4 R 11 . C122. The compound of any one of embodiments C117-C119, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged morpholine or thiomorpholine that is substituted with 0-4 R 11 . C123. The compound of any one of embodiments C117-C122, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , wherein at least one R 11 is selected from -OR 12 and a C 1-6 alkyl substituted with -OH. C124. The compound of any one of embodiments C117-C123, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle substituted with one or more R 11 , wherein at least one R 11 is an unsubstituted C 1-6 alkyl. C125. The compound of any one of embodiments C117-C122, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a bridged heterocycle that is unsubstituted. C126. The compound of embodiment C103 or C104, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a spirocycle. C127. The compound of embodiment C103 or C104, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a fused ring system including at least two rings. C128. The compound of any one of embodiments C103-C115, C117-C124, C126, and C127, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is substituted with one or more R 11 , wherein the one or more R 11 are independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1- 6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . C129. The compound of embodiment C128, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a 4-10 membered heterocycle that is substituted with one or more R 11 , wherein the one or more R 11 are independently selected from -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -N(R 14 )C(O)(C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . C130. The compound of any one of embodiments C103-C129, wherein R 2 and R 3 , together with the nitrogen atom to which they are attached, form a structure selected from: C131. The compound of any one of embodiments C103-C130, wherein the compound is a compound according to Formula IIIA: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from deuterium, hydrogen, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f and R g are each independently selected from hydrogen, deuterium, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , or R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C132. The compound of embodiment C131, wherein each R e , R f , and R g is independently selected from hydrogen, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C133. The compound of embodiment C131, wherein each R e , R f , and R g is independently selected from hydrogen, -OR 12 , -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . C134. The compound of any one of embodiments C131-C133, wherein each R e is hydrogen. C135. The compound of any one of embodiments C131-C134, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C136. The compound of embodiment C135, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted. C137. The compound of embodiment C135, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C138. The compound of embodiment C135, wherein R f and R g join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C139. The compound of embodiment C138, wherein R f and R g join together to form a cyclopropane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C140. The compound of embodiment C135, wherein R f and R g join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C141. The compound of embodiment C140, wherein R f and R g join together to form an oxetane that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C142. The compound of any one of embodiments C103-C130, wherein the compound is a compound according to Formula IIIB:

or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C143. The compound of embodiment C142, wherein each R e is hydrogen. C144. The compound of any one of embodiments C103-C130, wherein the compound is a compound according to Formula IIIC: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C145. The compound of embodiment C144, wherein each R e is hydrogen. C146. The compound of any one of embodiments C103-C130, wherein the compound is a compound according to Formula IIIC1: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: each R e is independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and R f , R g , and R h are each independently selected from hydrogen, deuterium, -OR 12 , =O, -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , optionally wherein (i) R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; or (ii) R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, - C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C147. The compound of embodiment C146, wherein each R e is hydrogen. C148. The compound of embodiment C146 or C147, wherein R f and R g join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C149. The compound of embodiment C148, wherein R f and R g join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C150. The compound of embodiment C148, wherein R f and R g join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C151. The compound of embodiment C146 or C147, wherein R g and R h join together to form a 3-6 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , - C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C152. The compound of embodiment C151, wherein R g and R h join together to form a 3-6 membered carbocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C153. The compound of embodiment C151, wherein R g and R h join together to form a 3-6 membered heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1- 6 alkyl is unsubstituted or substituted with one or more R 20 . C154. The compound of any one of embodiments C103-C130, wherein the compound is a compound according to Formula IIID: or a salt (e.g., pharmaceutically acceptable salt) thereof, wherein: Q is selected from CR h R j , NR g , O, S, and SO 2 ; each R e and R f is independently selected from R 11 and hydrogen, wherein: (i) an R e and an R f can optionally join together to form a 4-6 membered ring; (ii) a first R f and a second R f connected to adjacent atoms can optionally join together to form a 3-5 membered ring; (iii) a first R e and a second R e connected to adjacent atoms can optionally join together to form a 3-5 membered ring; or (iv) a first R f and a second R f connected to the same atom can optionally join together to form a 3-5 membered ring, wherein any ring formed by one or more R e and/or one or more R f is unsubstituted or substituted with one or more R 11 ; R g , when present, is R 11 ; and R h and R j , when present, are independently selected from R 11 and hydrogen, or can optionally join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted or substituted with one or more substituents selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1- 6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1- 6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C155. The compound of embodiment C154, wherein Q is NR g . C156. The compound of embodiment C155, wherein R g is selected from -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C157. The compound of embodiment C154, wherein Q is O, S, or SO 2 . C158. The compound of embodiment C157, wherein Q is O. C159. The compound of embodiment C154, wherein Q is CR h R j . C160. The compound of embodiment C159, wherein the compound is a compound according to Formula IIIE: or a salt (e.g., pharmaceutically acceptable salt) thereof. C161. The compound of embodiment C160, wherein an R e and an R f join together to form a 4-6 membered ring. C162. The compound of embodiment C160 or C161, wherein R h and R j are independently selected from R 11 and hydrogen. C163. The compound of any one of embodiments C160-C162, wherein R h and/or R j is selected from deuterium, -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C164. The compound of any one of embodiments C160-C162, wherein R h and R j are each hydrogen. C165. The compound of embodiment C160, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle. C166. The compound of embodiment C165, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is unsubstituted. C167. The compound of embodiment C165, wherein R h and R j join together to form a 3-4 membered carbocycle or heterocycle that is substituted with one or more substituents selected from -OR 12 , =O, -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -S(O) 2 (C 1-6 alkyl), - N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . C168. The compound of any one of embodiments C165-C167, wherein no combination of one or more R e s and/or one or more R f s join together to form a ring. C169. The compound of any one of embodiments C165-C168, wherein each R e and R f is hydrogen. C170. The compound of embodiment C154, wherein the compound is a compound according to Formula IIIF, IIIG, or IIIH: or a salt (e.g., pharmaceutically acceptable salt) thereof. C171. The compound of embodiment C170, wherein the compound is a compound of Formula IIIF or a salt (e.g., a pharmaceutically acceptable salt) thereof. C172. The compound of embodiment C170, wherein the compound is a compound of Formula IIIG or a salt (e.g., a pharmaceutically acceptable salt) thereof. C173. The compound of embodiment C170, wherein the compound is a compound of Formula IIIH or a salt (e.g., a pharmaceutically acceptable salt) thereof. C174. The compound of any one of embodiments C170-C173, wherein each R e and R f is independently selected from R 11 and hydrogen. C175. The compound of any one of embodiments C170-C173, wherein an R e and an R f join together to form a 4-6 membered ring. C176. The compound of embodiment C154, wherein the compound is a compound according to Formula IIIJ: or a salt (e.g., pharmaceutically acceptable salt) thereof. C177. The compound of embodiment C176, wherein each R e and R f is independently selected from R 11 and hydrogen. C178. The compound of embodiment C176, wherein an R e and an R f join together to form a 4-6 membered ring. C179. The compound of any one of embodiments C154-C178, wherein the compound is a compound according to Formula IIIK, IIIL, IIIM, IIIN, IIIP, IIIQ, or IIIR: or a salt (e.g., pharmaceutically acceptable salt) wherein: each R e and R f is independently selected from R 11 and hydrogen; R g , when present, is R 11 ; and R h and R j , when present, are each independently selected from R 11 and hydrogen. C180. The compound of embodiment C179, wherein the compound is a compound of Formula IIIK or a salt (e.g., a pharmaceutically acceptable salt) thereof. C181. The compound of embodiment C179, wherein the compound is a compound of Formula IIIL or a salt (e.g., a pharmaceutically acceptable salt) thereof. C182. The compound of embodiment C179, wherein the compound is a compound of Formula IIIM or a salt (e.g., a pharmaceutically acceptable salt) thereof. C183. The compound of embodiment C179, wherein the compound is a compound of Formula IIIN or a salt (e.g., a pharmaceutically acceptable salt) thereof. C184. The compound of embodiment C179, wherein the compound is a compound of Formula IIIP or a salt (e.g., a pharmaceutically acceptable salt) thereof. C185. The compound of embodiment C179, wherein the compound is a compound of Formula IIIQ or a salt (e.g., a pharmaceutically acceptable salt) thereof. C186. The compound of embodiment C179, wherein the compound is a compound of Formula IIIR or a salt (e.g., a pharmaceutically acceptable salt) thereof. C187. The compound of any one of embodiments C179-C186, wherein Q is selected from CR h R j , NR g , and O. C188. The compound of embodiment C187, wherein Q is CR h R j . C189. The compound of embodiment C188, wherein R h and R j , when present, are each independently selected from R 11 and hydrogen. C190. The compound of embodiment C189, wherein R h and/or R j , when present, is each independently selected from -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C191. The compound of embodiment C189, wherein R h and R j are each hydrogen. C192. The compound of embodiment C187, wherein Q is NR g . C193. The compound of embodiment C192, wherein R g is selected from -C(O)(C 1-6 alkylene)CN, - C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), -C(O)N(R 14 ) 2 , and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 . C194. The compound of embodiment C187, wherein Q is O. C195. The compound of any one of embodiments C179-C186, wherein Q is S or SO 2 . C196. The compound of any one of embodiments C179-C195, wherein each R e and R f is independently selected from R 11 and hydrogen. C197. The compound of embodiment C196, wherein R e and/or R f is each independently selected from deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1- 6 alkyl), -C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl that is unsubstituted or substituted with one or more R 20 . C198. The compound of embodiment C197, wherein each R e and R f is hydrogen. C199. The compound of any one of embodiments C103-C130, wherein the compound is a compound according to Formula IIIS: or a salt (e.g., pharmaceutically acceptable salt) wherein: Q 1 is selected from NR g1 , O, SR h 2, and CR i R j ; Q 2 is selected from NR g2 , O, SR h 2, and CR i R j ; R g1 and R g2 , when present, are independently selected from hydrogen, -C(O)(C 1-6 alkyl), and C 1- 6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R h is absent or, when present, is independently selected from =O, =N(R 14 ), and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; each R i and R j , when present, are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 ; and each R e1 , R e2 , R e3 , and R e4 are independently selected from hydrogen, deuterium, -OR 12 , =O, =N(R 14 ), -C(O)(C 1-6 alkylene)CN, -C(O)(C 1-6 alkylene)OR 14 , -C(O)(C 1-6 alkyl), - C(O)N(R 14 ) 2 , -S(O) 2 (C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkyl), -N(R 14 )C(O)(C 1-6 alkylene)OR 14 , halogen, and C 1-6 alkyl, wherein any C 1-6 alkyl is unsubstituted or substituted with one or more R 20 , wherein (i) an R e2